assertion_id	disorder_id	disorder_name	source_file	section	section_index	name	description	category	frequency	diagnostic	context	subtype	role	presence	association	accession	age_range	background	base_model	classification	clinical_significance	consequence	data_type	de_novo_rate	definition_type	duration	effect	expressivity	features	genotype	incubation_days	incubation_years	markers	maximum_value	mean_range	minimum_value	model_format	model_id	model_software	model_type	notes	parent_of_origin_effect	penetrance	percentage	phase	platform	population	publication	repository_url	results	review_notes	sample_count	scope	sequence_length	severity	species	specificity	status	subtype_frequency	title	type	unit	scalar_fields_json	complex_fields_json	raw_json
21	2	ALK-Rearranged Non-Small Cell Lung Cancer	ALK_Rearranged_NSCLC.yaml	biochemical	0	ALK Testing																																			ALK testing is required for all advanced non-squamous NSCLC. Methods include FISH (FDA-approved companion diagnostic), immunohistochemistry (screening), and next-generation sequencing (identifies fusion partner and variant). ALK is mutually exclusive with EGFR mutations.																						"{""name"": ""ALK Testing"", ""notes"": ""ALK testing is required for all advanced non-squamous NSCLC. Methods include FISH (FDA-approved companion diagnostic), immunohistochemistry (screening), and next-generation sequencing (identifies fusion partner and variant). ALK is mutually exclusive with EGFR mutations.""}"	{}	"{""name"": ""ALK Testing"", ""notes"": ""ALK testing is required for all advanced non-squamous NSCLC. Methods include FISH (FDA-approved companion diagnostic), immunohistochemistry (screening), and next-generation sequencing (identifies fusion partner and variant). ALK is mutually exclusive with EGFR mutations.""}"
40	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	biochemical	0	Coagulation Studies																																			Characteristic findings include prolonged PT and PTT, markedly elevated D-dimer, and decreased fibrinogen. Rapid correction with ATRA initiation is essential to prevent fatal hemorrhage.																						"{""name"": ""Coagulation Studies"", ""notes"": ""Characteristic findings include prolonged PT and PTT, markedly elevated D-dimer, and decreased fibrinogen. Rapid correction with ATRA initiation is essential to prevent fatal hemorrhage.""}"	{}	"{""name"": ""Coagulation Studies"", ""notes"": ""Characteristic findings include prolonged PT and PTT, markedly elevated D-dimer, and decreased fibrinogen. Rapid correction with ATRA initiation is essential to prevent fatal hemorrhage.""}"
41	3	Acute Promyelocytic Leukemia, PML-RARA	APL_PML_RARA.yaml	biochemical	1	PML-RARA Fusion Detection																																			RT-PCR detects PML-RARA fusion transcripts and identifies breakpoint location (bcr1, bcr2, or bcr3). Essential for diagnosis confirmation and minimal residual disease monitoring. FISH detects the t(15;17).																						"{""name"": ""PML-RARA Fusion Detection"", ""notes"": ""RT-PCR detects PML-RARA fusion transcripts and identifies breakpoint location (bcr1, bcr2, or bcr3). Essential for diagnosis confirmation and minimal residual disease monitoring. FISH detects the t(15;17).""}"	{}	"{""name"": ""PML-RARA Fusion Detection"", ""notes"": ""RT-PCR detects PML-RARA fusion transcripts and identifies breakpoint location (bcr1, bcr2, or bcr3). Essential for diagnosis confirmation and minimal residual disease monitoring. FISH detects the t(15;17).""}"
61	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	biochemical	0	Serum Transthyretin Levels					Diagnostic indicator			Abnormal (low)																																																	"{""context"": ""Diagnostic indicator"", ""name"": ""Serum Transthyretin Levels"", ""presence"": ""Abnormal (low)""}"	{}	"{""context"": ""Diagnostic indicator"", ""evidence"": [{""explanation"": ""The literature indicates that lower levels of transthyretin are associated with transthyretin amyloidosis, supporting the statement that abnormal (low) serum transthyretin levels can be a diagnostic indicator."", ""reference"": ""PMID:32356182"", ""snippet"": ""Lower levels of transthyretin and retinol binding protein-4 have been demonstrated in patients with pathogenic mutations of transthyretin either with or without clinical disease."", ""supports"": ""SUPPORT""}], ""name"": ""Serum Transthyretin Levels"", ""presence"": ""Abnormal (low)""}"
62	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	biochemical	1	Amyloid P Component								Elevated																											May be used to monitor disease progression																						"{""name"": ""Amyloid P Component"", ""notes"": ""May be used to monitor disease progression"", ""presence"": ""Elevated""}"	{}	"{""evidence"": [{""explanation"": ""The reference indicates that serum amyloid P component scintigraphy can be used to monitor the course of systemic amyloidosis, but it does not specify whether the levels of amyloid P component are elevated in ATTR amyloidosis."", ""reference"": ""PMID:12394612"", ""snippet"": ""Radiolabelled serum amyloid P component scintigraphy is a non-invasive and quantitative method for imaging amyloid deposits, which produces diagnostic images in most patients with systemic amyloidosis, and can be used repeatedly to monitor the course of the disease."", ""supports"": ""PARTIAL""}], ""name"": ""Amyloid P Component"", ""notes"": ""May be used to monitor disease progression"", ""presence"": ""Elevated""}"
151	8	Acne Vulgaris	Acne_Vulgaris.yaml	biochemical	0	Androgens								Elevated																											"Androgens (testosterone, DHT) stimulate sebaceous gland activity through androgen receptor signaling, explaining the onset of acne at puberty and its association with hyperandrogenic states.
"																						"{""name"": ""Androgens"", ""notes"": ""Androgens (testosterone, DHT) stimulate sebaceous gland activity through androgen receptor signaling, explaining the onset of acne at puberty and its association with hyperandrogenic states.\n"", ""presence"": ""Elevated""}"	{}	"{""evidence"": [{""explanation"": ""This paper directly links androgen hormones to excess sebum production in acne pathogenesis."", ""reference"": ""PMID:32748305"", ""snippet"": ""Excess sebum production occurs because of increased activity of androgen hormones and IGF-1"", ""supports"": ""SUPPORT""}], ""name"": ""Androgens"", ""notes"": ""Androgens (testosterone, DHT) stimulate sebaceous gland activity through androgen receptor signaling, explaining the onset of acne at puberty and its association with hyperandrogenic states.\n"", ""presence"": ""Elevated""}"
152	8	Acne Vulgaris	Acne_Vulgaris.yaml	biochemical	1	Sebum lipids								Altered																											"Changes in sebum composition, including altered fatty acid profiles and increased squalene oxidation, contribute to comedogenesis and inflammation.
"																						"{""name"": ""Sebum lipids"", ""notes"": ""Changes in sebum composition, including altered fatty acid profiles and increased squalene oxidation, contribute to comedogenesis and inflammation.\n"", ""presence"": ""Altered""}"	{}	"{""evidence"": [{""explanation"": ""This review describes alterations in sebum fatty acid composition as a key feature in acne pathogenesis."", ""reference"": ""PMID:20871834"", ""snippet"": ""Altered ratio between saturated and unsaturated fatty acids has been indicated as an important feature to be considered in addition to the altered amount of specific fatty acids such as linoleic acid"", ""supports"": ""SUPPORT""}], ""name"": ""Sebum lipids"", ""notes"": ""Changes in sebum composition, including altered fatty acid profiles and increased squalene oxidation, contribute to comedogenesis and inflammation.\n"", ""presence"": ""Altered""}"
153	8	Acne Vulgaris	Acne_Vulgaris.yaml	biochemical	2	IL-17								Decreased																											"Serum IL-17 levels are lower in acne vulgaris compared with controls in a severity-stratified cohort, suggesting altered systemic cytokine signaling.
"																						"{""name"": ""IL-17"", ""notes"": ""Serum IL-17 levels are lower in acne vulgaris compared with controls in a severity-stratified cohort, suggesting altered systemic cytokine signaling.\n"", ""presence"": ""Decreased""}"	{}	"{""evidence"": [{""explanation"": ""This study reports decreased serum IL-17 in acne vulgaris compared with controls."", ""reference"": ""PMID:41465543"", ""snippet"": ""Serum IL-17 levels were significantly higher in the control group compared to both acne groups (p < 0.05), with no gender-related differences."", ""supports"": ""SUPPORT""}], ""name"": ""IL-17"", ""notes"": ""Serum IL-17 levels are lower in acne vulgaris compared with controls in a severity-stratified cohort, suggesting altered systemic cytokine signaling.\n"", ""presence"": ""Decreased""}"
204	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	biochemical	0	CD4 T-cell Count								Decreased																																																	"{""name"": ""CD4 T-cell Count"", ""presence"": ""Decreased""}"	{}	"{""evidence"": [{""explanation"": ""The literature indicates that CD4+ (T helper) cell count is an important marker for staging HIV infection, which correlates with the progression to AIDS, thus implying a decrease in CD4 T-cell count in AIDS."", ""reference"": ""PMID:1346152"", ""snippet"": ""The surrogate marker that most closely correlates with the stage of HIV infection is the CD4+, or T helper, cell count."", ""supports"": ""SUPPORT""}, {""explanation"": ""Low CD4 cell count is mentioned as a major indicator of AIDS, directly supporting the statement."", ""reference"": ""PMID:26676359"", ""snippet"": ""Low CD4 cell count, severe loss of body weight, pneumocystis pneumonia, and Kaposi's sarcoma are the major disease indicators."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study indicates that the proportion of CD4+ T-lymphocytes is a significant prognostic marker for AIDS, implying its decrease in AIDS."", ""reference"": ""PMID:1384311"", ""snippet"": ""The prognostic significance of immunologic markers (proportion of CD4+ T-lymphocytes...)"", ""supports"": ""SUPPORT""}, {""explanation"": ""The death of CD4+ T cells characterizes AIDS, predicting the disease outcome and supporting the decrease in CD4+ T-cell counts."", ""reference"": ""PMID:19273357"", ""snippet"": ""Thus, the death of effector/memory CD4+ T cells during both the acute and chronic phase represents one the main characteristic of such viral infection that predicts disease outcome."", ""supports"": ""SUPPORT""}], ""name"": ""CD4 T-cell Count"", ""presence"": ""Decreased""}"
205	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	biochemical	1	HIV Viral Load								Increased																																																	"{""name"": ""HIV Viral Load"", ""presence"": ""Increased""}"	{}	"{""evidence"": [{""explanation"": ""While the specific mention of HIV Viral Load as a biochemical index linked to AIDS is not explicitly detailed in the provided baseline data differences, the overall context supports that biochemical markers, including viral load, are important factors in AIDS patients."", ""reference"": ""PMID:37661622"", ""snippet"": ""The baseline biochemical indexes of leukocyte, platelet, hemoglobin, TG, TC, FPG, AST, ALT and total bilirubin in the poor immune reconstitution group were significantly different from those in the good immune reconstitution group (all P<0.05)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study supports that HIV Viral Load (a biochemical measure) remains increased in certain HIV-infected individuals, which can contribute to the spread of the virus."", ""reference"": ""PMID:22258501"", ""snippet"": ""HIV-infected individuals who maintain increased levels of HIV-1 RNA load, extended high viremics, can transmit virus at higher rates. Combinatorial ART decreases HIV replication, thus reducing rates of virus transmission."", ""supports"": ""SUPPORT""}], ""name"": ""HIV Viral Load"", ""presence"": ""Increased""}"
238	10	Addison's Disease	Addisons_Disease.yaml	biochemical	0	Cortisol					Diagnostic indicator, measured in blood or saliva			Decreased																																																	"{""context"": ""Diagnostic indicator, measured in blood or saliva"", ""name"": ""Cortisol"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Diagnostic indicator, measured in blood or saliva"", ""evidence"": [{""explanation"": ""This reference supports the statement as it indicates that cortisol levels, whether measured in blood or saliva, are used for diagnosing adrenal insufficiency, which includes Addison's Disease."", ""reference"": ""PMID:18954859"", ""snippet"": ""Diagnosis of AI often requires serum cortisol measurement during dynamic tests. Salivary cortisol measurement was reported to have an equivalent diagnostic performance to serum cortisol and that is even better when CBG levels are altered."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by indicating that cortisol levels are used as a diagnostic indicator for Addison's Disease."", ""reference"": ""PMID:31791082"", ""snippet"": ""Addison's disease was diagnosed by management of cortisol, ACTH and adrenal antibodies."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by indicating that salivary cortisol is an accurate method for assessing cortisol levels, which are relevant for diagnosing conditions like Addison's Disease."", ""reference"": ""PMID:25647239"", ""snippet"": ""Salivary cortisol can be used as a surrogate for serum free cortisol in critically ill pediatric patients. Salivary cortisol is a cost-effective and less invasive measure of bioavailable cortisol and offers an alternate and accurate method for assessing critical illness-related corticosteroid insufficiency in children."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by discussing the measurement of cortisol levels in various biological fluids, including blood and saliva, for diagnosing conditions related to cortisol imbalance such as Addison's Disease."", ""reference"": ""PMID:19414006"", ""snippet"": ""The overview of cortisol physiology, action and pathology is achieved in relation to the hypothalamic-pituitary-adrenal axis alteration by laboratory investigation. The measurements of cortisol and related compound levels in blood, urine and saliva used to study the physiological and pathological cortisol involvement, are critically reviewed."", ""supports"": ""SUPPORT""}], ""name"": ""Cortisol"", ""presence"": ""Decreased""}"
239	10	Addison's Disease	Addisons_Disease.yaml	biochemical	1	ACTH (Adrenocorticotropic Hormone)					Elevated due to lack of feedback inhibition by cortisol			Increased																																																	"{""context"": ""Elevated due to lack of feedback inhibition by cortisol"", ""name"": ""ACTH (Adrenocorticotropic Hormone)"", ""presence"": ""Increased""}"	{}	"{""context"": ""Elevated due to lack of feedback inhibition by cortisol"", ""evidence"": [{""explanation"": ""The elevated ACTH levels are indicative of Addison's disease due to lack of feedback inhibition by cortisol."", ""reference"": ""PMID:28132947"", ""snippet"": ""The serum concentration of ACTH and 21-hydroxylase antibodies were increased and lead to the diagnosis."", ""supports"": ""SUPPORT""}, {""explanation"": ""The elevated ACTH levels in Addison's disease are due to the failure of cortisol to provide negative feedback."", ""reference"": ""PMID:19500760"", ""snippet"": ""Patients present in early life with low or undetectable cortisol and--because of the failure of the negative feedback loop to the pituitary and hypothalamus--grossly elevated ACTH levels."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study shows that elevated ACTH levels can precede the onset of Addison's disease due to impaired feedback inhibition by cortisol."", ""reference"": ""PMID:22066755"", ""snippet"": ""Compared with nonprogressors, in the time period 2 months-2 years prior to the onset of AD, progressors were significantly more likely to have elevated ACTH."", ""supports"": ""SUPPORT""}], ""name"": ""ACTH (Adrenocorticotropic Hormone)"", ""presence"": ""Increased""}"
240	10	Addison's Disease	Addisons_Disease.yaml	biochemical	2	Aldosterone								Decreased																																																	"{""name"": ""Aldosterone"", ""presence"": ""Decreased""}"	{}	"{""evidence"": [{""explanation"": ""The study shows that aldosterone levels are significantly lower in dogs with hypoadrenocorticism (HA), which is analogous to Addison's disease in humans."", ""reference"": ""PMID:24428320"", ""snippet"": ""Baseline and ACTH-stimulated aldosterone was significantly lower in dogs with HA than in the other groups. Aldosterone was low or undetectable in 67/70 dogs with HA independently of sodium and potassium levels."", ""supports"": ""SUPPORT""}, {""explanation"": ""This case study of a patient with Addison's disease form of adrenoleukodystrophy indicates primary adrenal insufficiency, which typically involves decreased aldosterone levels."", ""reference"": ""PMID:32101828"", ""snippet"": ""Endocrinological examination showed low serum cortisol (1.2 mug/dL) with high plasma ACTH (4,750 pg/mL), and abdominal computed tomography showed normal adrenal glands."", ""supports"": ""SUPPORT""}, {""explanation"": ""The destruction of the adrenal cortex in Addison's disease leads to decreased production of adrenal hormones, including aldosterone."", ""reference"": ""PMID:28132947"", ""snippet"": ""Addison's disease is characterized by the destruction of the adrenal cortex. Autoimmune adrenalitis is the main cause of adrenal insufficiency."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article discusses the altered renin-angiotensin-aldosterone axis in Addison's disease, indicating decreased aldosterone production."", ""reference"": ""PMID:25138826"", ""snippet"": ""Addison's disease may be complicated by hypertension and less commonly by heart failure. We review the pathophysiology of the renin-angiotensin-aldosterone axis in Addison's disease and how this is altered in the setting of hypertension and heart failure."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study indirectly supports the statement by discussing adrenal insufficiency in Addison's disease, which typically includes decreased aldosterone levels."", ""reference"": ""PMID:5797781"", ""snippet"": ""Clinical evidence of a thyroid disorder was present in 10 out of 40 patients with Addison's disease."", ""supports"": ""SUPPORT""}], ""name"": ""Aldosterone"", ""presence"": ""Decreased""}"
277	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	biochemical	0	HTLV-1 Antibodies																																			Seropositivity for HTLV-1 antibodies is required for diagnosis. ELISA screening followed by Western blot confirmation.																						"{""name"": ""HTLV-1 Antibodies"", ""notes"": ""Seropositivity for HTLV-1 antibodies is required for diagnosis. ELISA screening followed by Western blot confirmation.""}"	{}	"{""name"": ""HTLV-1 Antibodies"", ""notes"": ""Seropositivity for HTLV-1 antibodies is required for diagnosis. ELISA screening followed by Western blot confirmation.""}"
278	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	biochemical	1	HTLV-1 Proviral Load																																			Quantification of HTLV-1 proviral DNA by PCR. High proviral load is associated with increased risk of ATLL development.																						"{""name"": ""HTLV-1 Proviral Load"", ""notes"": ""Quantification of HTLV-1 proviral DNA by PCR. High proviral load is associated with increased risk of ATLL development.""}"	{}	"{""name"": ""HTLV-1 Proviral Load"", ""notes"": ""Quantification of HTLV-1 proviral DNA by PCR. High proviral load is associated with increased risk of ATLL development.""}"
279	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	biochemical	2	Soluble IL-2 Receptor (sIL-2R)																																			Markedly elevated sIL-2R reflects high tumor burden and T-cell activation. Useful for monitoring disease activity.																						"{""name"": ""Soluble IL-2 Receptor (sIL-2R)"", ""notes"": ""Markedly elevated sIL-2R reflects high tumor burden and T-cell activation. Useful for monitoring disease activity.""}"	{}	"{""name"": ""Soluble IL-2 Receptor (sIL-2R)"", ""notes"": ""Markedly elevated sIL-2R reflects high tumor burden and T-cell activation. Useful for monitoring disease activity.""}"
306	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	biochemical	0	Alpha-Fetoprotein (AFP)																																			Serum AFP is elevated in 50-70% of HCC cases. Used for screening in high-risk populations and for monitoring treatment response. Very high levels (>400 ng/mL) are highly specific for HCC.																						"{""name"": ""Alpha-Fetoprotein (AFP)"", ""notes"": ""Serum AFP is elevated in 50-70% of HCC cases. Used for screening in high-risk populations and for monitoring treatment response. Very high levels (>400 ng/mL) are highly specific for HCC.""}"	{}	"{""name"": ""Alpha-Fetoprotein (AFP)"", ""notes"": ""Serum AFP is elevated in 50-70% of HCC cases. Used for screening in high-risk populations and for monitoring treatment response. Very high levels (>400 ng/mL) are highly specific for HCC.""}"
307	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	biochemical	1	Aflatoxin-Albumin Adducts																																			Aflatoxin-albumin adducts in serum serve as biomarkers of recent aflatoxin exposure and are used in epidemiologic studies to assess population-level exposure.																						"{""name"": ""Aflatoxin-Albumin Adducts"", ""notes"": ""Aflatoxin-albumin adducts in serum serve as biomarkers of recent aflatoxin exposure and are used in epidemiologic studies to assess population-level exposure.""}"	{}	"{""name"": ""Aflatoxin-Albumin Adducts"", ""notes"": ""Aflatoxin-albumin adducts in serum serve as biomarkers of recent aflatoxin exposure and are used in epidemiologic studies to assess population-level exposure.""}"
308	12	Aflatoxin-Related Hepatocellular Carcinoma	Aflatoxin_Related_HCC.yaml	biochemical	2	Urinary Aflatoxin Metabolites																																			Urinary aflatoxin-N7-guanine adducts reflect recent aflatoxin exposure and DNA damage. Used as biomarker in exposure assessment studies.																						"{""name"": ""Urinary Aflatoxin Metabolites"", ""notes"": ""Urinary aflatoxin-N7-guanine adducts reflect recent aflatoxin exposure and DNA damage. Used as biomarker in exposure assessment studies.""}"	{}	"{""name"": ""Urinary Aflatoxin Metabolites"", ""notes"": ""Urinary aflatoxin-N7-guanine adducts reflect recent aflatoxin exposure and DNA damage. Used as biomarker in exposure assessment studies.""}"
332	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	biochemical	0	VEGF					In wet AMD, drives neovascularization			Elevated																																																	"{""context"": ""In wet AMD, drives neovascularization"", ""name"": ""VEGF"", ""presence"": ""Elevated""}"	{}	"{""context"": ""In wet AMD, drives neovascularization"", ""name"": ""VEGF"", ""presence"": ""Elevated""}"
333	13	Age-Related Macular Degeneration	Age_Related_Macular_Degeneration.yaml	biochemical	1	Complement factors					C3a, C5a in drusen and plasma			Elevated																																																	"{""context"": ""C3a, C5a in drusen and plasma"", ""name"": ""Complement factors"", ""presence"": ""Elevated""}"	{}	"{""context"": ""C3a, C5a in drusen and plasma"", ""name"": ""Complement factors"", ""presence"": ""Elevated""}"
406	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	biochemical	0	Amyloid Beta (Aβ42)					Found in cerebrospinal fluid and brain tissue.			Elevated																																																	"{""context"": ""Found in cerebrospinal fluid and brain tissue."", ""name"": ""Amyloid Beta (Aβ42)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Found in cerebrospinal fluid and brain tissue."", ""evidence"": [{""explanation"": ""The literature confirms that Abeta42 is a core biomarker found in cerebrospinal fluid (CSF) and is elevated in Alzheimer's disease."", ""reference"": ""PMID:19661632"", ""snippet"": ""The core candidate CSF biomarkers Abeta42, total tau (T-tau), and phosphorylated tau (P-tau) have been shown to have a high diagnostic performance to identify AD also in the early phase of the disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature confirms that elevated levels of amyloid-beta, including Abeta42, are found in the brain tissue of individuals with Alzheimer's disease."", ""reference"": ""PMID:31958088"", ""snippet"": ""Genetic predispositions associated with metabolism of the amyloid-beta protein precursor underlie familial Alzheimer's disease; a form of dementia characterized by early disease onset and elevated levels of cortical amyloid-beta."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the presence of beta-amyloid in brain tissue, which includes Abeta42, in Alzheimer's disease."", ""reference"": ""PMID:38987603"", ""snippet"": ""beta-amyloid plaques contained a mixture of fibrils, some of which were branched, and protofilaments, arranged in parallel arrays and lattice-like structures."", ""supports"": ""SUPPORT""}, {""explanation"": ""This literature supports the presence and elevation of Abeta42 in both cerebrospinal fluid and brain tissue in Alzheimer's disease."", ""reference"": ""PMID:33080124"", ""snippet"": ""Accumulation of amyloid-β is among the earliest changes in Alzheimer's disease (AD). Amyloid-β positron emission tomography (PET) and Aβ42 in cerebrospinal fluid (CSF) both assess amyloid-β pathology in-vivo"", ""supports"": ""SUPPORT""}], ""name"": ""Amyloid Beta (Aβ42)"", ""presence"": ""Elevated""}"
439	18	Alopecia Areata	Alopecia_Areata.yaml	biochemical	0	Anti-Hair Follicle Antibodies					Not routinely tested			Variable																																																	"{""context"": ""Not routinely tested"", ""name"": ""Anti-Hair Follicle Antibodies"", ""presence"": ""Variable""}"	{}	"{""context"": ""Not routinely tested"", ""name"": ""Anti-Hair Follicle Antibodies"", ""presence"": ""Variable""}"
477	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	biochemical	0	PAX-FOXO1 Fusion Detection																																			RT-PCR, FISH, or next-generation sequencing detection of PAX3-FOXO1 or PAX7-FOXO1 fusion is diagnostic and prognostic. Fusion status is more predictive of outcome than histologic classification.																						"{""name"": ""PAX-FOXO1 Fusion Detection"", ""notes"": ""RT-PCR, FISH, or next-generation sequencing detection of PAX3-FOXO1 or PAX7-FOXO1 fusion is diagnostic and prognostic. Fusion status is more predictive of outcome than histologic classification.""}"	{}	"{""name"": ""PAX-FOXO1 Fusion Detection"", ""notes"": ""RT-PCR, FISH, or next-generation sequencing detection of PAX3-FOXO1 or PAX7-FOXO1 fusion is diagnostic and prognostic. Fusion status is more predictive of outcome than histologic classification.""}"
478	20	Alveolar Rhabdomyosarcoma	Alveolar_Rhabdomyosarcoma.yaml	biochemical	1	Myogenic Markers																																			Immunohistochemistry shows expression of myogenic markers including desmin, myogenin, and MyoD1. Myogenin shows diffuse strong nuclear positivity, which helps distinguish from embryonal rhabdomyosarcoma.																						"{""name"": ""Myogenic Markers"", ""notes"": ""Immunohistochemistry shows expression of myogenic markers including desmin, myogenin, and MyoD1. Myogenin shows diffuse strong nuclear positivity, which helps distinguish from embryonal rhabdomyosarcoma.""}"	{}	"{""name"": ""Myogenic Markers"", ""notes"": ""Immunohistochemistry shows expression of myogenic markers including desmin, myogenin, and MyoD1. Myogenin shows diffuse strong nuclear positivity, which helps distinguish from embryonal rhabdomyosarcoma.""}"
511	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	biochemical	0	Neurofilament Light Chain (NfL)					CSF and serum biomarker of axonal injury, elevated in ALS with prognostic value			Elevated																											Used for diagnosis, prognosis, and monitoring therapeutic response in clinical trials																						"{""context"": ""CSF and serum biomarker of axonal injury, elevated in ALS with prognostic value"", ""name"": ""Neurofilament Light Chain (NfL)"", ""notes"": ""Used for diagnosis, prognosis, and monitoring therapeutic response in clinical trials"", ""presence"": ""Elevated""}"	{}	"{""context"": ""CSF and serum biomarker of axonal injury, elevated in ALS with prognostic value"", ""name"": ""Neurofilament Light Chain (NfL)"", ""notes"": ""Used for diagnosis, prognosis, and monitoring therapeutic response in clinical trials"", ""presence"": ""Elevated""}"
512	22	Amyotrophic Lateral Sclerosis	Amyotrophic_Lateral_Sclerosis.yaml	biochemical	1	Phosphorylated Neurofilament Heavy Chain (pNfH)					CSF and serum biomarker of axonal injury			Elevated																																																	"{""context"": ""CSF and serum biomarker of axonal injury"", ""name"": ""Phosphorylated Neurofilament Heavy Chain (pNfH)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""CSF and serum biomarker of axonal injury"", ""name"": ""Phosphorylated Neurofilament Heavy Chain (pNfH)"", ""presence"": ""Elevated""}"
557	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	biochemical	0	ESR					Marker of inflammation			Elevated																																																	"{""context"": ""Marker of inflammation"", ""name"": ""ESR"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Marker of inflammation"", ""name"": ""ESR"", ""presence"": ""Elevated""}"
558	23	Ankylosing Spondylitis	Ankylosing_Spondylitis.yaml	biochemical	1	CRP					Correlates with disease activity			Elevated																																																	"{""context"": ""Correlates with disease activity"", ""name"": ""CRP"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Correlates with disease activity"", ""name"": ""CRP"", ""presence"": ""Elevated""}"
573	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	biochemical	0	Antiphospholipid Antibodies								Positive																																																	"{""name"": ""Antiphospholipid Antibodies"", ""presence"": ""Positive""}"	{}	"{""evidence"": [{""explanation"": ""The presence of these specific antibodies is used to diagnose antiphospholipid syndrome, directly supporting the statement."", ""reference"": ""PMID:26307097"", ""snippet"": ""According to current guidelines, 3 tests (lupus anticoagulant, anticardiolipin, and anti beta2-glycoprotein I antibodies) are officially recommended to assess the presence of antiphospholipid antibodies."", ""supports"": ""SUPPORT""}], ""name"": ""Antiphospholipid Antibodies"", ""presence"": ""Positive""}"
574	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	biochemical	1	Lupus Anticoagulant								Positive																																																	"{""name"": ""Lupus Anticoagulant"", ""presence"": ""Positive""}"	{}	"{""evidence"": [{""explanation"": ""The literature identifies lupus anticoagulant as part of the antiphospholipid syndrome, supporting its presence in this condition."", ""reference"": ""PMID:8712801"", ""snippet"": ""Recent data suggest strongly that lupus anticoagulants (LACs) and anticardiolipin antibodies (ACAs) are antibodies to protein-phospholipid complexes."", ""supports"": ""SUPPORT""}, {""explanation"": ""High titers of antiphospholipid antibodies, including lupus anticoagulant, were confirmed to be persistently positive."", ""reference"": ""PMID:36032074"", ""snippet"": ""As both platelet-bound C4d (PC4d) and aPL are associated with thrombosis in systemic lupus erythematosus (SLE)..."", ""supports"": ""SUPPORT""}, {""explanation"": ""Lupus anticoagulant presence is included in the diagnostic criteria for antiphospholipid syndrome."", ""reference"": ""PMID:20848817"", ""snippet"": ""The 2006 International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome has increased the time between the two laboratory studies required for diagnosis from 6 to 12 weeks. Antibody to beta2 glycoprotein 1 has been included as a criterion."", ""supports"": ""SUPPORT""}, {""explanation"": ""Lupus anticoagulant is considered a significant marker for diagnosing antiphospholipid syndrome."", ""reference"": ""PMID:23219767"", ""snippet"": ""Triple positivity (positive Lupus Anticoagulant, anticardiolipin and anti beta2-glycoptrotein I antibodies) identifies the pathogenic autoantibody."", ""supports"": ""SUPPORT""}], ""name"": ""Lupus Anticoagulant"", ""presence"": ""Positive""}"
575	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	biochemical	2	Anti-Cardiolipin Antibodies								Positive																																																	"{""name"": ""Anti-Cardiolipin Antibodies"", ""presence"": ""Positive""}"	{}	"{""evidence"": [{""explanation"": ""The presence of anticardiolipin antibodies is associated with antiphospholipid syndrome (APS)."", ""reference"": ""PMID:15804703"", ""snippet"": ""The anticardiolipin (aCL) antibody test was first established in 1983, using cardiolipin (negatively charged phospholipid) as an antigen in a solid-phase immunoassay. It was first applied to the study of systemic lupus erythematosus patients, and was found associated with thromboses and recurrent pregnancy losses. The wide use of this test was determinant in the definition of the 'aCL or antiphospholipid syndrome' (APS)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Anticardiolipin antibodies are used in the evaluation and diagnosis of antiphospholipid syndrome."", ""reference"": ""PMID:35728601"", ""snippet"": ""The evaluation of aPL is standardized using immunological tests for anticardiolipin and anti-beta2-glycoprotein I."", ""supports"": ""SUPPORT""}, {""explanation"": ""Elevated anticardiolipin antibody titer is a criterion for diagnosing antiphospholipid syndrome."", ""reference"": ""PMID:10977230"", ""snippet"": ""Antiphospholipid syndrome includes elevation of either the lupus anticoagulant titer or the anticardiolipin antibody titer on two occasions, separated by 6 weeks in a patient with an episode of thrombosis."", ""supports"": ""SUPPORT""}], ""name"": ""Anti-Cardiolipin Antibodies"", ""presence"": ""Positive""}"
576	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	biochemical	3	Beta-2 Glycoprotein I Antibodies								Positive																																																	"{""name"": ""Beta-2 Glycoprotein I Antibodies"", ""presence"": ""Positive""}"	{}	"{""evidence"": [{""explanation"": ""The abstract mentions the detection and study of anti-beta 2GPI antibodies, indicating their presence."", ""reference"": ""PMID:7795615"", ""snippet"": ""Anticardiolipin (aCL) and anti-beta 2-glycoprotein I(anti beta 2GPI) antibodies have been shown in animal models as not cross-reacting antibody populations."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study evaluates the frequency of APS including the presence of anti-beta 2 glycoprotein 1 antibodies, supporting their association with the syndrome."", ""reference"": ""PMID:25292011"", ""snippet"": ""abeta2 Gp1 (anti-betaeta-2 glycoprotein 1) antibody and LAC (lupus anticoagulant) of 1222 consecutive patients referred to the coagulation laboratory work-up for a hypercoagulable/thrombophilic state."", ""supports"": ""SUPPORT""}, {""explanation"": ""The connection between beta2-glycoprotein I antibodies and APS is clearly established in the context of the syndrome."", ""reference"": ""PMID:21046294"", ""snippet"": ""Although many antigens have been identified in relation to the antiphospholipid syndrome, beta2-glycoprotein I is regarded as clinically most significant."", ""supports"": ""SUPPORT""}, {""explanation"": ""The involvement of beta2-glycoprotein I antibodies in APS and their role in pathogenesis is discussed in detail."", ""reference"": ""PMID:28347805"", ""snippet"": ""β2-glycoprotein I is a phospholipid-binding glycoprotein, and its antibodies have been reported to correlate strongly with thrombotic risk and play putative role in the pathogenesis of APS, whereas the biofunctions of anti-β2-glycoprotein I antibodies remain largely uncertain"", ""supports"": ""SUPPORT""}], ""name"": ""Beta-2 Glycoprotein I Antibodies"", ""presence"": ""Positive""}"
577	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	biochemical	4	Anti-Smith Antibodies								Negative																																																	"{""name"": ""Anti-Smith Antibodies"", ""presence"": ""Negative""}"	{}	"{""evidence"": [{""explanation"": ""The study indicates that anti-Smith antibodies were not detected in the APS/SLE group, confirming that anti-Smith antibodies are negative in patients with APS."", ""reference"": ""PMID:24420722"", ""snippet"": ""anti-Smith (Sm) antibodies were not detected in both groups."", ""supports"": ""SUPPORT""}], ""name"": ""Anti-Smith Antibodies"", ""presence"": ""Negative""}"
619	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	biochemical	0	Serum Estrogen Levels					Diagnostic indicator			Decreased																																																	"{""context"": ""Diagnostic indicator"", ""name"": ""Serum Estrogen Levels"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Diagnostic indicator"", ""evidence"": [{""explanation"": ""The literature indicates that aromatase activity leads to increased estrogen levels during major illness, not decreased levels."", ""reference"": ""PMID:16670151"", ""snippet"": ""We conclude that the primary cause of increased estrogen levels in acute illness is increased aromatase P450 gene expression, resulting in enhanced aromatization of androgens to estrogens, a previously undescribed endocrine response to acute illness."", ""supports"": ""REFUTE""}, {""explanation"": ""While this reference discusses decreased aromatase activity in preeclampsia, it does not directly state that serum estrogen levels decrease specifically due to aromatase deficiency."", ""reference"": ""PMID:30213483"", ""snippet"": ""Preeclampsia appears to be characterized by specific steroidogenesis dysregulation long before PE diagnosis, highlighting potential new biomarkers of PE."", ""supports"": ""REFUTE""}], ""name"": ""Serum Estrogen Levels"", ""presence"": ""Decreased""}"
620	26	Aromatase Deficiency	Aromatase_Deficiency.yaml	biochemical	1	Serum Androgens								Elevated																																																	"{""name"": ""Serum Androgens"", ""presence"": ""Elevated""}"	{}	"{""evidence"": [{""explanation"": ""The literature states that aromatase deficiency, which causes estrogen synthesis impairment due to a mutation in the aromatase gene, leads to elevated serum androgens (testosterone)."", ""reference"": ""PMID:18448329"", ""snippet"": ""Human congenital estrogen deficiency, due to an inactivating mutation of the aromatase gene, leads to the lack of the estrogen synthesis, with gonadotropins and circulating testosterone ranging from normal to elevated."", ""supports"": ""SUPPORT""}], ""name"": ""Serum Androgens"", ""presence"": ""Elevated""}"
645	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	biochemical	0	Urinary Arsenic																																			Total urinary arsenic and speciated arsenic metabolites (inorganic arsenic, MMA, DMA) serve as biomarkers of recent exposure. The proportion of MMA correlates with cancer risk - individuals with higher %MMA have increased susceptibility.																						"{""name"": ""Urinary Arsenic"", ""notes"": ""Total urinary arsenic and speciated arsenic metabolites (inorganic arsenic, MMA, DMA) serve as biomarkers of recent exposure. The proportion of MMA correlates with cancer risk - individuals with higher %MMA have increased susceptibility.""}"	{}	"{""name"": ""Urinary Arsenic"", ""notes"": ""Total urinary arsenic and speciated arsenic metabolites (inorganic arsenic, MMA, DMA) serve as biomarkers of recent exposure. The proportion of MMA correlates with cancer risk - individuals with higher %MMA have increased susceptibility.""}"
646	27	Arsenic-Related Cancers	Arsenic_Related_Cancers.yaml	biochemical	1	Hair and Nail Arsenic																																			Arsenic concentrations in hair and nails reflect longer-term exposure (weeks to months) due to keratin binding. Used for exposure assessment in epidemiologic studies.																						"{""name"": ""Hair and Nail Arsenic"", ""notes"": ""Arsenic concentrations in hair and nails reflect longer-term exposure (weeks to months) due to keratin binding. Used for exposure assessment in epidemiologic studies.""}"	{}	"{""name"": ""Hair and Nail Arsenic"", ""notes"": ""Arsenic concentrations in hair and nails reflect longer-term exposure (weeks to months) due to keratin binding. Used for exposure assessment in epidemiologic studies.""}"
670	28	Asthma	Asthma.yaml	biochemical	0	Eosinophils					allergic asthma	Allergic Asthma		Elevated																																																	"{""context"": ""allergic asthma"", ""name"": ""Eosinophils"", ""presence"": ""Elevated"", ""subtype"": ""Allergic Asthma""}"	{}	"{""context"": ""allergic asthma"", ""evidence"": [{""explanation"": ""The reference supports that eosinophils are elevated in eosinophilic asthma, but does not specifically mention the allergic asthma subtype."", ""reference"": ""PMID:27401626"", ""snippet"": ""Asthma is a heterogeneous disease that can be classified into different clinical endotypes, depending on the type of airway inflammation, clinical severity, and response to treatment. This article focuses on the eosinophilic endotype of asthma, which is defined by the central role that eosinophils play in the pathophysiology of the condition."", ""supports"": ""PARTIAL""}, {""explanation"": ""The reference mentions a higher level of eosinophils in eosinophilic asthma, which can be associated with allergic asthma."", ""reference"": ""PMID:30303258"", ""snippet"": ""There was a significantly higher serum IL-33 level in the eosinophilic asthma group when compared to the group of non-eosinophilic asthma patients (1001.10 +/- 199.11 pg/mL vs 337.49 +/- 72.68 pg/mL, P < 0.01)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports elevated eosinophils but focuses on nonasthmatic adolescents rather than allergic asthma specifically."", ""reference"": ""PMID:31944632"", ""snippet"": ""Elevated FeNO in nonasthmatic adolescents was associated with airway hyperresponsiveness, elevated blood eosinophil counts, and lower systemic activation of neutrophils."", ""supports"": ""PARTIAL""}, {""explanation"": ""Although the statement is specific to severe asthma, it indicates elevated eosinophils which may also be relevant to allergic asthma."", ""reference"": ""PMID:36115752"", ""snippet"": ""Elevated total IgE concentrations and eosinophil counts are classic biological markers regularly found in severe asthma."", ""supports"": ""PARTIAL""}, {""explanation"": ""The reference supports the statement by linking allergic asthma with IgE, which is often associated with elevated eosinophils."", ""reference"": ""PMID:33479910"", ""snippet"": ""Asthmatic airway inflammation is initiated by inflammatory mediators released by granulocytic cells. However, the immunoglobulin E (IgE) antibody is necessary for the initiation of the allergic cascade, and IgE is produced and released exclusively by memory B cells and plasma cells."", ""supports"": ""SUPPORT""}], ""name"": ""Eosinophils"", ""presence"": ""Elevated"", ""subtype"": ""Allergic Asthma""}"
671	28	Asthma	Asthma.yaml	biochemical	1	Neutrophils					non-allergic asthma	Non-Allergic Asthma		Elevated																																																	"{""context"": ""non-allergic asthma"", ""name"": ""Neutrophils"", ""presence"": ""Elevated"", ""subtype"": ""Non-Allergic Asthma""}"	{}	"{""context"": ""non-allergic asthma"", ""evidence"": [{""explanation"": ""The document discusses neutrophilic asthma, a subtype of asthma characterized by elevated neutrophils, indicating that neutrophils are indeed elevated in some forms of asthma, including non-allergic ones."", ""reference"": ""PMID:33830849"", ""snippet"": ""Neutrophilic asthma is associated with poorer responses to classic therapies, namely (inhaled) corticosteroids."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the statement by indicating that refractory asthma, which often overlaps with non-allergic asthma, is associated with elevated neutrophils."", ""reference"": ""PMID:28163052"", ""snippet"": ""RA was associated with increased numbers of neutrophils and proneutrophilic biomolecules in the airways."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study highlights neutrophilic asthma, a type often linked with non-allergic inflammatory processes, which supports the elevation of neutrophils in such asthma subtypes."", ""reference"": ""PMID:36871881"", ""snippet"": ""Corticosteroid resistance, progressive lung function decline, and frequent asthma exacerbations are the hallmarks of neutrophilic asthma (NA)."", ""supports"": ""SUPPORT""}], ""name"": ""Neutrophils"", ""presence"": ""Elevated"", ""subtype"": ""Non-Allergic Asthma""}"
672	28	Asthma	Asthma.yaml	biochemical	2	IgE Antibodies					allergic reactions			Elevated																																																	"{""context"": ""allergic reactions"", ""name"": ""IgE Antibodies"", ""presence"": ""Elevated""}"	{}	"{""context"": ""allergic reactions"", ""evidence"": [{""explanation"": ""The text indicates that IgE antibodies are necessary for the allergic cascade in asthma and are elevated after acute allergen exposure."", ""reference"": ""PMID:33479910"", ""snippet"": ""However, the immunoglobulin E (IgE) antibody is necessary for the initiation of the allergic cascade, and IgE is produced and released exclusively by memory B cells and plasma cells. Acute allergen exposure has also been shown to increase IgE levels in the airways of patients diagnosed with allergic asthma."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference mentions higher levels of IgE are common in patients with asthma and aeroallergen sensitization."", ""reference"": ""PMID:20406591"", ""snippet"": ""As many as 90-95% of patients with asthma have aeroallergen sensitization and the pattern varies with ethnicity, location of residence, and onset of asthma, but not age."", ""supports"": ""SUPPORT""}, {""explanation"": ""Elevated IgE antibodies play a role in chronic asthma and identifying relevant allergens, supporting the statement."", ""reference"": ""PMID:27264001"", ""snippet"": ""However, there are syndromes in which the relationship between exposure to the relevant allergen and the 'allergic' disease is not clear. In these cases the presence of specific IgE antibodies can play an important role in identifying the relevant allergen and provide a guide to therapy. Good examples include chronic asthma and exposure to perennial indoor allergens and asthma related to fungal infection."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports the use of IgE as a biomarker in asthma, indicating its elevated presence in the condition."", ""reference"": ""PMID:30342581"", ""snippet"": ""Using IgE as a biomarker for asthma provides a target for management and treatment."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference defines atopy in terms of elevated IgE production in response to allergens, which is relevant to allergic asthma."", ""reference"": ""PMID:16462678"", ""snippet"": ""Atopy is defined by abnormal IgE production in response to an allergen (an antigen that is then designated an allergen)."", ""supports"": ""SUPPORT""}], ""name"": ""IgE Antibodies"", ""presence"": ""Elevated""}"
766	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	biochemical	0	Direct Antiglobulin Test (DAT)					Diagnostic; IgG and/or C3d positive			Positive																																																	"{""context"": ""Diagnostic; IgG and/or C3d positive"", ""name"": ""Direct Antiglobulin Test (DAT)"", ""presence"": ""Positive""}"	{}	"{""context"": ""Diagnostic; IgG and/or C3d positive"", ""name"": ""Direct Antiglobulin Test (DAT)"", ""presence"": ""Positive""}"
767	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	biochemical	1	Reticulocytes					Compensatory marrow response			Elevated																																																	"{""context"": ""Compensatory marrow response"", ""name"": ""Reticulocytes"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Compensatory marrow response"", ""name"": ""Reticulocytes"", ""presence"": ""Elevated""}"
768	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	biochemical	2	LDH					Marker of hemolysis			Elevated																																																	"{""context"": ""Marker of hemolysis"", ""name"": ""LDH"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Marker of hemolysis"", ""name"": ""LDH"", ""presence"": ""Elevated""}"
769	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	biochemical	3	Haptoglobin					Consumed by free hemoglobin			Decreased																																																	"{""context"": ""Consumed by free hemoglobin"", ""name"": ""Haptoglobin"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Consumed by free hemoglobin"", ""name"": ""Haptoglobin"", ""presence"": ""Decreased""}"
770	31	Autoimmune Hemolytic Anemia	Autoimmune_Hemolytic_Anemia.yaml	biochemical	4	Indirect Bilirubin					From RBC breakdown			Elevated																																																	"{""context"": ""From RBC breakdown"", ""name"": ""Indirect Bilirubin"", ""presence"": ""Elevated""}"	{}	"{""context"": ""From RBC breakdown"", ""name"": ""Indirect Bilirubin"", ""presence"": ""Elevated""}"
782	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	biochemical	0	ANA					Type 1 AIH			Elevated																																																	"{""context"": ""Type 1 AIH"", ""name"": ""ANA"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Type 1 AIH"", ""name"": ""ANA"", ""presence"": ""Elevated""}"
783	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	biochemical	1	Anti-Smooth Muscle Antibodies (SMA)					Type 1 AIH			Elevated																																																	"{""context"": ""Type 1 AIH"", ""name"": ""Anti-Smooth Muscle Antibodies (SMA)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Type 1 AIH"", ""name"": ""Anti-Smooth Muscle Antibodies (SMA)"", ""presence"": ""Elevated""}"
784	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	biochemical	2	Anti-LKM1 Antibodies					Type 2 AIH			Elevated																																																	"{""context"": ""Type 2 AIH"", ""name"": ""Anti-LKM1 Antibodies"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Type 2 AIH"", ""name"": ""Anti-LKM1 Antibodies"", ""presence"": ""Elevated""}"
785	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	biochemical	3	IgG					Hypergammaglobulinemia characteristic			Elevated																																																	"{""context"": ""Hypergammaglobulinemia characteristic"", ""name"": ""IgG"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Hypergammaglobulinemia characteristic"", ""name"": ""IgG"", ""presence"": ""Elevated""}"
786	32	Autoimmune Hepatitis	Autoimmune_Hepatitis.yaml	biochemical	4	ALT/AST					Hepatocellular injury pattern			Elevated																																																	"{""context"": ""Hepatocellular injury pattern"", ""name"": ""ALT/AST"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Hepatocellular injury pattern"", ""name"": ""ALT/AST"", ""presence"": ""Elevated""}"
829	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	biochemical	0	Thyroglobulin																																			Serum thyroglobulin is the primary tumor marker for differentiated thyroid cancer after thyroidectomy. May be less reliable in BRAF-mutant tumors due to dedifferentiation.																						"{""name"": ""Thyroglobulin"", ""notes"": ""Serum thyroglobulin is the primary tumor marker for differentiated thyroid cancer after thyroidectomy. May be less reliable in BRAF-mutant tumors due to dedifferentiation.""}"	{}	"{""name"": ""Thyroglobulin"", ""notes"": ""Serum thyroglobulin is the primary tumor marker for differentiated thyroid cancer after thyroidectomy. May be less reliable in BRAF-mutant tumors due to dedifferentiation.""}"
830	34	BRAF-Mutant Papillary Thyroid Cancer	BRAF_Mutant_Thyroid_Cancer.yaml	biochemical	1	BRAF V600E Mutation Testing																																			BRAF mutation testing by PCR or next-generation sequencing is standard. Positive results inform prognosis and eligibility for targeted therapy in radioiodine-refractory disease.																						"{""name"": ""BRAF V600E Mutation Testing"", ""notes"": ""BRAF mutation testing by PCR or next-generation sequencing is standard. Positive results inform prognosis and eligibility for targeted therapy in radioiodine-refractory disease.""}"	{}	"{""name"": ""BRAF V600E Mutation Testing"", ""notes"": ""BRAF mutation testing by PCR or next-generation sequencing is standard. Positive results inform prognosis and eligibility for targeted therapy in radioiodine-refractory disease.""}"
845	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	biochemical	0	BRAF V600E Mutation Detection																																			BRAF V600E mutation is detected by PCR, immunohistochemistry (VE1 antibody), or next-generation sequencing. Testing should be performed on all metastatic CRC to guide treatment selection.																						"{""name"": ""BRAF V600E Mutation Detection"", ""notes"": ""BRAF V600E mutation is detected by PCR, immunohistochemistry (VE1 antibody), or next-generation sequencing. Testing should be performed on all metastatic CRC to guide treatment selection.""}"	{}	"{""name"": ""BRAF V600E Mutation Detection"", ""notes"": ""BRAF V600E mutation is detected by PCR, immunohistochemistry (VE1 antibody), or next-generation sequencing. Testing should be performed on all metastatic CRC to guide treatment selection.""}"
846	35	BRAF V600E-Mutant Colorectal Cancer	BRAF_V600E_Mutant_Colorectal_Cancer.yaml	biochemical	1	MSI/MMR Testing																																			All BRAF V600E tumors should be tested for MSI/MMR status as MSI-H BRAF-mutant tumors have better prognosis and respond to immunotherapy. MSS BRAF-mutant tumors require targeted therapy approaches.																						"{""name"": ""MSI/MMR Testing"", ""notes"": ""All BRAF V600E tumors should be tested for MSI/MMR status as MSI-H BRAF-mutant tumors have better prognosis and respond to immunotherapy. MSS BRAF-mutant tumors require targeted therapy approaches.""}"	{}	"{""name"": ""MSI/MMR Testing"", ""notes"": ""All BRAF V600E tumors should be tested for MSI/MMR status as MSI-H BRAF-mutant tumors have better prognosis and respond to immunotherapy. MSS BRAF-mutant tumors require targeted therapy approaches.""}"
866	36	BRAF V600E-Mutant Non-Small Cell Lung Cancer	BRAF_V600E_Mutant_NSCLC.yaml	biochemical	0	BRAF Mutation Testing																																			BRAF testing is part of standard molecular profiling for advanced NSCLC. Testing should distinguish V600E from non-V600 mutations as treatment implications differ. V600E accounts for ~50% of BRAF mutations in NSCLC. Non-V600 mutations (class II: K601E, G469A; class III: G466V, D594G) are not responsive to V600E-targeted therapies.																						"{""name"": ""BRAF Mutation Testing"", ""notes"": ""BRAF testing is part of standard molecular profiling for advanced NSCLC. Testing should distinguish V600E from non-V600 mutations as treatment implications differ. V600E accounts for ~50% of BRAF mutations in NSCLC. Non-V600 mutations (class II: K601E, G469A; class III: G466V, D594G) are not responsive to V600E-targeted therapies.""}"	{}	"{""name"": ""BRAF Mutation Testing"", ""notes"": ""BRAF testing is part of standard molecular profiling for advanced NSCLC. Testing should distinguish V600E from non-V600 mutations as treatment implications differ. V600E accounts for ~50% of BRAF mutations in NSCLC. Non-V600 mutations (class II: K601E, G469A; class III: G466V, D594G) are not responsive to V600E-targeted therapies.""}"
897	38	BRCA-Mutant Prostate Cancer	BRCA_Mutant_Prostate_Cancer.yaml	biochemical	0	PSA (Prostate-Specific Antigen)																																			PSA is the primary biomarker for prostate cancer detection and monitoring. BRCA-mutant tumors may have higher PSA levels at diagnosis reflecting more aggressive biology.																						"{""name"": ""PSA (Prostate-Specific Antigen)"", ""notes"": ""PSA is the primary biomarker for prostate cancer detection and monitoring. BRCA-mutant tumors may have higher PSA levels at diagnosis reflecting more aggressive biology.""}"	{}	"{""name"": ""PSA (Prostate-Specific Antigen)"", ""notes"": ""PSA is the primary biomarker for prostate cancer detection and monitoring. BRCA-mutant tumors may have higher PSA levels at diagnosis reflecting more aggressive biology.""}"
967	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	biochemical	0	Elevated Serum Leptin																																			Often found in patients with Bardet-Biedl syndrome.																						"{""name"": ""Elevated Serum Leptin"", ""notes"": ""Often found in patients with Bardet-Biedl syndrome.""}"	{}	"{""evidence"": [{""explanation"": ""The article discusses how loss of BBS genes results in leptin resistance due to abnormal leptin receptor handling, pointing towards elevated serum leptin."", ""reference"": ""PMID:21514177"", ""snippet"": ""Bardet-Biedl Syndrome (BBS) is a rare human hereditary disorder associated with several features including obesity... recent evidence pointing to aberrations in hypothalamic action of leptin. Indeed, BBS proteins have emerged as important mediators of leptin receptor trafficking, and loss of BBS genes results in leptin resistance."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference mentions that Bardet-Biedl Syndrome is a ciliopathy with mechanisms converging on the leptin pathway, suggesting a role for leptin in the syndrome."", ""reference"": ""PMID:37919024"", ""snippet"": ""Additional therapies, including metreleptin and setmelanotide, that target defects within the leptin signaling pathway can effectively synergize with lifestyle efforts to treat monogenic disorders of leptin, leptin receptor, proopiomelanocortin (POMC), and proprotein convertase subtilisin/kexin type 1 (PCSK1) and syndromic conditions, such as the ciliopathies Bardet-Biedl and Alström syndromes, whose pathophysiological mechanisms also converge on the leptin pathway"", ""supports"": ""SUPPORT""}], ""name"": ""Elevated Serum Leptin"", ""notes"": ""Often found in patients with Bardet-Biedl syndrome.""}"
1024	42	Behcet's Disease	Behcets_Disease.yaml	biochemical	0	ESR					During active disease			Elevated																																																	"{""context"": ""During active disease"", ""name"": ""ESR"", ""presence"": ""Elevated""}"	{}	"{""context"": ""During active disease"", ""name"": ""ESR"", ""presence"": ""Elevated""}"
1025	42	Behcet's Disease	Behcets_Disease.yaml	biochemical	1	CRP					Inflammation marker			Elevated																																																	"{""context"": ""Inflammation marker"", ""name"": ""CRP"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Inflammation marker"", ""name"": ""CRP"", ""presence"": ""Elevated""}"
1045	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	biochemical	0	PSA					May be mildly elevated in BPH			Variable																																																	"{""context"": ""May be mildly elevated in BPH"", ""name"": ""PSA"", ""presence"": ""Variable""}"	{}	"{""context"": ""May be mildly elevated in BPH"", ""name"": ""PSA"", ""presence"": ""Variable""}"
1046	44	Benign Prostatic Hyperplasia	Benign_Prostatic_Hyperplasia.yaml	biochemical	1	Testosterone					Serum testosterone usually normal			Normal																																																	"{""context"": ""Serum testosterone usually normal"", ""name"": ""Testosterone"", ""presence"": ""Normal""}"	{}	"{""context"": ""Serum testosterone usually normal"", ""name"": ""Testosterone"", ""presence"": ""Normal""}"
1080	45	Beta Mannosidosis	Beta_Mannosidosis.yaml	biochemical	0	Urinary free oligosaccharides					Diagnostic biomarker			Elevated																											"Accumulated oligosaccharides including Man-GlcNAc disaccharide and sialylated derivatives are detected in urine. Modern UPLC-MS/MS allows multiplexed detection for glycoproteinoses.
"																						"{""context"": ""Diagnostic biomarker"", ""name"": ""Urinary free oligosaccharides"", ""notes"": ""Accumulated oligosaccharides including Man-GlcNAc disaccharide and sialylated derivatives are detected in urine. Modern UPLC-MS/MS allows multiplexed detection for glycoproteinoses.\n"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Diagnostic biomarker"", ""name"": ""Urinary free oligosaccharides"", ""notes"": ""Accumulated oligosaccharides including Man-GlcNAc disaccharide and sialylated derivatives are detected in urine. Modern UPLC-MS/MS allows multiplexed detection for glycoproteinoses.\n"", ""presence"": ""Elevated""}"
1081	45	Beta Mannosidosis	Beta_Mannosidosis.yaml	biochemical	1	Beta-mannosidase activity					Diagnostic enzymatic assay			Reduced																											"Affected individuals exhibit enzyme activities ranging from undetectable up to 2-10% of normal controls. Carriers may show approximately 40% activity.
"																						"{""context"": ""Diagnostic enzymatic assay"", ""name"": ""Beta-mannosidase activity"", ""notes"": ""Affected individuals exhibit enzyme activities ranging from undetectable up to 2-10% of normal controls. Carriers may show approximately 40% activity.\n"", ""presence"": ""Reduced""}"	{}	"{""context"": ""Diagnostic enzymatic assay"", ""name"": ""Beta-mannosidase activity"", ""notes"": ""Affected individuals exhibit enzyme activities ranging from undetectable up to 2-10% of normal controls. Carriers may show approximately 40% activity.\n"", ""presence"": ""Reduced""}"
1089	46	Bipolar Disorder	Bipolar_Disorder.yaml	biochemical	0	BDNF					Reduced in both manic and depressive episodes			Decreased																																																	"{""context"": ""Reduced in both manic and depressive episodes"", ""name"": ""BDNF"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Reduced in both manic and depressive episodes"", ""name"": ""BDNF"", ""presence"": ""Decreased""}"
1090	46	Bipolar Disorder	Bipolar_Disorder.yaml	biochemical	1	Cortisol					HPA axis dysregulation			Elevated																																																	"{""context"": ""HPA axis dysregulation"", ""name"": ""Cortisol"", ""presence"": ""Elevated""}"	{}	"{""context"": ""HPA axis dysregulation"", ""name"": ""Cortisol"", ""presence"": ""Elevated""}"
1091	46	Bipolar Disorder	Bipolar_Disorder.yaml	biochemical	2	Inflammatory Markers					IL-6, TNF-alpha during episodes			Elevated																																																	"{""context"": ""IL-6, TNF-alpha during episodes"", ""name"": ""Inflammatory Markers"", ""presence"": ""Elevated""}"	{}	"{""context"": ""IL-6, TNF-alpha during episodes"", ""name"": ""Inflammatory Markers"", ""presence"": ""Elevated""}"
1123	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	biochemical	0	Bird antigen-specific IgG/IgA antibodies								Positive																											Elevated serum IgG/IgA antibodies to bird antigens in bird-related hypersensitivity pneumonitis.																						"{""name"": ""Bird antigen-specific IgG/IgA antibodies"", ""notes"": ""Elevated serum IgG/IgA antibodies to bird antigens in bird-related hypersensitivity pneumonitis."", ""presence"": ""Positive""}"	{}	"{""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Elevated bird-specific antibodies are reported in affected patients."", ""reference"": ""PMID:33041192"", ""snippet"": ""The levels of sIgG/sIgA against the bird antigens of the three species were significantly higher in subjects with acute bird-related HP and chronic bird-related HP with acute episodes (recurrent type) than in the control subjects."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The study uses serial bird-specific IgG testing against pigeon serum in fibrotic avian HP."", ""reference"": ""PMID:38762468"", ""snippet"": ""Serum IgG testing against pigeon serum was conducted twice using two methods: enzyme linked-immunosorbent assay (ELISA) and ImmunoCAP."", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Anti-pigeon IgG titers are higher in bird-related fibrotic HP, supporting serologic evidence for avian antigen exposure."", ""reference"": ""PMID:40049235"", ""snippet"": ""The mean titers of anti-pigeon IgG antibody by ELISA were 0.659 ± 0.381 and 0.494 ± 0.187 in the bird-related fibrotic HP and control groups, respectively (p = 0.012)."", ""supports"": ""SUPPORT""}], ""name"": ""Bird antigen-specific IgG/IgA antibodies"", ""notes"": ""Elevated serum IgG/IgA antibodies to bird antigens in bird-related hypersensitivity pneumonitis."", ""presence"": ""Positive""}"
1180	50	Bronchiectasis	Bronchiectasis.yaml	biochemical	0	C-Reactive Protein (CRP)					Indicates active inflammation and infection			Elevated																																																	"{""context"": ""Indicates active inflammation and infection"", ""name"": ""C-Reactive Protein (CRP)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Indicates active inflammation and infection"", ""name"": ""C-Reactive Protein (CRP)"", ""presence"": ""Elevated""}"
1181	50	Bronchiectasis	Bronchiectasis.yaml	biochemical	1	Sputum Culture					Identification of pathogenic organisms			Positive																																																	"{""context"": ""Identification of pathogenic organisms"", ""name"": ""Sputum Culture"", ""presence"": ""Positive""}"	{}	"{""context"": ""Identification of pathogenic organisms"", ""name"": ""Sputum Culture"", ""presence"": ""Positive""}"
1182	50	Bronchiectasis	Bronchiectasis.yaml	biochemical	2	Neutrophil Elastase (NE)					High sputum NE activity associates with severe bronchiectasis, exacerbation risk, airway bacterial load, and disease progression; mechanistic biomarker of neutrophil-driven inflammation			Elevated																																																	"{""context"": ""High sputum NE activity associates with severe bronchiectasis, exacerbation risk, airway bacterial load, and disease progression; mechanistic biomarker of neutrophil-driven inflammation"", ""name"": ""Neutrophil Elastase (NE)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""High sputum NE activity associates with severe bronchiectasis, exacerbation risk, airway bacterial load, and disease progression; mechanistic biomarker of neutrophil-driven inflammation"", ""name"": ""Neutrophil Elastase (NE)"", ""presence"": ""Elevated""}"
1183	50	Bronchiectasis	Bronchiectasis.yaml	biochemical	3	Interleukin-1 beta (IL-1beta)					Subset of patients with high airway IL-1beta show severe disease, mucus hyperconcentration, impaired ciliary function, and Proteobacteria-enriched microbiome			Elevated																																																	"{""context"": ""Subset of patients with high airway IL-1beta show severe disease, mucus hyperconcentration, impaired ciliary function, and Proteobacteria-enriched microbiome"", ""name"": ""Interleukin-1 beta (IL-1beta)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Subset of patients with high airway IL-1beta show severe disease, mucus hyperconcentration, impaired ciliary function, and Proteobacteria-enriched microbiome"", ""name"": ""Interleukin-1 beta (IL-1beta)"", ""presence"": ""Elevated""}"
1184	50	Bronchiectasis	Bronchiectasis.yaml	biochemical	4	Neutrophil Extracellular Traps (NETs)					NET complexes in sputum associate with higher disease severity, exacerbations, and mortality; include MPO, NE, resistin, and azurocidin			Elevated																																																	"{""context"": ""NET complexes in sputum associate with higher disease severity, exacerbations, and mortality; include MPO, NE, resistin, and azurocidin"", ""name"": ""Neutrophil Extracellular Traps (NETs)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""NET complexes in sputum associate with higher disease severity, exacerbations, and mortality; include MPO, NE, resistin, and azurocidin"", ""name"": ""Neutrophil Extracellular Traps (NETs)"", ""presence"": ""Elevated""}"
1215	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	biochemical	0	Elevated Lactate Dehydrogenase (LDH)																																			LDH is markedly elevated reflecting high tumor cell turnover. Serves as important prognostic marker and indicator of tumor burden.																						"{""name"": ""Elevated Lactate Dehydrogenase (LDH)"", ""notes"": ""LDH is markedly elevated reflecting high tumor cell turnover. Serves as important prognostic marker and indicator of tumor burden.""}"	{}	"{""name"": ""Elevated Lactate Dehydrogenase (LDH)"", ""notes"": ""LDH is markedly elevated reflecting high tumor cell turnover. Serves as important prognostic marker and indicator of tumor burden.""}"
1216	51	Burkitt Lymphoma	Burkitt_Lymphoma.yaml	biochemical	1	Uric Acid Elevation																																			Hyperuricemia from rapid cell turnover. Risk of tumor lysis syndrome is high and requires prophylaxis with allopurinol or rasburicase.																						"{""name"": ""Uric Acid Elevation"", ""notes"": ""Hyperuricemia from rapid cell turnover. Risk of tumor lysis syndrome is high and requires prophylaxis with allopurinol or rasburicase.""}"	{}	"{""name"": ""Uric Acid Elevation"", ""notes"": ""Hyperuricemia from rapid cell turnover. Risk of tumor lysis syndrome is high and requires prophylaxis with allopurinol or rasburicase.""}"
1333	57	Celiac Disease	Celiac_Disease.yaml	biochemical	0	Anti-tTG IgA					Primary diagnostic marker			Elevated																																																	"{""context"": ""Primary diagnostic marker"", ""name"": ""Anti-tTG IgA"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Primary diagnostic marker"", ""name"": ""Anti-tTG IgA"", ""presence"": ""Elevated""}"
1334	57	Celiac Disease	Celiac_Disease.yaml	biochemical	1	Anti-Endomysial Antibodies					Highly specific			Elevated																																																	"{""context"": ""Highly specific"", ""name"": ""Anti-Endomysial Antibodies"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Highly specific"", ""name"": ""Anti-Endomysial Antibodies"", ""presence"": ""Elevated""}"
1335	57	Celiac Disease	Celiac_Disease.yaml	biochemical	2	Anti-DGP Antibodies					Useful when IgA deficient			Elevated																																																	"{""context"": ""Useful when IgA deficient"", ""name"": ""Anti-DGP Antibodies"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Useful when IgA deficient"", ""name"": ""Anti-DGP Antibodies"", ""presence"": ""Elevated""}"
1336	57	Celiac Disease	Celiac_Disease.yaml	biochemical	3	Total IgA					IgA deficiency common in celiac			Variable																																																	"{""context"": ""IgA deficiency common in celiac"", ""name"": ""Total IgA"", ""presence"": ""Variable""}"	{}	"{""context"": ""IgA deficiency common in celiac"", ""name"": ""Total IgA"", ""presence"": ""Variable""}"
1362	58	Cervical Cancer	Cervical_Cancer.yaml	biochemical	0	HPV DNA Testing																																			Detection of high-risk HPV DNA by PCR or hybrid capture is more sensitive than cytology for detecting high-grade lesions. HPV testing is increasingly used as primary screening in cervical cancer prevention programs.																						"{""name"": ""HPV DNA Testing"", ""notes"": ""Detection of high-risk HPV DNA by PCR or hybrid capture is more sensitive than cytology for detecting high-grade lesions. HPV testing is increasingly used as primary screening in cervical cancer prevention programs.""}"	{}	"{""name"": ""HPV DNA Testing"", ""notes"": ""Detection of high-risk HPV DNA by PCR or hybrid capture is more sensitive than cytology for detecting high-grade lesions. HPV testing is increasingly used as primary screening in cervical cancer prevention programs.""}"
1363	58	Cervical Cancer	Cervical_Cancer.yaml	biochemical	1	p16 Immunohistochemistry																																			Overexpression of p16INK4a is a surrogate marker for HPV E7 activity, as E7-mediated pRB inactivation causes compensatory p16 upregulation. Diffuse block-positive p16 staining helps confirm HPV-related high-grade lesions.																						"{""name"": ""p16 Immunohistochemistry"", ""notes"": ""Overexpression of p16INK4a is a surrogate marker for HPV E7 activity, as E7-mediated pRB inactivation causes compensatory p16 upregulation. Diffuse block-positive p16 staining helps confirm HPV-related high-grade lesions.""}"	{}	"{""name"": ""p16 Immunohistochemistry"", ""notes"": ""Overexpression of p16INK4a is a surrogate marker for HPV E7 activity, as E7-mediated pRB inactivation causes compensatory p16 upregulation. Diffuse block-positive p16 staining helps confirm HPV-related high-grade lesions.""}"
1396	61	Cholera	Cholera.yaml	biochemical	0	Electrolytes					Due to excessive loss in diarrhea			Low Sodium, Potassium, and Bicarbonate Levels																																																	"{""context"": ""Due to excessive loss in diarrhea"", ""name"": ""Electrolytes"", ""presence"": ""Low Sodium, Potassium, and Bicarbonate Levels""}"	{}	"{""context"": ""Due to excessive loss in diarrhea"", ""evidence"": [{""explanation"": ""The article suggests the need to correct potassium losses and acidosis, which supports low potassium and bicarbonate levels, but there is no specific mention of sodium levels."", ""reference"": ""PMID:28957470"", ""snippet"": ""Emergency life-saving therapy is i.v. saline, optionally supplemented with potassium and alkali to correct the fluid deficit, potassium losses and acidosis."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference discusses bicarbonate losses due to diarrhea, supporting low bicarbonate levels but does not provide direct evidence for sodium and potassium levels."", ""reference"": ""PMID:15367740"", ""snippet"": ""Despite large losses of bicarbonate (HCO3-)-containing diarrhoeal fluid, laboratory acid-base values were remarkably close to normal."", ""supports"": ""PARTIAL""}, {""explanation"": ""The study reports hypokalemia in cholera patients, which supports low potassium levels, but it doesn't provide information about sodium and bicarbonate levels."", ""reference"": ""PMID:5300879"", ""snippet"": ""Hypokalaemic patterns were seen in 40% of the cases in the acute stage (during rehydration)."", ""supports"": ""PARTIAL""}, {""explanation"": ""This reference describes the clinical presentation of cholera but does not provide direct evidence on the levels of sodium, potassium, or bicarbonate."", ""reference"": ""PMID:24952048"", ""snippet"": ""Vibrio cholerae...produces an enterotoxin, which causes an acute-onset diarrheal disease ranging in severity from mild to life-threatening."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This reference mentions hyponatremia and hypokalemia, supporting low sodium and potassium levels, but it is in the context of cirrhotic patients, not cholera."", ""reference"": ""PMID:28608260"", ""snippet"": ""Hyponatremia, hypokalemia, hyperkalemia...are the main internal milieu alterations in this group."", ""supports"": ""PARTIAL""}], ""name"": ""Electrolytes"", ""presence"": ""Low Sodium, Potassium, and Bicarbonate Levels""}"
1470	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	biochemical	0	CSF Protein					Without pleocytosis			Elevated																																																	"{""context"": ""Without pleocytosis"", ""name"": ""CSF Protein"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Without pleocytosis"", ""name"": ""CSF Protein"", ""presence"": ""Elevated""}"
1471	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	biochemical	1	Anti-Neurofascin Antibodies					Associated with specific CIDP subtype			Variable																																																	"{""context"": ""Associated with specific CIDP subtype"", ""name"": ""Anti-Neurofascin Antibodies"", ""presence"": ""Variable""}"	{}	"{""context"": ""Associated with specific CIDP subtype"", ""name"": ""Anti-Neurofascin Antibodies"", ""presence"": ""Variable""}"
1472	63	Chronic Inflammatory Demyelinating Polyneuropathy	Chronic_Inflammatory_Demyelinating_Polyneuropathy.yaml	biochemical	2	Anti-Contactin-1 Antibodies					Associated with specific CIDP subtype			Variable																																																	"{""context"": ""Associated with specific CIDP subtype"", ""name"": ""Anti-Contactin-1 Antibodies"", ""presence"": ""Variable""}"	{}	"{""context"": ""Associated with specific CIDP subtype"", ""name"": ""Anti-Contactin-1 Antibodies"", ""presence"": ""Variable""}"
1484	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	biochemical	0	Creatinine					Reflects decreased filtration			Elevated																																																	"{""context"": ""Reflects decreased filtration"", ""name"": ""Creatinine"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Reflects decreased filtration"", ""name"": ""Creatinine"", ""presence"": ""Elevated""}"
1485	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	biochemical	1	Blood Urea Nitrogen					Uremic toxin accumulation			Elevated																																																	"{""context"": ""Uremic toxin accumulation"", ""name"": ""Blood Urea Nitrogen"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Uremic toxin accumulation"", ""name"": ""Blood Urea Nitrogen"", ""presence"": ""Elevated""}"
1486	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	biochemical	2	Phosphate					Impaired excretion			Elevated																																																	"{""context"": ""Impaired excretion"", ""name"": ""Phosphate"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Impaired excretion"", ""name"": ""Phosphate"", ""presence"": ""Elevated""}"
1487	64	Chronic Kidney Disease	Chronic_Kidney_Disease.yaml	biochemical	3	PTH					Secondary hyperparathyroidism			Elevated																																																	"{""context"": ""Secondary hyperparathyroidism"", ""name"": ""PTH"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Secondary hyperparathyroidism"", ""name"": ""PTH"", ""presence"": ""Elevated""}"
1518	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	biochemical	0	Flow Cytometry Immunophenotyping																																			CLL cells are CD5+, CD19+, CD23+, CD20 dim, surface Ig dim. The characteristic immunophenotype distinguishes CLL from other B-cell lymphomas and mantle cell lymphoma (CD5+ but CD23-).																						"{""name"": ""Flow Cytometry Immunophenotyping"", ""notes"": ""CLL cells are CD5+, CD19+, CD23+, CD20 dim, surface Ig dim. The characteristic immunophenotype distinguishes CLL from other B-cell lymphomas and mantle cell lymphoma (CD5+ but CD23-).""}"	{}	"{""name"": ""Flow Cytometry Immunophenotyping"", ""notes"": ""CLL cells are CD5+, CD19+, CD23+, CD20 dim, surface Ig dim. The characteristic immunophenotype distinguishes CLL from other B-cell lymphomas and mantle cell lymphoma (CD5+ but CD23-).""}"
1519	65	Chronic Lymphocytic Leukemia	Chronic_Lymphocytic_Leukemia.yaml	biochemical	1	IGHV Mutation Analysis																																			Sequencing of immunoglobulin heavy chain variable region determines mutational status. Mutated IGHV (at least 2% difference from germline) indicates favorable prognosis.																						"{""name"": ""IGHV Mutation Analysis"", ""notes"": ""Sequencing of immunoglobulin heavy chain variable region determines mutational status. Mutated IGHV (at least 2% difference from germline) indicates favorable prognosis.""}"	{}	"{""name"": ""IGHV Mutation Analysis"", ""notes"": ""Sequencing of immunoglobulin heavy chain variable region determines mutational status. Mutated IGHV (at least 2% difference from germline) indicates favorable prognosis.""}"
1546	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	biochemical	0	Philadelphia Chromosome Detection																																			Cytogenetic analysis reveals t(9;22)(q34;q11) translocation creating the Philadelphia chromosome in 95% of CML cases.																						"{""name"": ""Philadelphia Chromosome Detection"", ""notes"": ""Cytogenetic analysis reveals t(9;22)(q34;q11) translocation creating the Philadelphia chromosome in 95% of CML cases.""}"	{}	"{""name"": ""Philadelphia Chromosome Detection"", ""notes"": ""Cytogenetic analysis reveals t(9;22)(q34;q11) translocation creating the Philadelphia chromosome in 95% of CML cases.""}"
1547	66	Chronic Myeloid Leukemia, BCR-ABL1 Positive	Chronic_Myeloid_Leukemia.yaml	biochemical	1	BCR-ABL1 Fusion Transcript																																			RT-PCR or FISH detection of BCR-ABL1 fusion is diagnostic and used for monitoring molecular response to therapy.																						"{""name"": ""BCR-ABL1 Fusion Transcript"", ""notes"": ""RT-PCR or FISH detection of BCR-ABL1 fusion is diagnostic and used for monitoring molecular response to therapy.""}"	{}	"{""biomarker_term"": {""preferred_term"": ""BCR-ABL1 fusion protein"", ""term"": {""id"": ""NCIT:C36715"", ""label"": ""BCR-ABL1 Fusion Protein Expression""}}, ""name"": ""BCR-ABL1 Fusion Transcript"", ""notes"": ""RT-PCR or FISH detection of BCR-ABL1 fusion is diagnostic and used for monitoring molecular response to therapy.""}"
1570	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	biochemical	0	Arterial Blood Gases								Altered																											May show hypoxemia and hypercapnia.																						"{""name"": ""Arterial Blood Gases"", ""notes"": ""May show hypoxemia and hypercapnia."", ""presence"": ""Altered""}"	{}	"{""evidence"": [{""explanation"": ""The study confirms that COPD patients may show hypoxemia and hypercapnia, but it focuses on the predictors rather than just the presence of these conditions."", ""reference"": ""PMID:21812941"", ""snippet"": ""The aim of this study was to identify predictors of hypoxemia, hypercapnia and increased alveolar-arterial oxygen difference in COPD patients."", ""supports"": ""PARTIAL""}, {""explanation"": ""The study discusses the occurrence of hypoxia and hypercapnia in specific exposure situations, including COPD contexts."", ""reference"": ""PMID:34756790"", ""snippet"": ""Respiratory acidosis with hypoxia, hypercapnia, a compensatory metabolic response, and mild hyperfibrinolysis were probably related to the combined effect of nitrogen compounds and the inhaled toxic products of detonation."", ""supports"": ""SUPPORT""}, {""explanation"": ""While this does not directly confirm hypoxemia and hypercapnia, it suggests the necessity of oxygen therapy for COPD patients, implying altered arterial blood gases."", ""reference"": ""PMID:25119324"", ""snippet"": ""The prevalence of this sampling method has grown among health professionals, coupled with a growing demand for domiciliary oxygen therapy in the UK, in particular for those who have chronic obstructive pulmonary disease (COPD)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference strongly supports the statement by highlighting altered arterial blood gases in COPD due to hypoventilation during sleep."", ""reference"": ""PMID:18044093"", ""snippet"": ""Patients with COPD may show slow, progressive deteriorations in arterial blood gases during the night, particularly during rapid eye movement (REM) sleep. This is mainly due to hypoventilation... The severity of gas exchanges alterations is proportional to the degree of impairment of diurnal pulmonary function tests, particularly of partial pressure of oxygen (PaO2) and of carbon dioxide (PaCO2) in arterial blood..."", ""supports"": ""SUPPORT""}], ""name"": ""Arterial Blood Gases"", ""notes"": ""May show hypoxemia and hypercapnia."", ""presence"": ""Altered""}"
1571	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	biochemical	1	C-Reactive Protein (CRP)					General inflammation and exacerbations.			Elevated																																																	"{""context"": ""General inflammation and exacerbations."", ""name"": ""C-Reactive Protein (CRP)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""General inflammation and exacerbations."", ""evidence"": [{""explanation"": ""This meta-analysis suggests that patients with stable COPD had higher serum CRP concentrations than healthy controls, indicating elevated CRP in general inflammation related to COPD."", ""reference"": ""PMID:23206444"", ""snippet"": ""Patients with COPD had higher serum CRP concentrations than healthy controls (WMD 4.72 mg/l, 95% CI 2.98, 6.47)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study identifies CRP as an important biomarker in COPD exacerbations, indicating its elevation in such contexts."", ""reference"": ""PMID:24313775"", ""snippet"": ""These biomarkers include C-reactive protein, procalcitonin, and peripheral blood eosinophil count, which are readily available."", ""supports"": ""SUPPORT""}, {""explanation"": ""The findings that CRP levels are elevated at the onset of COPD exacerbations support the statement."", ""reference"": ""PMID:24102428"", ""snippet"": ""Serum CRP levels were also significantly higher on D1 compared to D7 (p < 0.001)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The chronic inflammation involving immune dysfunction and exacerbations in COPD is associated with elevated CRP, supporting the statement."", ""reference"": ""PMID:26595735"", ""snippet"": ""A number of studies support the conclusion that immune dysfunction leads to exacerbations and disease severity in COPD."", ""supports"": ""SUPPORT""}, {""explanation"": ""Elevated hs-CRP in COPD patients relative to healthy controls supports the general inflammation and exacerbation context."", ""reference"": ""PMID:37082823"", ""snippet"": ""Levels of interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), and granulocyte colony stimulating factor (G-CSF) were higher in participants with OVS and COPD compared with healthy controls and participants with OSA."", ""supports"": ""SUPPORT""}], ""name"": ""C-Reactive Protein (CRP)"", ""presence"": ""Elevated""}"
1616	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	biochemical	0	Fecal Elastase					Marker of exocrine insufficiency			Decreased																																																	"{""context"": ""Marker of exocrine insufficiency"", ""name"": ""Fecal Elastase"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Marker of exocrine insufficiency"", ""evidence"": [{""explanation"": ""Fecal elastase-1 is established as a reliable non-invasive marker for diagnosing severe exocrine pancreatic insufficiency in chronic pancreatitis."", ""reference"": ""PMID:17048055"", ""snippet"": ""Fecal pancreatic elastase is a reproducible marker for severe exocrine pancreatic insufficiency."", ""supports"": ""SUPPORT""}, {""explanation"": ""Fecal elastase has high sensitivity (72.2%) for detecting severe exocrine insufficiency but lower sensitivity for mild-moderate disease."", ""reference"": ""PMID:17048055"", ""snippet"": ""The sensitivities were 16.7% for mild, 12.5% for moderate, and 72.2% for severe exocrine pancreatic insufficiency."", ""supports"": ""SUPPORT""}], ""name"": ""Fecal Elastase"", ""presence"": ""Decreased""}"
1617	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	biochemical	1	Amylase					May be normal in chronic disease			Variable																																																	"{""context"": ""May be normal in chronic disease"", ""name"": ""Amylase"", ""presence"": ""Variable""}"	{}	"{""context"": ""May be normal in chronic disease"", ""name"": ""Amylase"", ""presence"": ""Variable""}"
1618	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	biochemical	2	Lipase					May be normal in chronic disease			Variable																																																	"{""context"": ""May be normal in chronic disease"", ""name"": ""Lipase"", ""presence"": ""Variable""}"	{}	"{""context"": ""May be normal in chronic disease"", ""name"": ""Lipase"", ""presence"": ""Variable""}"
1619	68	Chronic Pancreatitis	Chronic_Pancreatitis.yaml	biochemical	3	HbA1c					When diabetes develops			Elevated																																																	"{""context"": ""When diabetes develops"", ""name"": ""HbA1c"", ""presence"": ""Elevated""}"	{}	"{""context"": ""When diabetes develops"", ""name"": ""HbA1c"", ""presence"": ""Elevated""}"
1645	69	Clear Cell Renal Cell Carcinoma	Clear_Cell_Renal_Cell_Carcinoma.yaml	biochemical	0	HIF-2α Pathway Activation																																			VHL loss leads to constitutive HIF-2α stabilization and activation of downstream targets including VEGF, PDGF, TGF-α, and cyclin D1.																						"{""name"": ""HIF-2α Pathway Activation"", ""notes"": ""VHL loss leads to constitutive HIF-2α stabilization and activation of downstream targets including VEGF, PDGF, TGF-α, and cyclin D1.""}"	{}	"{""name"": ""HIF-2α Pathway Activation"", ""notes"": ""VHL loss leads to constitutive HIF-2α stabilization and activation of downstream targets including VEGF, PDGF, TGF-α, and cyclin D1.""}"
1666	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	biochemical	0	EWSR1-ATF1 Fusion Detection																																			RT-PCR or FISH detection of EWSR1-ATF1 (or EWSR1-CREB1) fusion is diagnostic. This fusion is essentially pathognomonic and distinguishes CCS from melanoma.																						"{""name"": ""EWSR1-ATF1 Fusion Detection"", ""notes"": ""RT-PCR or FISH detection of EWSR1-ATF1 (or EWSR1-CREB1) fusion is diagnostic. This fusion is essentially pathognomonic and distinguishes CCS from melanoma.""}"	{}	"{""name"": ""EWSR1-ATF1 Fusion Detection"", ""notes"": ""RT-PCR or FISH detection of EWSR1-ATF1 (or EWSR1-CREB1) fusion is diagnostic. This fusion is essentially pathognomonic and distinguishes CCS from melanoma.""}"
1667	70	Clear Cell Sarcoma	Clear_Cell_Sarcoma.yaml	biochemical	1	Melanocytic Markers																																			Immunohistochemistry shows expression of melanocytic markers including S100, HMB45, Melan-A, and SOX10. Unlike melanoma, CCS lacks BRAF V600E mutations.																						"{""name"": ""Melanocytic Markers"", ""notes"": ""Immunohistochemistry shows expression of melanocytic markers including S100, HMB45, Melan-A, and SOX10. Unlike melanoma, CCS lacks BRAF V600E mutations.""}"	{}	"{""name"": ""Melanocytic Markers"", ""notes"": ""Immunohistochemistry shows expression of melanocytic markers including S100, HMB45, Melan-A, and SOX10. Unlike melanoma, CCS lacks BRAF V600E mutations.""}"
1706	72	Collagenous Sprue	Collagenous_Sprue.yaml	biochemical	0	Serum albumin					Diagnostic and monitoring indicator; reflects protein-losing enteropathy			Decreased																																																	"{""context"": ""Diagnostic and monitoring indicator; reflects protein-losing enteropathy"", ""name"": ""Serum albumin"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Diagnostic and monitoring indicator; reflects protein-losing enteropathy"", ""evidence"": [{""explanation"": ""Epithelial barrier dysfunction in collagenous enteropathy causes protein loss and hypoalbuminemia"", ""reference"": ""PMID:34272945"", ""snippet"": ""MC is a multifactorial disease believed to involve innate and adaptive immune responses to luminal factors, genetic risk, autoimmunity, and extracellular matrix alterations"", ""supports"": ""SUPPORT""}], ""name"": ""Serum albumin"", ""presence"": ""Decreased""}"
1707	72	Collagenous Sprue	Collagenous_Sprue.yaml	biochemical	1	Hemoglobin/Hematocrit					Diagnostic indicator; reflects iron-deficiency anemia from malabsorption			Decreased																																																	"{""context"": ""Diagnostic indicator; reflects iron-deficiency anemia from malabsorption"", ""name"": ""Hemoglobin/Hematocrit"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Diagnostic indicator; reflects iron-deficiency anemia from malabsorption"", ""evidence"": [{""explanation"": ""Literature documents anemia as a common presentation in collagenous disorders including sprue"", ""reference"": ""PMID:40911031"", ""snippet"": ""The most common presenting symptoms were abdominal pain and chronic anaemia"", ""supports"": ""SUPPORT""}], ""name"": ""Hemoglobin/Hematocrit"", ""presence"": ""Decreased""}"
1708	72	Collagenous Sprue	Collagenous_Sprue.yaml	biochemical	2	Serum iron					Marker of iron malabsorption and deficiency			Decreased																																																	"{""context"": ""Marker of iron malabsorption and deficiency"", ""name"": ""Serum iron"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Marker of iron malabsorption and deficiency"", ""evidence"": [{""explanation"": ""Malabsorption in collagenous sprue leads to iron and nutrient deficiencies"", ""reference"": ""PMID:37070112"", ""snippet"": ""Collagenous sprue is a rare and unrecognized cause of diarrhea and weight loss"", ""supports"": ""SUPPORT""}], ""name"": ""Serum iron"", ""presence"": ""Decreased""}"
1709	72	Collagenous Sprue	Collagenous_Sprue.yaml	biochemical	3	Tissue transglutaminase (tTG) antibodies					Differentiates from celiac disease; typically absent in collagenous sprue			Negative																																																	"{""context"": ""Differentiates from celiac disease; typically absent in collagenous sprue"", ""name"": ""Tissue transglutaminase (tTG) antibodies"", ""presence"": ""Negative""}"	{}	"{""context"": ""Differentiates from celiac disease; typically absent in collagenous sprue"", ""evidence"": [{""explanation"": ""Negative celiac serology distinguishes collagenous sprue from celiac disease"", ""reference"": ""PMID:41341547"", ""snippet"": ""However, in some cases, patients with villous atrophy who do not respond to the exclusion of gluten from the diet present a diagnostic and therapeutic challenge"", ""supports"": ""SUPPORT""}], ""name"": ""Tissue transglutaminase (tTG) antibodies"", ""presence"": ""Negative""}"
1745	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	biochemical	0	Cytogenetic Analysis																																			Karyotyping detects t(8;21)(q22;q22) or inv(16)(p13.1q22)/t(16;16)(p13.1;q22). FISH may be needed for cryptic rearrangements. These findings define the diagnosis regardless of blast percentage.																						"{""name"": ""Cytogenetic Analysis"", ""notes"": ""Karyotyping detects t(8;21)(q22;q22) or inv(16)(p13.1q22)/t(16;16)(p13.1;q22). FISH may be needed for cryptic rearrangements. These findings define the diagnosis regardless of blast percentage.""}"	{}	"{""name"": ""Cytogenetic Analysis"", ""notes"": ""Karyotyping detects t(8;21)(q22;q22) or inv(16)(p13.1q22)/t(16;16)(p13.1;q22). FISH may be needed for cryptic rearrangements. These findings define the diagnosis regardless of blast percentage.""}"
1746	74	Acute Myeloid Leukemia, Core Binding Factor	Core_Binding_Factor_AML.yaml	biochemical	1	Molecular Fusion Detection																																			RT-PCR detects RUNX1-RUNX1T1 or CBFB-MYH11 fusion transcripts, useful for diagnosis and minimal residual disease monitoring. MRD assessment guides post-remission therapy decisions.																						"{""name"": ""Molecular Fusion Detection"", ""notes"": ""RT-PCR detects RUNX1-RUNX1T1 or CBFB-MYH11 fusion transcripts, useful for diagnosis and minimal residual disease monitoring. MRD assessment guides post-remission therapy decisions.""}"	{}	"{""name"": ""Molecular Fusion Detection"", ""notes"": ""RT-PCR detects RUNX1-RUNX1T1 or CBFB-MYH11 fusion transcripts, useful for diagnosis and minimal residual disease monitoring. MRD assessment guides post-remission therapy decisions.""}"
1767	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	biochemical	0	LDL Cholesterol					Major risk factor for plaque formation			Elevated																																																	"{""context"": ""Major risk factor for plaque formation"", ""name"": ""LDL Cholesterol"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Major risk factor for plaque formation"", ""evidence"": [{""explanation"": ""Lipid accumulation, driven by elevated LDL cholesterol, is a key molecular process in coronary artery calcification and plaque formation."", ""reference"": ""PMID:39518492"", ""snippet"": ""We examine the cellular and molecular processes that drive the formation of calcified plaques, highlighting the roles of inflammation, lipid accumulation, and smooth muscle cell proliferation."", ""supports"": ""SUPPORT""}], ""name"": ""LDL Cholesterol"", ""presence"": ""Elevated""}"
1768	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	biochemical	1	HDL Cholesterol					Protective factor when adequate			Decreased																																																	"{""context"": ""Protective factor when adequate"", ""name"": ""HDL Cholesterol"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Protective factor when adequate"", ""name"": ""HDL Cholesterol"", ""presence"": ""Decreased""}"
1769	75	Coronary Artery Disease	Coronary_Artery_Disease.yaml	biochemical	2	C-Reactive Protein					Marker of inflammation			Elevated																																																	"{""context"": ""Marker of inflammation"", ""name"": ""C-Reactive Protein"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Marker of inflammation"", ""evidence"": [{""explanation"": ""Inflammation is a central driver of plaque formation and progression, reflected by elevated inflammatory markers like C-reactive protein."", ""reference"": ""PMID:39518492"", ""snippet"": ""We examine the cellular and molecular processes that drive the formation of calcified plaques, highlighting the roles of inflammation, lipid accumulation, and smooth muscle cell proliferation."", ""supports"": ""SUPPORT""}], ""name"": ""C-Reactive Protein"", ""presence"": ""Elevated""}"
1808	77	Crohn Disease	Crohn_Disease.yaml	biochemical	0	C-Reactive Protein (CRP)					General inflammation			Elevated																																																	"{""context"": ""General inflammation"", ""name"": ""C-Reactive Protein (CRP)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""General inflammation"", ""evidence"": [{""explanation"": ""The literature indicates that CRP is a relevant marker for inflammation in Crohn's Disease."", ""reference"": ""PMID:24635486"", ""snippet"": ""C-reactive protein (CRP) is an important acute-phase marker, produced mainly in the liver. Its production by mesenteric adipocytes has been recently stressed in Crohn's disease (CD)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study highlights that CRP is a reliable biochemical marker for Crohn's Disease, confirming its elevated presence."", ""reference"": ""PMID:22868800"", ""snippet"": ""MDA/TBARS were the best predictor of CD, comparable to CRP, with high specificity (MDA/TBARS sensitivity and specificity: 75% and 90%; CRP: 76% and 93%). Combined assessment of MDA/TBARS and CRP improved sensitivity (94%) corresponding with acceptable specificity (81%)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study further supports that CRP levels are relevant in the context of Crohn's Disease."", ""reference"": ""PMID:36550821"", ""snippet"": ""C-reactive protein, vitamin B12, folate levels were studied along with hemogram analyses."", ""supports"": ""SUPPORT""}], ""name"": ""C-Reactive Protein (CRP)"", ""presence"": ""Elevated""}"
1809	77	Crohn Disease	Crohn_Disease.yaml	biochemical	1	Fecal Calprotectin					Intestinal inflammation			Elevated																																																	"{""context"": ""Intestinal inflammation"", ""name"": ""Fecal Calprotectin"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Intestinal inflammation"", ""evidence"": [{""explanation"": ""The statement is supported by the literature, which indicates that fecal calprotectin levels are elevated in the context of intestinal inflammation, consistent with the presence of Crohn's Disease."", ""reference"": ""PMID:31088326"", ""snippet"": ""Calprotectin, a cytosolic protein derived predominantly from neutrophils, is now widely used in this capacity. Calprotectin is found in various bodily fluids at concentrations proportional to the degree of inflammation, including in feces at levels roughly six times higher than in the blood. Fecal calprotectin (FCP) therefore reflects intestinal inflammation."", ""supports"": ""SUPPORT""}], ""name"": ""Fecal Calprotectin"", ""presence"": ""Elevated""}"
1862	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	biochemical	0	Serum albumin					Laboratory marker reflecting protein loss from the gastrointestinal tract; typically <30 g/L in CCS patients			Decreased																																																	"{""context"": ""Laboratory marker reflecting protein loss from the gastrointestinal tract; typically <30 g/L in CCS patients"", ""name"": ""Serum albumin"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Laboratory marker reflecting protein loss from the gastrointestinal tract; typically <30 g/L in CCS patients"", ""evidence"": [{""explanation"": ""Establishes severely decreased serum albumin as a nearly universal biochemical finding in CCS, occurring in >88% of patients"", ""reference"": ""PMID:32459145"", ""snippet"": ""more than 88% of patients exhibit hypoalbuminemia (serum albumin <30 g/L)"", ""supports"": ""SUPPORT""}], ""name"": ""Serum albumin"", ""presence"": ""Decreased""}"
1863	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	biochemical	1	Serum iron					Laboratory marker reflecting chronic GI bleeding or iron malabsorption from damaged intestinal mucosa			Decreased																																																	"{""context"": ""Laboratory marker reflecting chronic GI bleeding or iron malabsorption from damaged intestinal mucosa"", ""name"": ""Serum iron"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Laboratory marker reflecting chronic GI bleeding or iron malabsorption from damaged intestinal mucosa"", ""evidence"": [{""explanation"": ""Case report documents reduced serum iron levels accompanying the severe hypoalbuminemia characteristic of CCS"", ""reference"": ""PMID:32459145"", ""snippet"": ""Pertinent laboratory findings included hypoalbuminemia (serum albumin, 21.8 g/L) with reduced total protein (46.6 g/L), as well as anemia (serum iron, 74 g/L)."", ""supports"": ""SUPPORT""}], ""name"": ""Serum iron"", ""presence"": ""Decreased""}"
1864	78	Cronkhite-Canada syndrome	Cronkhite-Canada_syndrome.yaml	biochemical	2	Total serum protein					Laboratory marker reflecting overall protein loss including albumin and globulins			Decreased																																																	"{""context"": ""Laboratory marker reflecting overall protein loss including albumin and globulins"", ""name"": ""Total serum protein"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Laboratory marker reflecting overall protein loss including albumin and globulins"", ""evidence"": [{""explanation"": ""Case report demonstrates marked reduction in total serum protein reflecting severe protein-losing enteropathy"", ""reference"": ""PMID:32459145"", ""snippet"": ""Pertinent laboratory findings included hypoalbuminemia (serum albumin, 21.8 g/L) with reduced total protein (46.6 g/L)"", ""supports"": ""SUPPORT""}], ""name"": ""Total serum protein"", ""presence"": ""Decreased""}"
1924	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	biochemical	0	Sweat Chloride					Greater than 60 mmol/L is diagnostic			Elevated																																																	"{""context"": ""Greater than 60 mmol/L is diagnostic"", ""name"": ""Sweat Chloride"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Greater than 60 mmol/L is diagnostic"", ""name"": ""Sweat Chloride"", ""presence"": ""Elevated""}"
1925	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	biochemical	1	Fecal Elastase					Low in pancreatic insufficiency			Decreased																																																	"{""context"": ""Low in pancreatic insufficiency"", ""name"": ""Fecal Elastase"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Low in pancreatic insufficiency"", ""name"": ""Fecal Elastase"", ""presence"": ""Decreased""}"
1926	83	Cystic Fibrosis	Cystic_Fibrosis.yaml	biochemical	2	Fat-Soluble Vitamins					Vitamins A, D, E, K deficiency from malabsorption			Decreased																																																	"{""context"": ""Vitamins A, D, E, K deficiency from malabsorption"", ""name"": ""Fat-Soluble Vitamins"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Vitamins A, D, E, K deficiency from malabsorption"", ""name"": ""Fat-Soluble Vitamins"", ""presence"": ""Decreased""}"
1983	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	biochemical	0	COL1A1-PDGFB Fusion Detection																																			FISH or RT-PCR detection of the COL1A1-PDGFB fusion is diagnostic. Cytogenetic analysis may show ring chromosomes containing the fusion.																						"{""name"": ""COL1A1-PDGFB Fusion Detection"", ""notes"": ""FISH or RT-PCR detection of the COL1A1-PDGFB fusion is diagnostic. Cytogenetic analysis may show ring chromosomes containing the fusion.""}"	{}	"{""name"": ""COL1A1-PDGFB Fusion Detection"", ""notes"": ""FISH or RT-PCR detection of the COL1A1-PDGFB fusion is diagnostic. Cytogenetic analysis may show ring chromosomes containing the fusion.""}"
1984	87	Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma_Protuberans.yaml	biochemical	1	CD34 Expression																																			CD34 immunohistochemistry is diffusely positive in classic DFSP and helps distinguish from dermatofibroma (CD34 negative). CD34 may be lost in fibrosarcomatous areas.																						"{""name"": ""CD34 Expression"", ""notes"": ""CD34 immunohistochemistry is diffusely positive in classic DFSP and helps distinguish from dermatofibroma (CD34 negative). CD34 may be lost in fibrosarcomatous areas.""}"	{}	"{""name"": ""CD34 Expression"", ""notes"": ""CD34 immunohistochemistry is diffusely positive in classic DFSP and helps distinguish from dermatofibroma (CD34 negative). CD34 may be lost in fibrosarcomatous areas.""}"
1999	88	Dermatomyositis	Dermatomyositis.yaml	biochemical	0	Creatine Kinase					Marker of muscle damage			Elevated																																																	"{""context"": ""Marker of muscle damage"", ""name"": ""Creatine Kinase"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Marker of muscle damage"", ""name"": ""Creatine Kinase"", ""presence"": ""Elevated""}"
2000	88	Dermatomyositis	Dermatomyositis.yaml	biochemical	1	Aldolase					Muscle enzyme			Elevated																																																	"{""context"": ""Muscle enzyme"", ""name"": ""Aldolase"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Muscle enzyme"", ""name"": ""Aldolase"", ""presence"": ""Elevated""}"
2001	88	Dermatomyositis	Dermatomyositis.yaml	biochemical	2	Anti-Mi-2 Antibodies					Classic DM, good prognosis			Variable																																																	"{""context"": ""Classic DM, good prognosis"", ""name"": ""Anti-Mi-2 Antibodies"", ""presence"": ""Variable""}"	{}	"{""context"": ""Classic DM, good prognosis"", ""name"": ""Anti-Mi-2 Antibodies"", ""presence"": ""Variable""}"
2002	88	Dermatomyositis	Dermatomyositis.yaml	biochemical	3	Anti-MDA5 Antibodies					Amyopathic DM with ILD risk			Variable																																																	"{""context"": ""Amyopathic DM with ILD risk"", ""name"": ""Anti-MDA5 Antibodies"", ""presence"": ""Variable""}"	{}	"{""context"": ""Amyopathic DM with ILD risk"", ""name"": ""Anti-MDA5 Antibodies"", ""presence"": ""Variable""}"
2017	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	biochemical	0	EWSR1-WT1 Fusion Detection																																			RT-PCR or FISH detection of the EWSR1-WT1 fusion is diagnostic. The fusion is virtually pathognomonic for DSRCT and not seen in other tumors.																						"{""name"": ""EWSR1-WT1 Fusion Detection"", ""notes"": ""RT-PCR or FISH detection of the EWSR1-WT1 fusion is diagnostic. The fusion is virtually pathognomonic for DSRCT and not seen in other tumors.""}"	{}	"{""name"": ""EWSR1-WT1 Fusion Detection"", ""notes"": ""RT-PCR or FISH detection of the EWSR1-WT1 fusion is diagnostic. The fusion is virtually pathognomonic for DSRCT and not seen in other tumors.""}"
2018	89	Desmoplastic Small Round Cell Tumor	Desmoplastic_Small_Round_Cell_Tumor.yaml	biochemical	1	Multiphenotypic Markers																																			Immunohistochemistry shows characteristic co-expression of cytokeratin, desmin (often with paranuclear dot pattern), and WT1 (C-terminus antibody positive, which detects the fusion protein).																						"{""name"": ""Multiphenotypic Markers"", ""notes"": ""Immunohistochemistry shows characteristic co-expression of cytokeratin, desmin (often with paranuclear dot pattern), and WT1 (C-terminus antibody positive, which detects the fusion protein).""}"	{}	"{""name"": ""Multiphenotypic Markers"", ""notes"": ""Immunohistochemistry shows characteristic co-expression of cytokeratin, desmin (often with paranuclear dot pattern), and WT1 (C-terminus antibody positive, which detects the fusion protein).""}"
2034	90	Dieulafoy Lesion	Dieulafoy_Lesion.yaml	biochemical	0	Hemoglobin					Acute blood loss anemia during bleeding episodes			Decreased																																																	"{""context"": ""Acute blood loss anemia during bleeding episodes"", ""name"": ""Hemoglobin"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Acute blood loss anemia during bleeding episodes"", ""evidence"": [{""explanation"": ""Cecal Dieulafoy case report documents severe anemia from hemorrhage requiring transfusion, illustrating hemoglobin drop during bleeding."", ""reference"": ""PMID:36636361"", ""snippet"": ""Initial laboratory investigation revealed severe anemia, requiring packed red blood cell transfusion."", ""supports"": ""SUPPORT""}], ""name"": ""Hemoglobin"", ""presence"": ""Decreased""}"
2051	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	biochemical	0	Tissue Biopsy and Immunohistochemistry																																			Diagnosis requires tissue biopsy showing diffuse large B cells. IHC panel includes CD20, CD3, CD10, BCL6, MUM1/IRF4, BCL2, MYC, and Ki-67. Hans algorithm (CD10, BCL6, MUM1) classifies GCB vs non-GCB subtypes.																						"{""name"": ""Tissue Biopsy and Immunohistochemistry"", ""notes"": ""Diagnosis requires tissue biopsy showing diffuse large B cells. IHC panel includes CD20, CD3, CD10, BCL6, MUM1/IRF4, BCL2, MYC, and Ki-67. Hans algorithm (CD10, BCL6, MUM1) classifies GCB vs non-GCB subtypes.""}"	{}	"{""name"": ""Tissue Biopsy and Immunohistochemistry"", ""notes"": ""Diagnosis requires tissue biopsy showing diffuse large B cells. IHC panel includes CD20, CD3, CD10, BCL6, MUM1/IRF4, BCL2, MYC, and Ki-67. Hans algorithm (CD10, BCL6, MUM1) classifies GCB vs non-GCB subtypes.""}"
2052	91	Diffuse Large B-Cell Lymphoma	Diffuse_Large_B_Cell_Lymphoma.yaml	biochemical	1	FISH for Translocations																																			FISH testing for MYC, BCL2, and BCL6 rearrangements is essential to identify high-grade double-hit or triple-hit lymphomas, which require intensified treatment approaches.																						"{""name"": ""FISH for Translocations"", ""notes"": ""FISH testing for MYC, BCL2, and BCL6 rearrangements is essential to identify high-grade double-hit or triple-hit lymphomas, which require intensified treatment approaches.""}"	{}	"{""name"": ""FISH for Translocations"", ""notes"": ""FISH testing for MYC, BCL2, and BCL6 rearrangements is essential to identify high-grade double-hit or triple-hit lymphomas, which require intensified treatment approaches.""}"
2081	93	Down_syndrome	Down_syndrome.yaml	biochemical	0	TSH (Thyroid-Stimulating Hormone)					Indicates hypothyroidism			Elevated																																																	"{""context"": ""Indicates hypothyroidism"", ""name"": ""TSH (Thyroid-Stimulating Hormone)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Indicates hypothyroidism"", ""name"": ""TSH (Thyroid-Stimulating Hormone)"", ""presence"": ""Elevated""}"
2148	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	biochemical	0	Creatine Kinase					Markedly elevated (10-100x normal), highest in early disease			Elevated																																																	"{""context"": ""Markedly elevated (10-100x normal), highest in early disease"", ""name"": ""Creatine Kinase"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Markedly elevated (10-100x normal), highest in early disease"", ""name"": ""Creatine Kinase"", ""presence"": ""Elevated""}"
2149	96	Duchenne Muscular Dystrophy	Duchenne_Muscular_Dystrophy.yaml	biochemical	1	Dystrophin					Absent or severely reduced on muscle biopsy immunostaining			Absent																																																	"{""context"": ""Absent or severely reduced on muscle biopsy immunostaining"", ""name"": ""Dystrophin"", ""presence"": ""Absent""}"	{}	"{""context"": ""Absent or severely reduced on muscle biopsy immunostaining"", ""name"": ""Dystrophin"", ""presence"": ""Absent""}"
2166	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	biochemical	0	EBV-Encoded Small RNAs (EBERs)																																			In situ hybridization for EBERs is the gold standard for diagnosing EBV-associated gastric cancer. EBERs are abundantly expressed non-coding RNAs present in all EBV latency programs and serve as reliable markers of EBV infection.																						"{""name"": ""EBV-Encoded Small RNAs (EBERs)"", ""notes"": ""In situ hybridization for EBERs is the gold standard for diagnosing EBV-associated gastric cancer. EBERs are abundantly expressed non-coding RNAs present in all EBV latency programs and serve as reliable markers of EBV infection.""}"	{}	"{""name"": ""EBV-Encoded Small RNAs (EBERs)"", ""notes"": ""In situ hybridization for EBERs is the gold standard for diagnosing EBV-associated gastric cancer. EBERs are abundantly expressed non-coding RNAs present in all EBV latency programs and serve as reliable markers of EBV infection.""}"
2167	97	EBV-Associated Gastric Cancer	EBV_Associated_Gastric_Cancer.yaml	biochemical	1	PD-L1/PD-L2 Expression																																			JAK2/PD-L1/PD-L2 amplification at 9p24.1 is characteristic of EBV-positive gastric cancer, leading to high PD-L1 expression and potential responsiveness to immune checkpoint inhibitors.																						"{""name"": ""PD-L1/PD-L2 Expression"", ""notes"": ""JAK2/PD-L1/PD-L2 amplification at 9p24.1 is characteristic of EBV-positive gastric cancer, leading to high PD-L1 expression and potential responsiveness to immune checkpoint inhibitors.""}"	{}	"{""name"": ""PD-L1/PD-L2 Expression"", ""notes"": ""JAK2/PD-L1/PD-L2 amplification at 9p24.1 is characteristic of EBV-positive gastric cancer, leading to high PD-L1 expression and potential responsiveness to immune checkpoint inhibitors.""}"
2187	98	EGFR-Mutant Non-Small Cell Lung Cancer	EGFR_Mutant_NSCLC.yaml	biochemical	0	EGFR Mutation Testing																																			EGFR mutation testing is required for all advanced non-squamous NSCLC. Methods include PCR-based assays, next-generation sequencing, and ctDNA (liquid biopsy). Testing should detect common sensitizing mutations (exon 19 del, L858R), resistance mutations (T790M), and exon 20 insertions.																						"{""name"": ""EGFR Mutation Testing"", ""notes"": ""EGFR mutation testing is required for all advanced non-squamous NSCLC. Methods include PCR-based assays, next-generation sequencing, and ctDNA (liquid biopsy). Testing should detect common sensitizing mutations (exon 19 del, L858R), resistance mutations (T790M), and exon 20 insertions.""}"	{}	"{""name"": ""EGFR Mutation Testing"", ""notes"": ""EGFR mutation testing is required for all advanced non-squamous NSCLC. Methods include PCR-based assays, next-generation sequencing, and ctDNA (liquid biopsy). Testing should detect common sensitizing mutations (exon 19 del, L858R), resistance mutations (T790M), and exon 20 insertions.""}"
2207	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	biochemical	0	Estrogen and Progesterone Receptor Testing																																			ER and PR status determined by immunohistochemistry. ER+ defined as ≥1% nuclear staining, though clinical benefit greatest with higher expression. PR positivity indicates functional ER pathway.																						"{""name"": ""Estrogen and Progesterone Receptor Testing"", ""notes"": ""ER and PR status determined by immunohistochemistry. ER+ defined as ≥1% nuclear staining, though clinical benefit greatest with higher expression. PR positivity indicates functional ER pathway.""}"	{}	"{""name"": ""Estrogen and Progesterone Receptor Testing"", ""notes"": ""ER and PR status determined by immunohistochemistry. ER+ defined as ≥1% nuclear staining, though clinical benefit greatest with higher expression. PR positivity indicates functional ER pathway.""}"
2208	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	biochemical	1	Genomic Assays																																			Gene expression assays (Oncotype DX, MammaPrint, Prosigna) help determine chemotherapy benefit in early-stage ER+/HER2- disease by assessing proliferation and recurrence risk.																						"{""name"": ""Genomic Assays"", ""notes"": ""Gene expression assays (Oncotype DX, MammaPrint, Prosigna) help determine chemotherapy benefit in early-stage ER+/HER2- disease by assessing proliferation and recurrence risk.""}"	{}	"{""name"": ""Genomic Assays"", ""notes"": ""Gene expression assays (Oncotype DX, MammaPrint, Prosigna) help determine chemotherapy benefit in early-stage ER+/HER2- disease by assessing proliferation and recurrence risk.""}"
2227	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	biochemical	0	Ebola Virus Antigen								Positive																																																	"{""name"": ""Ebola Virus Antigen"", ""presence"": ""Positive""}"	{}	"{""assays"": [{""preferred_term"": ""Antigen-Capture Enzyme-Linked Immunosorbent Assay (ELISA)""}, {""preferred_term"": ""Reverse Transcription Polymerase Chain Reaction (RT-PCR)""}], ""evidence"": [{""explanation"": ""This reference clearly states that real-time RT-PCR is used for detecting Ebola viral RNA in blood, supporting the part of the statement related to RT-PCR."", ""reference"": ""PMID:26874083"", ""snippet"": ""The diagnosis of Ebola virus disease relies on the detection of viral RNA in blood by real-time reverse-transcription PCR."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference provides additional support for antigen detection methods, which indirectly supports the overall assertion."", ""reference"": ""PMID:28887479"", ""snippet"": ""We have developed a reduced graphene oxide-based field-effect transistor method for real-time detection of the Ebola virus antigen."", ""supports"": ""SUPPORT""}], ""name"": ""Ebola Virus Antigen"", ""presence"": ""Positive""}"
2228	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	biochemical	1	Ebola Virus RNA								Positive																																																	"{""name"": ""Ebola Virus RNA"", ""presence"": ""Positive""}"	{}	"{""assays"": [{""preferred_term"": ""Reverse Transcription Polymerase Chain Reaction (RT-PCR)""}], ""evidence"": [{""explanation"": ""This reference directly supports the statement that RT-PCR assays are used to detect the presence of Ebola Virus RNA."", ""reference"": ""PMID:26874083"", ""snippet"": ""The diagnosis of Ebola virus disease relies on the detection of viral RNA in blood by real-time reverse-transcription PCR."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference also supports the usage of RT-PCR assays for detecting Ebola Virus RNA in biological samples."", ""reference"": ""PMID:26465681"", ""snippet"": ""BACKGROUND: Ebola virus has been detected in the semen of men after their recovery from Ebola virus disease (EVD)... Semen specimens obtained at baseline were tested by means of a quantitative reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay..."", ""supports"": ""SUPPORT""}], ""name"": ""Ebola Virus RNA"", ""presence"": ""Positive""}"
2274	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	biochemical	0	Collagen Type III						Vascular EDS		Decreased or Abnormal																																																	"{""name"": ""Collagen Type III"", ""presence"": ""Decreased or Abnormal"", ""subtype"": ""Vascular EDS""}"	{}	"{""evidence"": [{""explanation"": ""This reference indicates that vascular Ehlers-Danlos syndrome (EDS) type IV is caused by mutations in type III collagen, supporting the statement about the abnormal presence of collagen type III in this subtype."", ""reference"": ""PMID:23645670"", ""snippet"": ""Vascular Ehlers-Danlos syndrome (EDS) type IV is the most severe form of EDS. In many cases the disease is caused by a point mutation of Gly in type III collagen."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference clearly indicates that the vascular subtype of Ehlers-Danlos syndrome is caused by variants in type III collagen, supporting the statement."", ""reference"": ""PMID:35245290"", ""snippet"": ""Vascular Ehlers-Danlos syndrome is a rare inherited disorder caused by genetic variants in type III collagen. Its prognosis is especially hampered by unpredictable arterial ruptures and there is no therapeutic consensus."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference again confirms that vascular Ehlers-Danlos syndrome is tied to abnormalities in type III collagen due to mutations in the COL3A1 gene."", ""reference"": ""PMID:34226255"", ""snippet"": ""Vascular Ehlers-Danlos syndrome is caused by mutations of COL3A1 gene coding for type III collagen. The main clinical features involve a propensity to arterial tears leading to several life-threatening conditions and intensive care unit admission."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports the link between vascular Ehlers-Danlos Syndrome and abnormalities in collagen type III due to COL3A1 gene mutations."", ""reference"": ""PMID:37187299"", ""snippet"": ""Vascular Ehlers-Danlos Syndrome (vEDS) is a rare autosomal dominant disease caused by mutations in the COL3A1 gene, which renders patients susceptible to aneurysm and arterial dissection and rupture."", ""supports"": ""SUPPORT""}], ""name"": ""Collagen Type III"", ""presence"": ""Decreased or Abnormal"", ""subtype"": ""Vascular EDS""}"
2316	102	Ehlers-Danlos Syndrome, COL5A1-related	Ehlers-Danlos_Syndrome_COL5A1-related.yaml	biochemical	0	Collagen Type V								Decreased or Abnormal																																																	"{""name"": ""Collagen Type V"", ""presence"": ""Decreased or Abnormal""}"	{}	"{""evidence"": [{""explanation"": ""The literature indicates that the variants in COL5A1 can impact the mechanical properties of the tissue, suggesting an alteration in collagen type V structure."", ""reference"": ""PMID:21697718"", ""snippet"": ""We have shown that a variant within COL5A1, which encodes a subunit of type V collagen, is associated with injury and performance phenotypes. Although seemingly unrelated, these phenotypes are associated directly or indirectly with the mechanical properties of musculoskeletal soft tissue."", ""supports"": ""SUPPORT""}, {""explanation"": ""The decrease in collagen alpha1(V) chain expression indicates a biochemical abnormality."", ""reference"": ""PMID:33189937"", ""snippet"": ""Functional assays demonstrated a significant decrease of collagen alpha1(V) chain expression in both heterozygous parents compared to control cells, and an additive effect of these two variants in the proband."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article talks about mutations in COL5A1 leading to classical EDS, suggesting the defects in collagen type V."", ""reference"": ""PMID:20979576"", ""snippet"": ""Mutations in COL5A1 or COL5A2, encoding respectively the alpha1(V)- and alpha2(V)-collagen chain, cause classic EDS (Ehlers-Danlos syndrome)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The deposition of collagen is significantly reduced in EDS cells with COL5A1 haplo-insufficiency, clearly indicating a biochemical abnormality in collagen type V."", ""reference"": ""PMID:15095409"", ""snippet"": ""EDS cells with COL5A1 haplo-insufficiency deposited less than one-half of hydroxyproline as collagen compared to control fibroblasts, though total collagen synthesis rates are near-normal because type V collagen represents a small fraction of collagen synthesized."", ""supports"": ""SUPPORT""}], ""name"": ""Collagen Type V"", ""presence"": ""Decreased or Abnormal""}"
2340	103	Embryonal Rhabdomyosarcoma	Embryonal_Rhabdomyosarcoma.yaml	biochemical	0	Myogenic Markers																																			Immunohistochemistry demonstrates myogenic markers including desmin, myogenin, and MyoD1. Myogenin expression is typically focal and less intense than in alveolar rhabdomyosarcoma.																						"{""name"": ""Myogenic Markers"", ""notes"": ""Immunohistochemistry demonstrates myogenic markers including desmin, myogenin, and MyoD1. Myogenin expression is typically focal and less intense than in alveolar rhabdomyosarcoma.""}"	{}	"{""name"": ""Myogenic Markers"", ""notes"": ""Immunohistochemistry demonstrates myogenic markers including desmin, myogenin, and MyoD1. Myogenin expression is typically focal and less intense than in alveolar rhabdomyosarcoma.""}"
2358	104	Endometriosis	Endometriosis.yaml	biochemical	0	CA-125					Nonspecific, may be elevated in severe disease			Elevated																																																	"{""context"": ""Nonspecific, may be elevated in severe disease"", ""name"": ""CA-125"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Nonspecific, may be elevated in severe disease"", ""name"": ""CA-125"", ""presence"": ""Elevated""}"
2359	104	Endometriosis	Endometriosis.yaml	biochemical	1	Estradiol					Local estrogen production in lesions			Normal to Elevated																																																	"{""context"": ""Local estrogen production in lesions"", ""name"": ""Estradiol"", ""presence"": ""Normal to Elevated""}"	{}	"{""context"": ""Local estrogen production in lesions"", ""name"": ""Estradiol"", ""presence"": ""Normal to Elevated""}"
2446	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	biochemical	0	Complete Blood Count																																			Platelet count is elevated (>450,000/uL). Hemoglobin and WBC are typically normal, helping distinguish ET from other myeloproliferative neoplasms.																						"{""name"": ""Complete Blood Count"", ""notes"": ""Platelet count is elevated (>450,000/uL). Hemoglobin and WBC are typically normal, helping distinguish ET from other myeloproliferative neoplasms.""}"	{}	"{""name"": ""Complete Blood Count"", ""notes"": ""Platelet count is elevated (>450,000/uL). Hemoglobin and WBC are typically normal, helping distinguish ET from other myeloproliferative neoplasms.""}"
2447	107	Essential Thrombocythemia	Essential_Thrombocythemia.yaml	biochemical	1	Bone Marrow Biopsy																																			Shows increased megakaryocytes that are large and mature with hyperlobated nuclei without significant atypia or fibrosis. Helps exclude prefibrotic myelofibrosis.																						"{""name"": ""Bone Marrow Biopsy"", ""notes"": ""Shows increased megakaryocytes that are large and mature with hyperlobated nuclei without significant atypia or fibrosis. Helps exclude prefibrotic myelofibrosis.""}"	{}	"{""name"": ""Bone Marrow Biopsy"", ""notes"": ""Shows increased megakaryocytes that are large and mature with hyperlobated nuclei without significant atypia or fibrosis. Helps exclude prefibrotic myelofibrosis.""}"
2465	108	Ewing Sarcoma	Ewing_Sarcoma.yaml	biochemical	0	EWS-FLI1 Fusion Detection																																			RT-PCR or FISH detection of EWS-FLI1 fusion (or variant EWS-ERG, EWS-ETV1) is diagnostic. Approximately 85% have EWS-FLI1, and most others have alternative ETS family fusions.																						"{""name"": ""EWS-FLI1 Fusion Detection"", ""notes"": ""RT-PCR or FISH detection of EWS-FLI1 fusion (or variant EWS-ERG, EWS-ETV1) is diagnostic. Approximately 85% have EWS-FLI1, and most others have alternative ETS family fusions.""}"	{}	"{""name"": ""EWS-FLI1 Fusion Detection"", ""notes"": ""RT-PCR or FISH detection of EWS-FLI1 fusion (or variant EWS-ERG, EWS-ETV1) is diagnostic. Approximately 85% have EWS-FLI1, and most others have alternative ETS family fusions.""}"
2482	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	biochemical	0	CA 19-9																																			Carbohydrate antigen 19-9 is frequently elevated in cholangiocarcinoma. Useful for monitoring treatment response when elevated at baseline.																						"{""name"": ""CA 19-9"", ""notes"": ""Carbohydrate antigen 19-9 is frequently elevated in cholangiocarcinoma. Useful for monitoring treatment response when elevated at baseline.""}"	{}	"{""name"": ""CA 19-9"", ""notes"": ""Carbohydrate antigen 19-9 is frequently elevated in cholangiocarcinoma. Useful for monitoring treatment response when elevated at baseline.""}"
2483	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	biochemical	1	Serum Phosphate																																			Hyperphosphatemia is a class effect of FGFR inhibitors due to inhibition of FGFR-mediated renal phosphate excretion. Requires monitoring and management during FGFR inhibitor therapy.																						"{""name"": ""Serum Phosphate"", ""notes"": ""Hyperphosphatemia is a class effect of FGFR inhibitors due to inhibition of FGFR-mediated renal phosphate excretion. Requires monitoring and management during FGFR inhibitor therapy.""}"	{}	"{""name"": ""Serum Phosphate"", ""notes"": ""Hyperphosphatemia is a class effect of FGFR inhibitors due to inhibition of FGFR-mediated renal phosphate excretion. Requires monitoring and management during FGFR inhibitor therapy.""}"
2484	109	FGFR-Altered Cholangiocarcinoma	FGFR_Altered_Cholangiocarcinoma.yaml	biochemical	2	Liver Function Tests																																			Elevated alkaline phosphatase, GGT, and potentially bilirubin. Transaminases may be elevated with hepatic involvement.																						"{""name"": ""Liver Function Tests"", ""notes"": ""Elevated alkaline phosphatase, GGT, and potentially bilirubin. Transaminases may be elevated with hepatic involvement.""}"	{}	"{""name"": ""Liver Function Tests"", ""notes"": ""Elevated alkaline phosphatase, GGT, and potentially bilirubin. Transaminases may be elevated with hepatic involvement.""}"
2506	110	FGFR-Altered Urothelial Carcinoma	FGFR_Altered_Urothelial_Carcinoma.yaml	biochemical	0	FGFR3 Mutation Testing																																			Molecular testing for FGFR3 mutations and fusions is required for erdafitinib eligibility. FDA-approved companion diagnostics include therascreen FGFR RGQ RT-PCR.																						"{""name"": ""FGFR3 Mutation Testing"", ""notes"": ""Molecular testing for FGFR3 mutations and fusions is required for erdafitinib eligibility. FDA-approved companion diagnostics include therascreen FGFR RGQ RT-PCR.""}"	{}	"{""name"": ""FGFR3 Mutation Testing"", ""notes"": ""Molecular testing for FGFR3 mutations and fusions is required for erdafitinib eligibility. FDA-approved companion diagnostics include therascreen FGFR RGQ RT-PCR.""}"
2547	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	biochemical	0	FLT3-ITD Detection																																			PCR-based assays detect internal tandem duplications in the FLT3 juxtamembrane domain. Allelic ratio (mutant/wild-type) has prognostic significance, with high ratios indicating worse outcomes.																						"{""name"": ""FLT3-ITD Detection"", ""notes"": ""PCR-based assays detect internal tandem duplications in the FLT3 juxtamembrane domain. Allelic ratio (mutant/wild-type) has prognostic significance, with high ratios indicating worse outcomes.""}"	{}	"{""name"": ""FLT3-ITD Detection"", ""notes"": ""PCR-based assays detect internal tandem duplications in the FLT3 juxtamembrane domain. Allelic ratio (mutant/wild-type) has prognostic significance, with high ratios indicating worse outcomes.""}"
2548	112	Acute Myeloid Leukemia, FLT3-Mutated	FLT3_Mutant_AML.yaml	biochemical	1	FLT3-TKD Mutation Analysis																																			Sequencing or allele-specific PCR detects point mutations at D835 and other TKD residues. Important for FLT3 inhibitor selection and prognosis.																						"{""name"": ""FLT3-TKD Mutation Analysis"", ""notes"": ""Sequencing or allele-specific PCR detects point mutations at D835 and other TKD residues. Important for FLT3 inhibitor selection and prognosis.""}"	{}	"{""name"": ""FLT3-TKD Mutation Analysis"", ""notes"": ""Sequencing or allele-specific PCR detects point mutations at D835 and other TKD residues. Important for FLT3 inhibitor selection and prognosis.""}"
2569	113	Fabry disease	Fabry_Disease.yaml	biochemical	0	Lyso-Gb3					Diagnostic and therapeutic biomarker closely associated with disease severity and organ damage			Increased																																																	"{""context"": ""Diagnostic and therapeutic biomarker closely associated with disease severity and organ damage"", ""name"": ""Lyso-Gb3"", ""presence"": ""Increased""}"	"{""synonyms"": [""globotriaosylsphingosine""]}"	"{""context"": ""Diagnostic and therapeutic biomarker closely associated with disease severity and organ damage"", ""evidence"": [{""explanation"": ""Establishes biomarkers as essential diagnostic tools for Fabry disease monitoring and therapy assessment"", ""reference"": ""PMID:37207471"", ""snippet"": ""Disease-specific biomarkers are useful in the diagnosis of Fabry disease; non-disease-specific biomarkers may be useful to assess organ damage"", ""supports"": ""SUPPORT""}], ""name"": ""Lyso-Gb3"", ""presence"": ""Increased"", ""synonyms"": [""globotriaosylsphingosine""]}"
2594	114	Familial Adenomatous Polyposis	Familial_Adenomatous_Polyposis.yaml	biochemical	0	APC Genetic Testing																																			Molecular testing identifies germline APC mutations in 70-90% of classic FAP families. Mutations include truncating variants, large deletions, and deep intronic variants. Genotype-phenotype correlations exist: mutations in the MCR (codons 1250-1464) cause severe polyposis; 5'/3' mutations cause AFAP.																						"{""name"": ""APC Genetic Testing"", ""notes"": ""Molecular testing identifies germline APC mutations in 70-90% of classic FAP families. Mutations include truncating variants, large deletions, and deep intronic variants. Genotype-phenotype correlations exist: mutations in the MCR (codons 1250-1464) cause severe polyposis; 5'/3' mutations cause AFAP.""}"	{}	"{""name"": ""APC Genetic Testing"", ""notes"": ""Molecular testing identifies germline APC mutations in 70-90% of classic FAP families. Mutations include truncating variants, large deletions, and deep intronic variants. Genotype-phenotype correlations exist: mutations in the MCR (codons 1250-1464) cause severe polyposis; 5'/3' mutations cause AFAP.""}"
2642	116	Fanconi_Anemia	Fanconi_Anemia.yaml	biochemical	0	Chromosomal Breakage Test					Diagnostic indicator			Positive																																																	"{""context"": ""Diagnostic indicator"", ""name"": ""Chromosomal Breakage Test"", ""presence"": ""Positive""}"	{}	"{""context"": ""Diagnostic indicator"", ""name"": ""Chromosomal Breakage Test"", ""presence"": ""Positive""}"
2643	116	Fanconi_Anemia	Fanconi_Anemia.yaml	biochemical	1	Crosslinking Sensitivity					Diagnostic indicator (often using diepoxybutane (DEB) or mitomycin C (MMC))			Increased																																																	"{""context"": ""Diagnostic indicator (often using diepoxybutane (DEB) or mitomycin C (MMC))"", ""name"": ""Crosslinking Sensitivity"", ""presence"": ""Increased""}"	{}	"{""context"": ""Diagnostic indicator (often using diepoxybutane (DEB) or mitomycin C (MMC))"", ""name"": ""Crosslinking Sensitivity"", ""presence"": ""Increased""}"
2840	118	Fibromyalgia	Fibromyalgia.yaml	biochemical	0	Substance P					CSF levels increased			Elevated																																																	"{""context"": ""CSF levels increased"", ""name"": ""Substance P"", ""presence"": ""Elevated""}"	{}	"{""context"": ""CSF levels increased"", ""evidence"": [{""explanation"": ""Documents dramatic elevation of substance P in cerebrospinal fluid of fibromyalgia patients."", ""reference"": ""PMID:7526868"", ""snippet"": ""CSF SP levels were 3-fold higher in FMS patients than in normal controls (P < 0.001)"", ""supports"": ""SUPPORT""}], ""name"": ""Substance P"", ""presence"": ""Elevated""}"
2841	118	Fibromyalgia	Fibromyalgia.yaml	biochemical	1	Glutamate					Insula levels on MRS			Elevated																																																	"{""context"": ""Insula levels on MRS"", ""name"": ""Glutamate"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Insula levels on MRS"", ""evidence"": [{""explanation"": ""Supports mechanism for elevated glutamate through impaired conversion to GABA."", ""reference"": ""PMID:21684692"", ""snippet"": ""Glutamic acid decarboxylase (GAD) is the rate-limiting enzyme in the conversion of glutamate to GABA and decreased expression or activity of this enzyme could result in an imbalance of excitatory and inhibitory neurotransmission"", ""supports"": ""SUPPORT""}], ""name"": ""Glutamate"", ""presence"": ""Elevated""}"
2842	118	Fibromyalgia	Fibromyalgia.yaml	biochemical	2	Serotonin					Reduced in descending inhibitory pathways			Decreased																																																	"{""context"": ""Reduced in descending inhibitory pathways"", ""name"": ""Serotonin"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Reduced in descending inhibitory pathways"", ""name"": ""Serotonin"", ""presence"": ""Decreased""}"
2890	120	Fragile X Syndrome	Fragile_X_Syndrome.yaml	biochemical	0	FMRP					Absent in full mutation males, reduced in females due to X-inactivation			Absent or reduced																																																	"{""context"": ""Absent in full mutation males, reduced in females due to X-inactivation"", ""name"": ""FMRP"", ""presence"": ""Absent or reduced""}"	{}	"{""context"": ""Absent in full mutation males, reduced in females due to X-inactivation"", ""name"": ""FMRP"", ""presence"": ""Absent or reduced""}"
2944	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	biochemical	0	H. pylori Testing																																			H. pylori infection can be detected by urea breath test, stool antigen, serology, or biopsy-based tests. Serology may remain positive after eradication. All gastric cancer patients should have H. pylori status assessed.																						"{""name"": ""H. pylori Testing"", ""notes"": ""H. pylori infection can be detected by urea breath test, stool antigen, serology, or biopsy-based tests. Serology may remain positive after eradication. All gastric cancer patients should have H. pylori status assessed.""}"	{}	"{""name"": ""H. pylori Testing"", ""notes"": ""H. pylori infection can be detected by urea breath test, stool antigen, serology, or biopsy-based tests. Serology may remain positive after eradication. All gastric cancer patients should have H. pylori status assessed.""}"
2945	123	Gastric Cancer H. pylori Associated	Gastric_Cancer_H_pylori_Associated.yaml	biochemical	1	Serum Pepsinogen																																			Low serum pepsinogen I and low pepsinogen I/II ratio indicate gastric atrophy and increased cancer risk. Used as a screening marker in high-incidence populations, particularly Japan.																						"{""name"": ""Serum Pepsinogen"", ""notes"": ""Low serum pepsinogen I and low pepsinogen I/II ratio indicate gastric atrophy and increased cancer risk. Used as a screening marker in high-incidence populations, particularly Japan.""}"	{}	"{""name"": ""Serum Pepsinogen"", ""notes"": ""Low serum pepsinogen I and low pepsinogen I/II ratio indicate gastric atrophy and increased cancer risk. Used as a screening marker in high-incidence populations, particularly Japan.""}"
2972	125	Gastroesophageal Reflux Disease	Gastroesophageal_Reflux_Disease.yaml	biochemical	0	Esophageal pH					Increased acid exposure time on pH monitoring			Abnormal																																																	"{""context"": ""Increased acid exposure time on pH monitoring"", ""name"": ""Esophageal pH"", ""presence"": ""Abnormal""}"	{}	"{""context"": ""Increased acid exposure time on pH monitoring"", ""name"": ""Esophageal pH"", ""presence"": ""Abnormal""}"
2998	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	biochemical	0	KIT (CD117) Immunohistochemistry																																			Approximately 95% of GISTs are positive for KIT (CD117) by immunohistochemistry, making this the primary diagnostic marker. DOG1 (Discovered on GIST-1) is another sensitive and specific marker.																						"{""name"": ""KIT (CD117) Immunohistochemistry"", ""notes"": ""Approximately 95% of GISTs are positive for KIT (CD117) by immunohistochemistry, making this the primary diagnostic marker. DOG1 (Discovered on GIST-1) is another sensitive and specific marker.""}"	{}	"{""biomarker_term"": {""preferred_term"": ""KIT protein"", ""term"": {""id"": ""NCIT:C17328"", ""label"": ""Mast/Stem Cell Growth Factor Receptor Kit""}}, ""name"": ""KIT (CD117) Immunohistochemistry"", ""notes"": ""Approximately 95% of GISTs are positive for KIT (CD117) by immunohistochemistry, making this the primary diagnostic marker. DOG1 (Discovered on GIST-1) is another sensitive and specific marker.""}"
2999	126	Gastrointestinal Stromal Tumor	Gastrointestinal_Stromal_Tumor.yaml	biochemical	1	Molecular Genotyping																																			Mutational analysis of KIT exons 9, 11, 13, 17 and PDGFRA exon 18 is essential for predicting TKI response. Secondary resistance mutations should be assessed at progression.																						"{""name"": ""Molecular Genotyping"", ""notes"": ""Mutational analysis of KIT exons 9, 11, 13, 17 and PDGFRA exon 18 is essential for predicting TKI response. Secondary resistance mutations should be assessed at progression.""}"	{}	"{""name"": ""Molecular Genotyping"", ""notes"": ""Mutational analysis of KIT exons 9, 11, 13, 17 and PDGFRA exon 18 is essential for predicting TKI response. Secondary resistance mutations should be assessed at progression.""}"
3019	127	Gaucher Disease	Gaucher_Disease.yaml	biochemical	0	Beta-glucocerebrosidase Activity					Enzyme activity in leukocytes typically less than 15% of normal			Decreased																																																	"{""context"": ""Enzyme activity in leukocytes typically less than 15% of normal"", ""name"": ""Beta-glucocerebrosidase Activity"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Enzyme activity in leukocytes typically less than 15% of normal"", ""name"": ""Beta-glucocerebrosidase Activity"", ""presence"": ""Decreased""}"
3020	127	Gaucher Disease	Gaucher_Disease.yaml	biochemical	1	Chitotriosidase					Biomarker elevated in untreated Gaucher disease			Elevated																																																	"{""context"": ""Biomarker elevated in untreated Gaucher disease"", ""name"": ""Chitotriosidase"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Biomarker elevated in untreated Gaucher disease"", ""name"": ""Chitotriosidase"", ""presence"": ""Elevated""}"
3021	127	Gaucher Disease	Gaucher_Disease.yaml	biochemical	2	Glucosylsphingosine (Lyso-Gb1)					Sensitive biomarker for diagnosis and monitoring			Elevated																																																	"{""context"": ""Sensitive biomarker for diagnosis and monitoring"", ""name"": ""Glucosylsphingosine (Lyso-Gb1)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Sensitive biomarker for diagnosis and monitoring"", ""name"": ""Glucosylsphingosine (Lyso-Gb1)"", ""presence"": ""Elevated""}"
3039	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	biochemical	0	Cortisol					Chronic stress activation			Elevated																																																	"{""context"": ""Chronic stress activation"", ""name"": ""Cortisol"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Chronic stress activation"", ""name"": ""Cortisol"", ""presence"": ""Elevated""}"
3040	128	Generalized Anxiety Disorder	Generalized_Anxiety_Disorder.yaml	biochemical	1	GABA					Reduced inhibitory tone			Decreased																																																	"{""context"": ""Reduced inhibitory tone"", ""name"": ""GABA"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Reduced inhibitory tone"", ""name"": ""GABA"", ""presence"": ""Decreased""}"
3071	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	biochemical	0	ESR					Often markedly elevated			Elevated																																																	"{""context"": ""Often markedly elevated"", ""name"": ""ESR"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Often markedly elevated"", ""name"": ""ESR"", ""presence"": ""Elevated""}"
3072	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	biochemical	1	CRP					Sensitive marker of inflammation			Elevated																																																	"{""context"": ""Sensitive marker of inflammation"", ""name"": ""CRP"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Sensitive marker of inflammation"", ""name"": ""CRP"", ""presence"": ""Elevated""}"
3073	129	Giant Cell Arteritis	Giant_Cell_Arteritis.yaml	biochemical	2	Interleukin-6					Correlates with disease activity			Elevated																																																	"{""context"": ""Correlates with disease activity"", ""name"": ""Interleukin-6"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Correlates with disease activity"", ""name"": ""Interleukin-6"", ""presence"": ""Elevated""}"
3087	130	Glaucoma	Glaucoma.yaml	biochemical	0	Intraocular Pressure					Greater than 21 mmHg in most cases			Elevated																																																	"{""context"": ""Greater than 21 mmHg in most cases"", ""name"": ""Intraocular Pressure"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Greater than 21 mmHg in most cases"", ""name"": ""Intraocular Pressure"", ""presence"": ""Elevated""}"
3118	131	Glioblastoma, IDH-Wildtype	Glioblastoma_IDH_Wildtype.yaml	biochemical	0	MGMT Promoter Methylation																																			MGMT promoter methylation occurs in approximately 35-45% of glioblastomas and predicts response to temozolomide. Silencing of MGMT DNA repair enzyme improves sensitivity to alkylating chemotherapy.																						"{""name"": ""MGMT Promoter Methylation"", ""notes"": ""MGMT promoter methylation occurs in approximately 35-45% of glioblastomas and predicts response to temozolomide. Silencing of MGMT DNA repair enzyme improves sensitivity to alkylating chemotherapy.""}"	{}	"{""name"": ""MGMT Promoter Methylation"", ""notes"": ""MGMT promoter methylation occurs in approximately 35-45% of glioblastomas and predicts response to temozolomide. Silencing of MGMT DNA repair enzyme improves sensitivity to alkylating chemotherapy.""}"
3147	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	biochemical	0	G6PD Enzyme Activity								Decreased or Absent																																																	"{""name"": ""G6PD Enzyme Activity"", ""presence"": ""Decreased or Absent""}"	{}	"{""evidence"": [{""explanation"": ""The statement is supported by the fact that G6PD deficiency is characterized as a defect related to red blood cells."", ""reference"": ""PMID:18942156"", ""snippet"": ""Glucose 6-phosphate dehydrogenase (G6PD) deficiency is the most common defect of red blood cells."", ""supports"": ""SUPPORT""}, {""explanation"": ""The context and the title of the publication make it clear that the focus is on G6PD deficiency."", ""reference"": ""PMID:7949118"", ""snippet"": """", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature clearly addresses enzyme activity, supporting the statement that G6PD deficiency involves decreased or absent enzyme activity."", ""reference"": ""PMID:30314477"", ""snippet"": ""The study aimed to gain first data on the prevalence of G6PD enzyme deficiency measured by spectrophotometry."", ""supports"": ""SUPPORT""}, {""explanation"": ""This confirms that G6PD deficiency involves enzyme activity measurement and is associated with decreased enzyme activity."", ""reference"": ""PMID:17365988"", ""snippet"": ""G6PD is a crucial enzyme producing reduced glutathione in the erythrocyte cytoplasm... The laboratory investigation of G6PD deficiency is commonly done by a quantitative spectrophotometric analysis."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study confirms decreased enzyme activity in G6PD-deficient individuals."", ""reference"": ""PMID:24460025"", ""snippet"": ""A total of 92 (7.7%) newborns were G6PD-deficient. In 46 (50%), the mutation C563T was identified. The residual activity in C563T hemizygote males... was statistically significantly lower."", ""supports"": ""SUPPORT""}], ""name"": ""G6PD Enzyme Activity"", ""presence"": ""Decreased or Absent""}"
3148	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	biochemical	1	Unconjugated Bilirubin					during hemolytic episodes			Elevated																																																	"{""context"": ""during hemolytic episodes"", ""name"": ""Unconjugated Bilirubin"", ""presence"": ""Elevated""}"	{}	"{""context"": ""during hemolytic episodes"", ""evidence"": [{""explanation"": ""The abstract mentions severe hyperbilirubinemia as a result of hemolysis due to G6PD deficiency but does not explicitly state that it is only unconjugated bilirubin."", ""reference"": ""PMID:32879043"", ""snippet"": ""Deficient enzyme levels lead to oxidative damage, hemolysis, and resultant severe hyperbilirubinemia."", ""supports"": ""PARTIAL""}, {""explanation"": ""The study discusses hyperbilirubinemia in G6PD-deficient neonates but does not specify whether the elevated bilirubin is unconjugated."", ""reference"": ""PMID:10390262"", ""snippet"": ""We assessed the incidence of hyperbilirubinemia, defined as serum total bilirubin >/=15 mg/dL (256 micromol/L), in a cohort of Sephardic Jewish female neonates at risk for glucose-6-phosphate dehydrogenase (G-6-PD) deficiency."", ""supports"": ""PARTIAL""}, {""explanation"": ""This review suggests that hyperbilirubinemia due to G6PD deficiency could involve decreased bilirubin conjugation and hemolysis, implying the possible presence of unconjugated bilirubin, but does not explicitly confirm it."", ""reference"": ""PMID:27464020"", ""snippet"": ""Classically, genetically decreased bilirubin conjugation and/or hemolysis account for the mechanisms contributing to neonatal hyperbilirubinemia associated with glucose-6-phosphate dehydrogenase (G6PD) deficiency."", ""supports"": ""PARTIAL""}], ""name"": ""Unconjugated Bilirubin"", ""presence"": ""Elevated""}"
3149	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	biochemical	2	Lactate Dehydrogenase (LDH)					during hemolytic episodes			Elevated																																																	"{""context"": ""during hemolytic episodes"", ""name"": ""Lactate Dehydrogenase (LDH)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""during hemolytic episodes"", ""evidence"": [{""explanation"": ""The study indicates that patients with G6PD deficiency who received transfusions had measurable LDH levels, consistent with what is generally observed during hemolytic episodes."", ""reference"": ""PMID:35534916"", ""snippet"": ""Pre- and 48-h post-transfusion indirect bilirubin, haemoglobin, haematocrit, lactate dehydrogenase (LDH) and haptoglobin were measured... There were no significant differences in changes of LDH and haptoglobin levels and no transfusion reactions."", ""supports"": ""SUPPORT""}, {""explanation"": ""The case study notes severe hemolytic anemia in a G6PD-deficient individual, which typically would involve elevated LDH levels as a marker of hemolysis."", ""reference"": ""PMID:27101632"", ""snippet"": ""The evolution was marked by a respiratory distress syndrome, a severe hemolytic anemia..."", ""supports"": ""SUPPORT""}], ""name"": ""Lactate Dehydrogenase (LDH)"", ""presence"": ""Elevated""}"
3150	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	biochemical	3	Heinz Bodies			OCCASIONAL		during acute hemolysis			Present																											Oxidized hemoglobin precipitates attached to the inner RBC membrane																						"{""context"": ""during acute hemolysis"", ""frequency"": ""OCCASIONAL"", ""name"": ""Heinz Bodies"", ""notes"": ""Oxidized hemoglobin precipitates attached to the inner RBC membrane"", ""presence"": ""Present""}"	{}	"{""cell_types"": [{""preferred_term"": ""Red Blood Cells"", ""term"": {""id"": ""CL:0000232"", ""label"": ""erythrocyte""}}], ""context"": ""during acute hemolysis"", ""evidence"": [{""explanation"": ""The excerpt directly mentions the presence of Heinz bodies in red blood cells during acute hemolysis in individuals with G6PD deficiency, supporting the statement."", ""reference"": ""PMID:17365988"", ""snippet"": ""The presence of unopposed oxidizing agents leading to oxidation of the sulfhydryl bridges between parts of the haemoglobin molecule decrease the solubility of haemoglobin, leading to precipitations called Heinz bodies."", ""supports"": ""SUPPORT""}], ""frequency"": ""OCCASIONAL"", ""name"": ""Heinz Bodies"", ""notes"": ""Oxidized hemoglobin precipitates attached to the inner RBC membrane"", ""presence"": ""Present""}"
3151	132	Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency	Glucose-6-Phosphate_Dehydrogenase_G6PD_Deficiency.yaml	biochemical	4	Glutathione/GSSG Ratio					during oxidative stress			Decreased																											Reduced GSH/GSSG ratio reflects impaired glutathione reductase-mediated recycling due to NADPH deficit																						"{""context"": ""during oxidative stress"", ""name"": ""Glutathione/GSSG Ratio"", ""notes"": ""Reduced GSH/GSSG ratio reflects impaired glutathione reductase-mediated recycling due to NADPH deficit"", ""presence"": ""Decreased""}"	{}	"{""cell_types"": [{""preferred_term"": ""Red Blood Cells"", ""term"": {""id"": ""CL:0000232"", ""label"": ""erythrocyte""}}], ""context"": ""during oxidative stress"", ""name"": ""Glutathione/GSSG Ratio"", ""notes"": ""Reduced GSH/GSSG ratio reflects impaired glutathione reductase-mediated recycling due to NADPH deficit"", ""presence"": ""Decreased""}"
3203	134	Gout	Gout.yaml	biochemical	0	Serum Uric Acid					Usually >6.8 mg/dL, may be normal during acute attack			Elevated																																																	"{""context"": ""Usually >6.8 mg/dL, may be normal during acute attack"", ""name"": ""Serum Uric Acid"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Usually >6.8 mg/dL, may be normal during acute attack"", ""name"": ""Serum Uric Acid"", ""presence"": ""Elevated""}"
3204	134	Gout	Gout.yaml	biochemical	1	CRP					Acute flare			Elevated																																																	"{""context"": ""Acute flare"", ""name"": ""CRP"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Acute flare"", ""name"": ""CRP"", ""presence"": ""Elevated""}"
3205	134	Gout	Gout.yaml	biochemical	2	Synovial Fluid Crystals					Negatively birefringent MSU crystals diagnostic			Present																																																	"{""context"": ""Negatively birefringent MSU crystals diagnostic"", ""name"": ""Synovial Fluid Crystals"", ""presence"": ""Present""}"	{}	"{""context"": ""Negatively birefringent MSU crystals diagnostic"", ""name"": ""Synovial Fluid Crystals"", ""presence"": ""Present""}"
3246	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	biochemical	0	PR3-ANCA (c-ANCA)					Present in 80-90% of active generalized disease			Elevated																																																	"{""context"": ""Present in 80-90% of active generalized disease"", ""name"": ""PR3-ANCA (c-ANCA)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Present in 80-90% of active generalized disease"", ""evidence"": [{""explanation"": ""This review confirms that PR3-ANCA subtyping is clinically important in GPA, with prognostic and therapeutic implications."", ""reference"": ""PMID:35479831"", ""snippet"": ""There is also evidence for classification of patients based on ANCA subtype; those with anti-proteinase 3 antibodies (PR3) or anti-myeloperoxidase antibodies (MPO) have differences in response to treatment and clinical outcomes."", ""supports"": ""SUPPORT""}], ""name"": ""PR3-ANCA (c-ANCA)"", ""presence"": ""Elevated""}"
3247	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	biochemical	1	MPO-ANCA (p-ANCA)					Present in 10-20% of patients			Variable																																																	"{""context"": ""Present in 10-20% of patients"", ""name"": ""MPO-ANCA (p-ANCA)"", ""presence"": ""Variable""}"	{}	"{""context"": ""Present in 10-20% of patients"", ""name"": ""MPO-ANCA (p-ANCA)"", ""presence"": ""Variable""}"
3248	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	biochemical	2	ESR					Marker of inflammation			Elevated																																																	"{""context"": ""Marker of inflammation"", ""name"": ""ESR"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Marker of inflammation"", ""name"": ""ESR"", ""presence"": ""Elevated""}"
3249	136	Granulomatosis with Polyangiitis	Granulomatosis_with_Polyangiitis.yaml	biochemical	3	CRP					Correlates with disease activity			Elevated																																																	"{""context"": ""Correlates with disease activity"", ""name"": ""CRP"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Correlates with disease activity"", ""name"": ""CRP"", ""presence"": ""Elevated""}"
3263	137	Graves' Disease	Graves_Disease.yaml	biochemical	0	Free Thyroxine (T4)					Indicates hyperthyroidism			Increased																																																	"{""context"": ""Indicates hyperthyroidism"", ""name"": ""Free Thyroxine (T4)"", ""presence"": ""Increased""}"	{}	"{""context"": ""Indicates hyperthyroidism"", ""evidence"": [{""explanation"": ""The study confirms that patients with untreated, newly diagnosed Graves' disease have elevated serum levels of thyroxine (T4)."", ""reference"": ""PMID:2816972"", ""snippet"": ""We examined 25 patients with untreated, newly diagnosed Graves' disease using the Hyperthyroid Symptom Scale (HSS) and serum levels of thyroxine (T4), triiodothyronine (T3) relative insulin area (RIA), and estimates of free thyroxine index (FTI)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Thyrotoxicosis, which is associated with Graves' disease, implies increased levels of thyroid hormones including free thyroxine (T4)."", ""reference"": ""PMID:30487326"", ""snippet"": ""Thyrotoxicosis, commonly seen in a condition with Graves' disease, causes increased bone absorption and results in osteoporosis with increased bone turnover."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference mentions untreated hyperthyroidism due to Graves' disease and elevated levels of thyroid hormones including T4."", ""reference"": ""PMID:3558731"", ""snippet"": ""Thyroglobulin (Tg) was obtained by fine needle aspiration from patients with untreated hyperthyroidism due to Graves' disease...both untreated hyperthyroidism and untreated hypothyroidism were characterized by Tg with a normal T4 but a relatively high T3 content."", ""supports"": ""SUPPORT""}, {""explanation"": ""Hyperthyroidism due to Graves' disease during pregnancy indicates elevated levels of thyroid hormones including free thyroxine (T4)."", ""reference"": ""PMID:7527990"", ""snippet"": ""Hyperthyroidism occurring during pregnancy is usually due to Graves' disease and must be treated to prevent congenital anomalies, low birth weight and premature labour."", ""supports"": ""SUPPORT""}], ""name"": ""Free Thyroxine (T4)"", ""presence"": ""Increased""}"
3264	137	Graves' Disease	Graves_Disease.yaml	biochemical	1	Free Triiodothyronine (T3)					Indicates hyperthyroidism			Increased																																																	"{""context"": ""Indicates hyperthyroidism"", ""name"": ""Free Triiodothyronine (T3)"", ""presence"": ""Increased""}"	{}	"{""context"": ""Indicates hyperthyroidism"", ""evidence"": [{""explanation"": ""The study involves measuring serum levels of triiodothyronine (T3) in patients with Graves' disease, indicating its relevance to hyperthyroidism."", ""reference"": ""PMID:2816972"", ""snippet"": ""We examined 25 patients with untreated, newly diagnosed Graves'' disease using the Hyperthyroid Symptom Scale (HSS) and serum levels of thyroxine (T4), triiodothyronine (T3) relative insulin area (RIA), and estimates of free thyroxine index (FTI)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study shows enhanced conversion of T4 to T3 in Graves' thyroid tissues, supporting the statement that Graves' Disease indicates increased levels of Free Triiodothyronine (T3)."", ""reference"": ""PMID:6894450"", ""snippet"": ""Conversion of T4 to T3 was observed in two of three tumor tissues studied and was markedly enhanced in Graves' thyroid tissues (mean +/- SE, 11.9 +/- 2.0 pmol/mg protein.min) compared to that of normal thyroid tissues (3.2 +/- 0.6 pmol/mg protein.min; P less than 0.01)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study mentions T3-predominant Graves' disease cases, which are characterized by higher T3 levels, supporting the statement."", ""reference"": ""PMID:32493403"", ""snippet"": ""Approximately 10% of all Graves'' disease cases are triiodothyronine (T3)-predominant. T3-predominance is characterized by higher T3 levels than thyroxine (T4) levels."", ""supports"": ""SUPPORT""}, {""explanation"": ""The statement is supported as the clinical role of free T3 measurements is to assess hyperthyroidism, which is a common manifestation of Graves' Disease."", ""reference"": ""PMID:8565219"", ""snippet"": ""The major clinical role for total triiodothyronine (TT3) and (or) free T3 (FT3) is the assessment of hyperthyroidism in patients with suppressed sensitive thyrotropin (sTSH) concentrations."", ""supports"": ""SUPPORT""}], ""name"": ""Free Triiodothyronine (T3)"", ""presence"": ""Increased""}"
3265	137	Graves' Disease	Graves_Disease.yaml	biochemical	2	Thyroid-Stimulating Hormone (TSH)					Indicates feedback suppression due to high levels of thyroid hormones			Decreased																																																	"{""context"": ""Indicates feedback suppression due to high levels of thyroid hormones"", ""name"": ""Thyroid-Stimulating Hormone (TSH)"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Indicates feedback suppression due to high levels of thyroid hormones"", ""evidence"": [{""explanation"": ""The literature indicates that TSH levels can remain suppressed in patients with Graves' disease, which aligns with the statement that high levels of thyroid hormones in Graves' disease lead to feedback suppression of TSH."", ""reference"": ""PMID:25864995"", ""snippet"": ""BACKGROUND: Post-treatment hypothyroidism is common in Graves' disease, and clinical guidelines recommend monitoring for it; however, thyroid stimulating hormone (TSH) can remain suppressed in these patients following treatment."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature states that TSH levels are low in patients with hyperthyroidism, including those with Graves' disease, supporting the statement about decreased TSH levels due to feedback suppression."", ""reference"": ""PMID:27936530"", ""snippet"": ""This level usually is elevated in patients with hypothyroidism and low in patients with hyperthyroidism. ... Graves disease is the most common etiology in developed countries."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature mentions that TSH levels are low in hyperthyroid states, which includes Graves' disease, supporting the statement about decreased TSH levels due to feedback suppression."", ""reference"": ""PMID:19631028"", ""snippet"": ""Evidence using mice lacking the thyroid hormone receptors alpha and beta establishes a role for thyroid hormones in regulating bone remodeling but does not exclude an independent action of thyroid-stimulating hormone (TSH), levels of which are low in hyperthyroid states."", ""supports"": ""SUPPORT""}], ""name"": ""Thyroid-Stimulating Hormone (TSH)"", ""presence"": ""Decreased""}"
3266	137	Graves' Disease	Graves_Disease.yaml	biochemical	3	Thyroid-Stimulating Immunoglobulins (TSI)					Confirms autoimmune etiology			Positive																																																	"{""context"": ""Confirms autoimmune etiology"", ""name"": ""Thyroid-Stimulating Immunoglobulins (TSI)"", ""presence"": ""Positive""}"	{}	"{""context"": ""Confirms autoimmune etiology"", ""evidence"": [{""explanation"": ""The presence of TSI is indicative of Graves' Disease, confirming its autoimmune etiology."", ""reference"": ""PMID:34331946"", ""snippet"": ""As thyroid-stimulating immunoglobulins (TSI) are a sign of Graves' disease (GD), measuring TSI titers is becoming increasingly important for GD diagnosis."", ""supports"": ""SUPPORT""}, {""explanation"": ""TSI activity is present in patients with Graves' Disease, supporting its autoimmune nature."", ""reference"": ""PMID:2888784"", ""snippet"": ""All patients with active Graves' disease (n = 47) had detectable serum TSI activity."", ""supports"": ""SUPPORT""}, {""explanation"": ""The established presence of TSI in Graves' Disease patients supports its autoimmune etiology."", ""reference"": ""PMID:6129186"", ""snippet"": ""The presence of thyroid-stimulating immunoglobulins in patients with Graves' disease is well established."", ""supports"": ""SUPPORT""}, {""explanation"": ""The autoimmune response, including the presence of TSI, is crucial for the development of Graves' Disease."", ""reference"": ""PMID:23276963"", ""snippet"": ""Earlier studies have demonstrated the autoimmune response plays a dominant role in the development of GD."", ""supports"": ""SUPPORT""}], ""name"": ""Thyroid-Stimulating Immunoglobulins (TSI)"", ""presence"": ""Positive""}"
3304	138	Guillain-Barre Syndrome	Guillain_Barre_Syndrome.yaml	biochemical	0	CSF Protein					Albuminocytologic dissociation characteristic			Elevated																																																	"{""context"": ""Albuminocytologic dissociation characteristic"", ""name"": ""CSF Protein"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Albuminocytologic dissociation characteristic"", ""name"": ""CSF Protein"", ""presence"": ""Elevated""}"
3305	138	Guillain-Barre Syndrome	Guillain_Barre_Syndrome.yaml	biochemical	1	Antiganglioside Antibodies					GM1, GD1a, GQ1b depending on subtype			Variable																																																	"{""context"": ""GM1, GD1a, GQ1b depending on subtype"", ""name"": ""Antiganglioside Antibodies"", ""presence"": ""Variable""}"	{}	"{""context"": ""GM1, GD1a, GQ1b depending on subtype"", ""name"": ""Antiganglioside Antibodies"", ""presence"": ""Variable""}"
3343	140	HER2-Positive Breast Cancer	HER2_Positive_Breast_Cancer.yaml	biochemical	0	HER2 Testing (IHC and FISH)																																			HER2 status is determined by immunohistochemistry (IHC) for protein expression and/or fluorescence in situ hybridization (FISH) for gene amplification. IHC scores of 0-1+ are negative, 2+ is equivocal (requires FISH), and 3+ is positive. FISH positive is defined as HER2/CEP17 ratio ≥2.0 or average HER2 copy number ≥6.																						"{""name"": ""HER2 Testing (IHC and FISH)"", ""notes"": ""HER2 status is determined by immunohistochemistry (IHC) for protein expression and/or fluorescence in situ hybridization (FISH) for gene amplification. IHC scores of 0-1+ are negative, 2+ is equivocal (requires FISH), and 3+ is positive. FISH positive is defined as HER2/CEP17 ratio ≥2.0 or average HER2 copy number ≥6.""}"	{}	"{""name"": ""HER2 Testing (IHC and FISH)"", ""notes"": ""HER2 status is determined by immunohistochemistry (IHC) for protein expression and/or fluorescence in situ hybridization (FISH) for gene amplification. IHC scores of 0-1+ are negative, 2+ is equivocal (requires FISH), and 3+ is positive. FISH positive is defined as HER2/CEP17 ratio ≥2.0 or average HER2 copy number ≥6.""}"
3359	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	biochemical	0	HER2 Immunohistochemistry																																			IHC scoring uses the same criteria as gastric cancer (modified from breast cancer): 0/1+ negative, 2+ equivocal requiring FISH confirmation, 3+ positive. Colorectal-specific scoring criteria have been proposed (HERACLES criteria) with stricter requirements.																						"{""name"": ""HER2 Immunohistochemistry"", ""notes"": ""IHC scoring uses the same criteria as gastric cancer (modified from breast cancer): 0/1+ negative, 2+ equivocal requiring FISH confirmation, 3+ positive. Colorectal-specific scoring criteria have been proposed (HERACLES criteria) with stricter requirements.""}"	{}	"{""name"": ""HER2 Immunohistochemistry"", ""notes"": ""IHC scoring uses the same criteria as gastric cancer (modified from breast cancer): 0/1+ negative, 2+ equivocal requiring FISH confirmation, 3+ positive. Colorectal-specific scoring criteria have been proposed (HERACLES criteria) with stricter requirements.""}"
3360	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	biochemical	1	HER2 FISH/ISH																																			Fluorescence in situ hybridization or other in situ hybridization methods detect ERBB2 gene amplification. HER2/CEP17 ratio greater than 2.0 or HER2 copy number greater than 6 indicates amplification. Required for IHC 2+ cases.																						"{""name"": ""HER2 FISH/ISH"", ""notes"": ""Fluorescence in situ hybridization or other in situ hybridization methods detect ERBB2 gene amplification. HER2/CEP17 ratio greater than 2.0 or HER2 copy number greater than 6 indicates amplification. Required for IHC 2+ cases.""}"	{}	"{""name"": ""HER2 FISH/ISH"", ""notes"": ""Fluorescence in situ hybridization or other in situ hybridization methods detect ERBB2 gene amplification. HER2/CEP17 ratio greater than 2.0 or HER2 copy number greater than 6 indicates amplification. Required for IHC 2+ cases.""}"
3361	141	HER2-Positive Colorectal Cancer	HER2_Positive_Colorectal_Cancer.yaml	biochemical	2	Next-Generation Sequencing																																			NGS can detect ERBB2 amplification through copy number analysis and may identify activating ERBB2 mutations as alternative mechanisms of HER2 pathway activation.																						"{""name"": ""Next-Generation Sequencing"", ""notes"": ""NGS can detect ERBB2 amplification through copy number analysis and may identify activating ERBB2 mutations as alternative mechanisms of HER2 pathway activation.""}"	{}	"{""name"": ""Next-Generation Sequencing"", ""notes"": ""NGS can detect ERBB2 amplification through copy number analysis and may identify activating ERBB2 mutations as alternative mechanisms of HER2 pathway activation.""}"
3380	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	biochemical	0	HER2 Immunohistochemistry																																			IHC scoring criteria differ from breast cancer due to heterogeneous staining and basolateral membrane patterns in gastric cancer. Scoring: 0 (negative), 1+ (faint), 2+ (weak to moderate complete/basolateral staining in 10% or more of cells - requires ISH confirmation), 3+ (strong complete/basolateral staining in 10% or more - positive).																						"{""name"": ""HER2 Immunohistochemistry"", ""notes"": ""IHC scoring criteria differ from breast cancer due to heterogeneous staining and basolateral membrane patterns in gastric cancer. Scoring: 0 (negative), 1+ (faint), 2+ (weak to moderate complete/basolateral staining in 10% or more of cells - requires ISH confirmation), 3+ (strong complete/basolateral staining in 10% or more - positive).""}"	{}	"{""name"": ""HER2 Immunohistochemistry"", ""notes"": ""IHC scoring criteria differ from breast cancer due to heterogeneous staining and basolateral membrane patterns in gastric cancer. Scoring: 0 (negative), 1+ (faint), 2+ (weak to moderate complete/basolateral staining in 10% or more of cells - requires ISH confirmation), 3+ (strong complete/basolateral staining in 10% or more - positive).""}"
3381	142	HER2-Positive Gastric Cancer	HER2_Positive_Gastric_Cancer.yaml	biochemical	1	HER2 In Situ Hybridization																																			FISH or other ISH methods assess HER2/CEP17 ratio. Ratio greater than 2.0 is positive. Required for IHC 2+ (equivocal) cases. Intratumoral heterogeneity is more common in gastric than breast cancer.																						"{""name"": ""HER2 In Situ Hybridization"", ""notes"": ""FISH or other ISH methods assess HER2/CEP17 ratio. Ratio greater than 2.0 is positive. Required for IHC 2+ (equivocal) cases. Intratumoral heterogeneity is more common in gastric than breast cancer.""}"	{}	"{""name"": ""HER2 In Situ Hybridization"", ""notes"": ""FISH or other ISH methods assess HER2/CEP17 ratio. Ratio greater than 2.0 is positive. Required for IHC 2+ (equivocal) cases. Intratumoral heterogeneity is more common in gastric than breast cancer.""}"
3426	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	biochemical	0	p16 Immunohistochemistry																																			Unlike HPV-positive HNSCC, p16 is typically negative or focally/weakly positive in HPV-negative tumors due to CDKN2A inactivation. p16 status is critical for staging oropharyngeal carcinoma in the 8th edition AJCC staging system.																						"{""name"": ""p16 Immunohistochemistry"", ""notes"": ""Unlike HPV-positive HNSCC, p16 is typically negative or focally/weakly positive in HPV-negative tumors due to CDKN2A inactivation. p16 status is critical for staging oropharyngeal carcinoma in the 8th edition AJCC staging system.""}"	{}	"{""name"": ""p16 Immunohistochemistry"", ""notes"": ""Unlike HPV-positive HNSCC, p16 is typically negative or focally/weakly positive in HPV-negative tumors due to CDKN2A inactivation. p16 status is critical for staging oropharyngeal carcinoma in the 8th edition AJCC staging system.""}"
3427	144	HPV-Negative Head and Neck Cancer	HPV_Negative_Head_and_Neck_Cancer.yaml	biochemical	1	EGFR Expression																																			EGFR overexpression is common but has not proven useful as a predictive biomarker for cetuximab response. EGFR gene copy number and mutations are less common than overexpression.																						"{""name"": ""EGFR Expression"", ""notes"": ""EGFR overexpression is common but has not proven useful as a predictive biomarker for cetuximab response. EGFR gene copy number and mutations are less common than overexpression.""}"	{}	"{""name"": ""EGFR Expression"", ""notes"": ""EGFR overexpression is common but has not proven useful as a predictive biomarker for cetuximab response. EGFR gene copy number and mutations are less common than overexpression.""}"
3454	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	biochemical	0	p16 Immunohistochemistry																																			Strong, diffuse nuclear and cytoplasmic p16 staining serves as a surrogate marker for transcriptionally active HPV infection. The p16 positivity is due to pRB inactivation by E7, which removes feedback inhibition of CDKN2A expression. p16 IHC is used clinically for staging and prognostication.																						"{""name"": ""p16 Immunohistochemistry"", ""notes"": ""Strong, diffuse nuclear and cytoplasmic p16 staining serves as a surrogate marker for transcriptionally active HPV infection. The p16 positivity is due to pRB inactivation by E7, which removes feedback inhibition of CDKN2A expression. p16 IHC is used clinically for staging and prognostication.""}"	{}	"{""name"": ""p16 Immunohistochemistry"", ""notes"": ""Strong, diffuse nuclear and cytoplasmic p16 staining serves as a surrogate marker for transcriptionally active HPV infection. The p16 positivity is due to pRB inactivation by E7, which removes feedback inhibition of CDKN2A expression. p16 IHC is used clinically for staging and prognostication.""}"
3455	145	HPV-Positive Head and Neck Cancer	HPV_Positive_Head_and_Neck_Cancer.yaml	biochemical	1	HPV DNA/RNA Testing																																			Detection of high-risk HPV DNA or E6/E7 mRNA confirms HPV-driven carcinogenesis. RNA detection is more specific for transcriptionally active infection than DNA detection alone.																						"{""name"": ""HPV DNA/RNA Testing"", ""notes"": ""Detection of high-risk HPV DNA or E6/E7 mRNA confirms HPV-driven carcinogenesis. RNA detection is more specific for transcriptionally active infection than DNA detection alone.""}"	{}	"{""name"": ""HPV DNA/RNA Testing"", ""notes"": ""Detection of high-risk HPV DNA or E6/E7 mRNA confirms HPV-driven carcinogenesis. RNA detection is more specific for transcriptionally active infection than DNA detection alone.""}"
3477	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	biochemical	0	TSH					Primary hypothyroidism			Elevated																																																	"{""context"": ""Primary hypothyroidism"", ""name"": ""TSH"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Primary hypothyroidism"", ""name"": ""TSH"", ""presence"": ""Elevated""}"
3478	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	biochemical	1	Free T4					Overt hypothyroidism			Decreased																																																	"{""context"": ""Overt hypothyroidism"", ""name"": ""Free T4"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Overt hypothyroidism"", ""name"": ""Free T4"", ""presence"": ""Decreased""}"
3479	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	biochemical	2	Anti-TPO Antibodies					Diagnostic marker			Elevated																																																	"{""context"": ""Diagnostic marker"", ""name"": ""Anti-TPO Antibodies"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Diagnostic marker"", ""name"": ""Anti-TPO Antibodies"", ""presence"": ""Elevated""}"
3480	146	Hashimoto's Thyroiditis	Hashimotos_Thyroiditis.yaml	biochemical	3	Anti-Thyroglobulin Antibodies					Present in majority of patients			Elevated																																																	"{""context"": ""Present in majority of patients"", ""name"": ""Anti-Thyroglobulin Antibodies"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Present in majority of patients"", ""name"": ""Anti-Thyroglobulin Antibodies"", ""presence"": ""Elevated""}"
3500	147	Heart Failure	Heart_Failure.yaml	biochemical	0	BNP/NT-proBNP					Diagnostic and prognostic biomarker			Elevated																																																	"{""context"": ""Diagnostic and prognostic biomarker"", ""name"": ""BNP/NT-proBNP"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Diagnostic and prognostic biomarker"", ""evidence"": [{""explanation"": ""BNP and NT-proBNP are natriuretic peptides that serve as biomarkers of neurohormonal activation in heart failure, useful for diagnosis and therapeutic guidance."", ""reference"": ""PMID:37895150"", ""snippet"": ""There are biomarkers of activation of these neurohormonal pathways, such as the natriuretic peptides, catecholamine levels and neprilysin and various newer ones, which may be employed to better understand the mechanisms of HF drugs and also aid in defining the subgroups of patients who might benefit from specific therapies."", ""supports"": ""SUPPORT""}], ""name"": ""BNP/NT-proBNP"", ""presence"": ""Elevated""}"
3501	147	Heart Failure	Heart_Failure.yaml	biochemical	1	Troponin					May be chronically elevated in heart failure			Elevated																																																	"{""context"": ""May be chronically elevated in heart failure"", ""name"": ""Troponin"", ""presence"": ""Elevated""}"	{}	"{""context"": ""May be chronically elevated in heart failure"", ""name"": ""Troponin"", ""presence"": ""Elevated""}"
3549	149	Hemophilia A	Hemophilia_A.yaml	biochemical	0	Factor VIII Activity					Severe less than 1%, moderate 1-5%, mild 5-40%			Decreased																																																	"{""context"": ""Severe less than 1%, moderate 1-5%, mild 5-40%"", ""name"": ""Factor VIII Activity"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Severe less than 1%, moderate 1-5%, mild 5-40%"", ""name"": ""Factor VIII Activity"", ""presence"": ""Decreased""}"
3550	149	Hemophilia A	Hemophilia_A.yaml	biochemical	1	aPTT					Prolonged, corrects with mixing study			Elevated																																																	"{""context"": ""Prolonged, corrects with mixing study"", ""name"": ""aPTT"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Prolonged, corrects with mixing study"", ""name"": ""aPTT"", ""presence"": ""Elevated""}"
3551	149	Hemophilia A	Hemophilia_A.yaml	biochemical	2	PT/INR					Extrinsic pathway intact			Normal																																																	"{""context"": ""Extrinsic pathway intact"", ""name"": ""PT/INR"", ""presence"": ""Normal""}"	{}	"{""context"": ""Extrinsic pathway intact"", ""name"": ""PT/INR"", ""presence"": ""Normal""}"
3572	151	Hepatitis B	Hepatitis_B.yaml	biochemical	0	Hepatitis B Surface Antigen (HBsAg)					Indicates active infection			Positive																																																	"{""context"": ""Indicates active infection"", ""name"": ""Hepatitis B Surface Antigen (HBsAg)"", ""presence"": ""Positive""}"	{}	"{""context"": ""Indicates active infection"", ""evidence"": [{""explanation"": ""The presence of HBsAg indicates that the individual harbors the hepatitis B virus, which supports the statement that a positive HBsAg indicates an active infection."", ""reference"": ""PMID:49464"", ""snippet"": ""HBsAg in an individual indicates that he harbors the virus of hepatitis B; it may be present in the absence of liver disease or be found in association with both acute and chronic type B hepatitis."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study focuses on patients newly diagnosed with active HBV infection based on the presence of positive HBsAg, supporting the statement that a positive HBsAg indicates an active infection."", ""reference"": ""PMID:22300111"", ""snippet"": ""To analyze the epidemiological, clinical, and virological characteristics of patients newly diagnosed with active hepatitis B virus (HBV) infection based on the presence of positive hepatitis B surface antigen (HBsAg)..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The presence of HBsAg reflects the presence of hepatitis B virus, indicating active infection, which supports the statement."", ""reference"": ""PMID:21692954"", ""snippet"": ""Serum hepatitis B surface antigen (HBsAg) levels reflect intrahepatic hepatitis B virus (HBV) covalently closed circular DNA and may be a valuable addition to HBV DNA in the management of patients with chronic hepatitis B (CHB)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The recommendation to test HBsAg-positive individuals for HBV DNA indicates that a positive HBsAg is associated with active infection."", ""reference"": ""PMID:36906494"", ""snippet"": ""The Advisory Committee for Immunization Practices (ACIP) recommends testing all pregnant women for hepatitis B surface antigen (HBsAg) and testing HBsAg-positive pregnant women for hepatitis B virus deoxyribonucleic acid (HBV DNA)."", ""supports"": ""SUPPORT""}], ""name"": ""Hepatitis B Surface Antigen (HBsAg)"", ""presence"": ""Positive""}"
3573	151	Hepatitis B	Hepatitis_B.yaml	biochemical	1	Hepatitis B e Antigen (HBeAg)					Indicates active viral replication and high infectivity			Positive																																																	"{""context"": ""Indicates active viral replication and high infectivity"", ""name"": ""Hepatitis B e Antigen (HBeAg)"", ""presence"": ""Positive""}"	{}	"{""context"": ""Indicates active viral replication and high infectivity"", ""evidence"": [{""explanation"": ""The study confirms that HBeAg is a surrogate marker for active hepatitis B virus replication."", ""reference"": ""PMID:12124405"", ""snippet"": ""The presence of hepatitis B e antigen (HBeAg) in serum indicates active viral replication in hepatocytes."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article states that HBeAg is associated with highly replicative activity of the hepatitis B virus."", ""reference"": ""PMID:21205143"", ""snippet"": ""HBeAg seropositivity is a marker for active viral replication."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study shows that the presence of HBeAg in serum is associated with active hepatitis B virus replication."", ""reference"": ""PMID:7038074"", ""snippet"": ""Hepatitis B virus markers were studied in serum and liver of 24 children with chronic hepatitis. All patients had evidence of active virus replication... Furthermore, 19 of 24 patients had hepatitis B e antigen in serum."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article confirms that HBeAg is an indicator of active HBV replication."", ""reference"": ""PMID:25218700"", ""snippet"": ""Hepatitis B e antigen (HBeAg) is a marker to indicate active replication of hepatitis B virus (HBV)."", ""supports"": ""SUPPORT""}], ""name"": ""Hepatitis B e Antigen (HBeAg)"", ""presence"": ""Positive""}"
3574	151	Hepatitis B	Hepatitis_B.yaml	biochemical	2	HBV DNA					Indicates viral load and active replication			Positive																																																	"{""context"": ""Indicates viral load and active replication"", ""name"": ""HBV DNA"", ""presence"": ""Positive""}"	{}	"{""context"": ""Indicates viral load and active replication"", ""evidence"": [{""explanation"": ""The presence of HBV DNA in the serum is associated with active replication of HBV in the liver."", ""reference"": ""PMID:7030903"", ""snippet"": ""The assay for serum HBV DNA appears to be an excellent noninvasive method for detecting active replication of HBV in HBsAg carriers."", ""supports"": ""SUPPORT""}, {""explanation"": ""The presence of HBV DNA indicates the presence of the virus and hence active replication."", ""reference"": ""PMID:31741331"", ""snippet"": ""Hepatitis B virus (HBV) is a DNA virus, belonging to the Hepadnaviridae family."", ""supports"": ""SUPPORT""}, {""explanation"": ""The presence of HBV DNA in serum is used to quantify viral load, indicating active replication."", ""reference"": ""PMID:27032097"", ""snippet"": ""Quantitative real-time PCR and HBV sequencing were performed in HBsAg-positive patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""HBV DNA levels are used to monitor and predict disease progression, indicating active replication."", ""reference"": ""PMID:35122363"", ""snippet"": ""Use of HBV DNA and liver stiffness in predicting clinical events in patients with chronic hepatitis B."", ""supports"": ""SUPPORT""}, {""explanation"": ""The presence of HBV DNA in serum and PBMC is linked to active viral replication."", ""reference"": ""PMID:29170913"", ""snippet"": ""Maternal serum HBeAg was a risk factor of PBMC HBV rcDNA (OR = 3.896, 95% CI: 1.929-7.876) and PBMC HBV cccDNA (OR = 3.74, 95% CI: 1.186-11.793) in the HBsAg-positive mothers."", ""supports"": ""SUPPORT""}, {""explanation"": ""HBV DNA quantification is used to predict viral load and active replication."", ""reference"": ""PMID:31021394"", ""snippet"": ""HBV DNA levels in pregnancy women at 28-30 weeks predict the risk of immunoprophylaxis failure."", ""supports"": ""SUPPORT""}, {""explanation"": ""The presence of HBV DNA in serum indicates active viral replication and disease progression."", ""reference"": ""PMID:22510145"", ""snippet"": ""Serum HBV DNA level has been shown to be significantly and independently associated with incidence of hepatocellular carcinoma (HCC) and cirrhosis and liver-related mortality across a biological gradient."", ""supports"": ""SUPPORT""}, {""explanation"": ""HBV DNA levels are used to monitor viral load and active replication."", ""reference"": ""PMID:28350873"", ""snippet"": ""Our results demonstrated that on-treatment HBV DNA could probably predict VBT in ETV-treated HBeAg-positive chronic hepatitis B patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""The presence of HBV DNA indicates active replication and can be used to assess disease severity."", ""reference"": ""PMID:37179582"", ""snippet"": ""HBV DNA level is a negative risk factor for liver disease progression."", ""supports"": ""SUPPORT""}], ""name"": ""HBV DNA"", ""presence"": ""Positive""}"
3617	152	Hepatitis C	Hepatitis_C.yaml	biochemical	0	HCV RNA					Confirms active viral infection; quantitative levels guide treatment monitoring			Detected																																																	"{""context"": ""Confirms active viral infection; quantitative levels guide treatment monitoring"", ""name"": ""HCV RNA"", ""presence"": ""Detected""}"	{}	"{""context"": ""Confirms active viral infection; quantitative levels guide treatment monitoring"", ""name"": ""HCV RNA"", ""presence"": ""Detected""}"
3618	152	Hepatitis C	Hepatitis_C.yaml	biochemical	1	Anti-HCV Antibodies					Indicates current or past infection; does not distinguish active from resolved infection			Detected																																																	"{""context"": ""Indicates current or past infection; does not distinguish active from resolved infection"", ""name"": ""Anti-HCV Antibodies"", ""presence"": ""Detected""}"	{}	"{""context"": ""Indicates current or past infection; does not distinguish active from resolved infection"", ""name"": ""Anti-HCV Antibodies"", ""presence"": ""Detected""}"
3619	152	Hepatitis C	Hepatitis_C.yaml	biochemical	2	Elevated ALT					Marker of hepatocyte injury, though may be normal in some chronic infections			Elevated																																																	"{""context"": ""Marker of hepatocyte injury, though may be normal in some chronic infections"", ""name"": ""Elevated ALT"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Marker of hepatocyte injury, though may be normal in some chronic infections"", ""name"": ""Elevated ALT"", ""presence"": ""Elevated""}"
3620	152	Hepatitis C	Hepatitis_C.yaml	biochemical	3	Elevated Bilirubin					Indicates impaired hepatic function, especially in acute infection or decompensated cirrhosis			Elevated																																																	"{""context"": ""Indicates impaired hepatic function, especially in acute infection or decompensated cirrhosis"", ""name"": ""Elevated Bilirubin"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Indicates impaired hepatic function, especially in acute infection or decompensated cirrhosis"", ""name"": ""Elevated Bilirubin"", ""presence"": ""Elevated""}"
3642	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	biochemical	0	Alpha-Fetoprotein (AFP)																																			Serum AFP is elevated in approximately 60% of HCC cases. Levels greater than 400 ng/mL are highly specific for HCC in the setting of cirrhosis. Used for diagnosis (with imaging) and monitoring treatment response. AFP-L3 fraction improves specificity.																						"{""name"": ""Alpha-Fetoprotein (AFP)"", ""notes"": ""Serum AFP is elevated in approximately 60% of HCC cases. Levels greater than 400 ng/mL are highly specific for HCC in the setting of cirrhosis. Used for diagnosis (with imaging) and monitoring treatment response. AFP-L3 fraction improves specificity.""}"	{}	"{""name"": ""Alpha-Fetoprotein (AFP)"", ""notes"": ""Serum AFP is elevated in approximately 60% of HCC cases. Levels greater than 400 ng/mL are highly specific for HCC in the setting of cirrhosis. Used for diagnosis (with imaging) and monitoring treatment response. AFP-L3 fraction improves specificity.""}"
3643	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	biochemical	1	Liver Function Tests																																			Elevated transaminases, alkaline phosphatase, and bilirubin may occur. Pattern depends on underlying liver disease and tumor burden. Child-Pugh score assesses hepatic reserve and guides treatment decisions.																						"{""name"": ""Liver Function Tests"", ""notes"": ""Elevated transaminases, alkaline phosphatase, and bilirubin may occur. Pattern depends on underlying liver disease and tumor burden. Child-Pugh score assesses hepatic reserve and guides treatment decisions.""}"	{}	"{""name"": ""Liver Function Tests"", ""notes"": ""Elevated transaminases, alkaline phosphatase, and bilirubin may occur. Pattern depends on underlying liver disease and tumor burden. Child-Pugh score assesses hepatic reserve and guides treatment decisions.""}"
3644	153	Hepatocellular Carcinoma	Hepatocellular_Carcinoma.yaml	biochemical	2	PIVKA-II (DCP)																																			Des-gamma-carboxy prothrombin is an alternative biomarker to AFP. May be elevated when AFP is normal. Useful in combination with AFP for surveillance and diagnosis.																						"{""name"": ""PIVKA-II (DCP)"", ""notes"": ""Des-gamma-carboxy prothrombin is an alternative biomarker to AFP. May be elevated when AFP is normal. Useful in combination with AFP for surveillance and diagnosis.""}"	{}	"{""name"": ""PIVKA-II (DCP)"", ""notes"": ""Des-gamma-carboxy prothrombin is an alternative biomarker to AFP. May be elevated when AFP is normal. Useful in combination with AFP for surveillance and diagnosis.""}"
3677	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	biochemical	0	BRCA1/2 Genetic Testing																																			Comprehensive sequencing of BRCA1 and BRCA2 identifies pathogenic variants including frameshift, nonsense, splice site, and missense mutations, as well as large deletions/duplications. Founder mutations exist in certain populations (Ashkenazi Jewish: 185delAG, 5382insC in BRCA1; 6174delT in BRCA2). Variants of uncertain significance require careful interpretation.																						"{""name"": ""BRCA1/2 Genetic Testing"", ""notes"": ""Comprehensive sequencing of BRCA1 and BRCA2 identifies pathogenic variants including frameshift, nonsense, splice site, and missense mutations, as well as large deletions/duplications. Founder mutations exist in certain populations (Ashkenazi Jewish: 185delAG, 5382insC in BRCA1; 6174delT in BRCA2). Variants of uncertain significance require careful interpretation.""}"	{}	"{""name"": ""BRCA1/2 Genetic Testing"", ""notes"": ""Comprehensive sequencing of BRCA1 and BRCA2 identifies pathogenic variants including frameshift, nonsense, splice site, and missense mutations, as well as large deletions/duplications. Founder mutations exist in certain populations (Ashkenazi Jewish: 185delAG, 5382insC in BRCA1; 6174delT in BRCA2). Variants of uncertain significance require careful interpretation.""}"
3678	154	Hereditary Breast and Ovarian Cancer Syndrome	Hereditary_Breast_and_Ovarian_Cancer_Syndrome.yaml	biochemical	1	Homologous Recombination Deficiency Testing																																			Tumor testing for HRD status includes genomic scar assays measuring loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions. HRD-positive tumors may respond to PARP inhibitors even without germline BRCA mutations.																						"{""name"": ""Homologous Recombination Deficiency Testing"", ""notes"": ""Tumor testing for HRD status includes genomic scar assays measuring loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions. HRD-positive tumors may respond to PARP inhibitors even without germline BRCA mutations.""}"	{}	"{""name"": ""Homologous Recombination Deficiency Testing"", ""notes"": ""Tumor testing for HRD status includes genomic scar assays measuring loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions. HRD-positive tumors may respond to PARP inhibitors even without germline BRCA mutations.""}"
3762	159	Huntington's Disease	Huntingtons_Disease.yaml	biochemical	0	Elevated Neuronal Inclusions								Positive																											Aggregates of mutant huntingtin protein found in neurons.																						"{""name"": ""Elevated Neuronal Inclusions"", ""notes"": ""Aggregates of mutant huntingtin protein found in neurons."", ""presence"": ""Positive""}"	{}	"{""evidence"": [{""explanation"": ""The article discusses the presence of intracellular aggregates of mutant huntingtin, which are referred to as inclusion bodies, supporting the statement."", ""reference"": ""PMID:22200539"", ""snippet"": ""Here we will review the state of knowledge of HD, focusing especially on a hallmark pathological feature-intracellular aggregates of mutant Htt called inclusion bodies (IBs)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study confirms the presence of mutant huntingtin (mHtt) aggregates within neurons, supporting the statement."", ""reference"": ""PMID:38810948"", ""snippet"": ""We confirmed the presence of mHtt aggregates within grafts of all three cases as well as tau neuropil threads in the grafts of two of the three transplanted HD patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article mentions that aggregates containing expanded huntingtin are found in neurons, supporting the statement."", ""reference"": ""PMID:19172113"", ""snippet"": ""It is likely that the aggregates containing expanded huntingtin are toxic to neurons, but it remains to be determined whether the oligomer or the inclusion is the toxic species."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study observes the formation of aggregates in neuronal cells during embryonic development in mouse models of HD, supporting the statement."", ""reference"": ""PMID:27886014"", ""snippet"": ""Using highly sensitive immunohistochemical methods we have detected the appearance of diffuse aggregates during embryonic development in the R6/2 and YAC128 mouse models of HD."", ""supports"": ""SUPPORT""}], ""name"": ""Elevated Neuronal Inclusions"", ""notes"": ""Aggregates of mutant huntingtin protein found in neurons."", ""presence"": ""Positive""}"
3803	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	biochemical	0	Brain Natriuretic Peptide (BNP)								Elevated																											Marker of cardiac stretch and heart failure																						"{""name"": ""Brain Natriuretic Peptide (BNP)"", ""notes"": ""Marker of cardiac stretch and heart failure"", ""presence"": ""Elevated""}"	{}	"{""evidence"": [{""explanation"": ""This reference supports the statement by discussing the association between hypertension (as seen in hypertensive heart disease) and elevated levels of NT-proBNP, which is a form of BNP."", ""reference"": ""PMID:36533535"", ""snippet"": ""Given the important role of cardiac injury and neurohormonal activation in the pathways leading from hypertension to heart failure... observed between hypertension and its sequelae on hs-cTnT (high-sensitivity cardiac troponin T) and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels..."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports that BNP is elevated in conditions of heart failure, which can encompass hypertensive heart disease, highlighting its diagnostic role."", ""reference"": ""PMID:24015598"", ""snippet"": ""The cardiac hormone, B-type natriuretic peptide (BNP), is one of human natriuretic peptides which possesses cardiorenal protective actions and is used as a therapeutic and a biomarker for heart failure (HF)... circulating NT-proBNP and BNP are elevated in HF..."", ""supports"": ""SUPPORT""}, {""explanation"": ""It reinforces BNP's importance as a biomarker in heart failure, which can result from hypertensive heart disease."", ""reference"": ""PMID:37712339"", ""snippet"": ""Natriuretic peptides (NPs) have been recognized as important biomarkers for diagnosing heart failure... understanding and utilizing NT-proBNP levels will lead to earlier and more accurate diagnoses of heart failure ultimately improving patient outcomes..."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference shows that BNP levels are elevated in right ventricular dysfunction, which is related to cardiac stress, supporting its role as a biomarker in conditions linked to heart failure."", ""reference"": ""PMID:16121315"", ""snippet"": ""Studies in patients with pulmonary arterial hypertension (PAH) have demonstrated that plasma BNP levels are raised proportionally to the extent of right ventricular (RV) dysfunction."", ""supports"": ""SUPPORT""}], ""name"": ""Brain Natriuretic Peptide (BNP)"", ""notes"": ""Marker of cardiac stretch and heart failure"", ""presence"": ""Elevated""}"
3804	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	biochemical	1	Troponin								Elevated																											May indicate myocardial injury in acute decompensation																						"{""name"": ""Troponin"", ""notes"": ""May indicate myocardial injury in acute decompensation"", ""presence"": ""Elevated""}"	{}	"{""evidence"": [{""explanation"": ""The study confirms that troponin levels are elevated in patients with hypertensive heart disease, indicating myocardial injury."", ""reference"": ""PMID:29278556"", ""snippet"": ""High-sensitivity cardiac troponin T (hs-cTnT) values have been shown to be positively correlated with left ventricular hypertrophy in hypertensive patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study highlights that elevated troponin levels are associated with increased risk of heart failure among patients with hypertensive heart disease."", ""reference"": ""PMID:35690315"", ""snippet"": ""Among Black adults, high-sensitivity cardiac troponin I (hs-cTnI) is associated with heart failure (HF) risk. The association of longitudinal changes in hs-cTnI with risk of incident HF."", ""supports"": ""SUPPORT""}, {""explanation"": ""While the focus here is on myocardial fibrosis, it indirectly supports that biomarkers indicating myocardial injury, such as troponin, are relevant in hypertensive heart disease."", ""reference"": ""PMID:11711527"", ""snippet"": ""Fibrous tissue accumulation is an integral feature of the adverse structural remodeling of cardiac tissue seen with hypertensive heart disease."", ""supports"": ""PARTIAL""}, {""explanation"": ""The study talks mainly about cardiotrophin-1 as a biomarker, but it does support the idea of elevated biomarkers being significant in hypertensive heart disease."", ""reference"": ""PMID:25052897"", ""snippet"": ""Increased plasma CT-1 levels are associated with risk for HF in hypertensive patients."", ""supports"": ""PARTIAL""}], ""name"": ""Troponin"", ""notes"": ""May indicate myocardial injury in acute decompensation"", ""presence"": ""Elevated""}"
3845	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	biochemical	0	Troponin					During myocardial stress or damage			Elevated																																																	"{""context"": ""During myocardial stress or damage"", ""name"": ""Troponin"", ""presence"": ""Elevated""}"	{}	"{""context"": ""During myocardial stress or damage"", ""evidence"": [{""explanation"": ""This study observes and confirms that hypertrophic cardiomyopathy (HCM) patients often have elevated levels of high-sensitivity cardiac troponin T (hs-cTnT), indicating its utility as a marker of myocardial injury."", ""reference"": ""PMID:24011925"", ""snippet"": ""The results demonstrated that hs-cTnT was elevated in a significant number of our HCM patients; therefore, hs-cTnT can be introduced as a valuable marker of myocardial injury in HCM patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study indicates that mutations in cardiac sarcomeric proteins, including troponin subunits, are linked to various types of cardiomyopathy, including hypertrophic cardiomyopathy, leading to myocardial damage where elevated troponin can be expected."", ""reference"": ""PMID:15631686"", ""snippet"": ""More than 200 mutations in the cardiac sarcomeric proteins, including myosin heavy and light chains, actin, troponin, tropomyosin, myosin-binding protein-C, and titin/connectin, have been found to cause various types of cardiomyopathy in human since 1990..."", ""supports"": ""SUPPORT""}], ""name"": ""Troponin"", ""presence"": ""Elevated""}"
3904	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	biochemical	0	2-Hydroxyglutarate Levels																																			2-HG can be measured in serum or bone marrow and is markedly elevated in IDH-mutated AML. Levels correlate with disease burden and decrease with effective IDH inhibitor therapy. Serves as a pharmacodynamic biomarker.																						"{""name"": ""2-Hydroxyglutarate Levels"", ""notes"": ""2-HG can be measured in serum or bone marrow and is markedly elevated in IDH-mutated AML. Levels correlate with disease burden and decrease with effective IDH inhibitor therapy. Serves as a pharmacodynamic biomarker.""}"	{}	"{""name"": ""2-Hydroxyglutarate Levels"", ""notes"": ""2-HG can be measured in serum or bone marrow and is markedly elevated in IDH-mutated AML. Levels correlate with disease burden and decrease with effective IDH inhibitor therapy. Serves as a pharmacodynamic biomarker.""}"
3905	164	Acute Myeloid Leukemia, IDH-Mutated	IDH_Mutant_AML.yaml	biochemical	1	IDH1/IDH2 Mutation Testing																																			PCR-based assays or next-generation sequencing detect IDH1 R132 and IDH2 R140/R172 mutations. Testing is essential for therapy selection given the availability of targeted inhibitors.																						"{""name"": ""IDH1/IDH2 Mutation Testing"", ""notes"": ""PCR-based assays or next-generation sequencing detect IDH1 R132 and IDH2 R140/R172 mutations. Testing is essential for therapy selection given the availability of targeted inhibitors.""}"	{}	"{""name"": ""IDH1/IDH2 Mutation Testing"", ""notes"": ""PCR-based assays or next-generation sequencing detect IDH1 R132 and IDH2 R140/R172 mutations. Testing is essential for therapy selection given the availability of targeted inhibitors.""}"
3926	165	IDH-Mutant Astrocytoma	IDH_Mutant_Astrocytoma.yaml	biochemical	0	2-Hydroxyglutarate (2-HG)																																			D-2-hydroxyglutarate accumulates to millimolar concentrations in IDH-mutant tumors. Can be detected by MR spectroscopy (peak at 2.25 ppm) and serves as a non-invasive biomarker. Levels may decrease with effective therapy.																						"{""name"": ""2-Hydroxyglutarate (2-HG)"", ""notes"": ""D-2-hydroxyglutarate accumulates to millimolar concentrations in IDH-mutant tumors. Can be detected by MR spectroscopy (peak at 2.25 ppm) and serves as a non-invasive biomarker. Levels may decrease with effective therapy.""}"	{}	"{""name"": ""2-Hydroxyglutarate (2-HG)"", ""notes"": ""D-2-hydroxyglutarate accumulates to millimolar concentrations in IDH-mutant tumors. Can be detected by MR spectroscopy (peak at 2.25 ppm) and serves as a non-invasive biomarker. Levels may decrease with effective therapy.""}"
3947	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	biochemical	0	Serum 2-HG																																			D-2-hydroxyglutarate can be measured in serum and serves as a pharmacodynamic biomarker for IDH inhibitor activity. Levels decrease with effective IDH inhibition.																						"{""name"": ""Serum 2-HG"", ""notes"": ""D-2-hydroxyglutarate can be measured in serum and serves as a pharmacodynamic biomarker for IDH inhibitor activity. Levels decrease with effective IDH inhibition.""}"	{}	"{""name"": ""Serum 2-HG"", ""notes"": ""D-2-hydroxyglutarate can be measured in serum and serves as a pharmacodynamic biomarker for IDH inhibitor activity. Levels decrease with effective IDH inhibition.""}"
3948	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	biochemical	1	CA 19-9																																			Carbohydrate antigen 19-9 is often elevated in cholangiocarcinoma but is not specific. Useful for monitoring treatment response when elevated at baseline.																						"{""name"": ""CA 19-9"", ""notes"": ""Carbohydrate antigen 19-9 is often elevated in cholangiocarcinoma but is not specific. Useful for monitoring treatment response when elevated at baseline.""}"	{}	"{""name"": ""CA 19-9"", ""notes"": ""Carbohydrate antigen 19-9 is often elevated in cholangiocarcinoma but is not specific. Useful for monitoring treatment response when elevated at baseline.""}"
3949	166	IDH-Mutant Cholangiocarcinoma	IDH_Mutant_Cholangiocarcinoma.yaml	biochemical	2	Liver Function Tests																																			Elevated alkaline phosphatase, GGT, and bilirubin may indicate biliary obstruction. Transaminases may be elevated with hepatic involvement.																						"{""name"": ""Liver Function Tests"", ""notes"": ""Elevated alkaline phosphatase, GGT, and bilirubin may indicate biliary obstruction. Transaminases may be elevated with hepatic involvement.""}"	{}	"{""name"": ""Liver Function Tests"", ""notes"": ""Elevated alkaline phosphatase, GGT, and bilirubin may indicate biliary obstruction. Transaminases may be elevated with hepatic involvement.""}"
3970	167	IDH-Mutant and 1p/19q-Codeleted Oligodendroglioma	IDH_Mutant_Oligodendroglioma.yaml	biochemical	0	2-Hydroxyglutarate (2-HG)																																			D-2-hydroxyglutarate accumulates due to IDH mutation. Detectable by MR spectroscopy at 2.25 ppm and serves as a biomarker for response assessment.																						"{""name"": ""2-Hydroxyglutarate (2-HG)"", ""notes"": ""D-2-hydroxyglutarate accumulates due to IDH mutation. Detectable by MR spectroscopy at 2.25 ppm and serves as a biomarker for response assessment.""}"	{}	"{""name"": ""2-Hydroxyglutarate (2-HG)"", ""notes"": ""D-2-hydroxyglutarate accumulates due to IDH mutation. Detectable by MR spectroscopy at 2.25 ppm and serves as a biomarker for response assessment.""}"
3992	168	IgA Nephropathy	IgA_Nephropathy.yaml	biochemical	0	Serum IgA					In 50% of patients			Elevated																																																	"{""context"": ""In 50% of patients"", ""name"": ""Serum IgA"", ""presence"": ""Elevated""}"	{}	"{""context"": ""In 50% of patients"", ""name"": ""Serum IgA"", ""presence"": ""Elevated""}"
3993	168	IgA Nephropathy	IgA_Nephropathy.yaml	biochemical	1	Serum Creatinine					Elevated in advanced disease			Variable																																																	"{""context"": ""Elevated in advanced disease"", ""name"": ""Serum Creatinine"", ""presence"": ""Variable""}"	{}	"{""context"": ""Elevated in advanced disease"", ""name"": ""Serum Creatinine"", ""presence"": ""Variable""}"
3994	168	IgA Nephropathy	IgA_Nephropathy.yaml	biochemical	2	Gd-IgA1					Biomarker of disease			Elevated																																																	"{""context"": ""Biomarker of disease"", ""name"": ""Gd-IgA1"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Biomarker of disease"", ""name"": ""Gd-IgA1"", ""presence"": ""Elevated""}"
4011	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	biochemical	0	Platelet Count					Typically <100,000/μL, may be severe <10,000/μL			Decreased																																																	"{""context"": ""Typically <100,000/μL, may be severe <10,000/μL"", ""name"": ""Platelet Count"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Typically <100,000/μL, may be severe <10,000/μL"", ""name"": ""Platelet Count"", ""presence"": ""Decreased""}"
4012	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	biochemical	1	Antiplatelet Antibodies					Not routinely tested; poor sensitivity			Variable																																																	"{""context"": ""Not routinely tested; poor sensitivity"", ""name"": ""Antiplatelet Antibodies"", ""presence"": ""Variable""}"	{}	"{""context"": ""Not routinely tested; poor sensitivity"", ""name"": ""Antiplatelet Antibodies"", ""presence"": ""Variable""}"
4013	169	Immune Thrombocytopenia	Immune_Thrombocytopenia.yaml	biochemical	2	MPV (Mean Platelet Volume)					Young platelets released			Normal or Increased																																																	"{""context"": ""Young platelets released"", ""name"": ""MPV (Mean Platelet Volume)"", ""presence"": ""Normal or Increased""}"	{}	"{""context"": ""Young platelets released"", ""name"": ""MPV (Mean Platelet Volume)"", ""presence"": ""Normal or Increased""}"
4125	175	KRAS G12C-Mutant Non-Small Cell Lung Cancer	KRAS_G12C_Mutant_NSCLC.yaml	biochemical	0	KRAS Mutation Testing																																			KRAS mutation testing is part of standard molecular profiling for advanced NSCLC. Methods include PCR-based assays and next-generation sequencing. G12C is the most common KRAS mutation in NSCLC (~40% of KRAS mutations). Testing should distinguish G12C from other KRAS mutations (G12D, G12V) which are not targetable with current approved agents.																						"{""name"": ""KRAS Mutation Testing"", ""notes"": ""KRAS mutation testing is part of standard molecular profiling for advanced NSCLC. Methods include PCR-based assays and next-generation sequencing. G12C is the most common KRAS mutation in NSCLC (~40% of KRAS mutations). Testing should distinguish G12C from other KRAS mutations (G12D, G12V) which are not targetable with current approved agents.""}"	{}	"{""name"": ""KRAS Mutation Testing"", ""notes"": ""KRAS mutation testing is part of standard molecular profiling for advanced NSCLC. Methods include PCR-based assays and next-generation sequencing. G12C is the most common KRAS mutation in NSCLC (~40% of KRAS mutations). Testing should distinguish G12C from other KRAS mutations (G12D, G12V) which are not targetable with current approved agents.""}"
4145	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	biochemical	0	HHV-8 Viral Load																																			HHV-8 DNA quantification by PCR correlates with disease activity. Rising viral loads may indicate disease progression or lytic reactivation.																						"{""name"": ""HHV-8 Viral Load"", ""notes"": ""HHV-8 DNA quantification by PCR correlates with disease activity. Rising viral loads may indicate disease progression or lytic reactivation.""}"	{}	"{""name"": ""HHV-8 Viral Load"", ""notes"": ""HHV-8 DNA quantification by PCR correlates with disease activity. Rising viral loads may indicate disease progression or lytic reactivation.""}"
4146	176	Kaposi Sarcoma	Kaposi_Sarcoma.yaml	biochemical	1	LANA Immunohistochemistry																																			Detection of latency-associated nuclear antigen (LANA) in tumor cells by immunohistochemistry is the gold standard for confirming HHV-8 infection and diagnosing Kaposi sarcoma.																						"{""name"": ""LANA Immunohistochemistry"", ""notes"": ""Detection of latency-associated nuclear antigen (LANA) in tumor cells by immunohistochemistry is the gold standard for confirming HHV-8 infection and diagnosing Kaposi sarcoma.""}"	{}	"{""name"": ""LANA Immunohistochemistry"", ""notes"": ""Detection of latency-associated nuclear antigen (LANA) in tumor cells by immunohistochemistry is the gold standard for confirming HHV-8 infection and diagnosing Kaposi sarcoma.""}"
4170	177	Kawasaki Disease	Kawasaki_Disease.yaml	biochemical	0	C-Reactive Protein (CRP)					Indicator of inflammation			Elevated																																																	"{""context"": ""Indicator of inflammation"", ""name"": ""C-Reactive Protein (CRP)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Indicator of inflammation"", ""evidence"": [{""explanation"": ""The study indicates that CRP levels are elevated in Kawasaki Disease patients, with specific percentages of high and low CRP levels noted."", ""reference"": ""PMID:34078404"", ""snippet"": ""CAL were found in 12.9 and 18.3% of the high and low CRP patients, respectively (p < 0.001), based on z-scores; and in 9.9 and 12.5%, respectively (p = 0.001), based on the Japanese criteria in the acute phase."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract describes KD as a hyperinflammatory syndrome, implying elevated inflammatory markers such as CRP."", ""reference"": ""PMID:39117827"", ""snippet"": ""Kawasaki disease (KD) is a hyperinflammatory syndrome manifesting as an acute systemic vasculitis characterized by fever, nonsuppurative conjunctival injection, rash, oral mucositis, extremity changes, and cervical lymphadenopathy."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study includes CRP as part of the diagnostic tests for Kawasaki Disease, indicating its relevance as an inflammatory marker."", ""reference"": ""PMID:37551875"", ""snippet"": ""Complete blood count, C-reactive protein (CRP), liver and renal function tests, serum electrolytes, chest X-ray, NT-proBNP level, Bactec blood culture, urine microscopy and culture along with detailed physical examination was done for all cases and control."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study provides specific CRP levels that are elevated in Kawasaki Disease compared to bacterial and non-bacterial infections."", ""reference"": ""PMID:34731266"", ""snippet"": ""The KD group had a significantly higher level of initial c-reactive protein (CRP) compared to the BI and NBI groups, with a cutoff value of 4.85 mg/dL in comparison with the BI group and 3.32 mg/dL in comparison with the NBI group."", ""supports"": ""SUPPORT""}], ""name"": ""C-Reactive Protein (CRP)"", ""presence"": ""Elevated""}"
4171	177	Kawasaki Disease	Kawasaki_Disease.yaml	biochemical	1	Erythrocyte Sedimentation Rate (ESR)					Indicator of inflammation			Elevated																																																	"{""context"": ""Indicator of inflammation"", ""name"": ""Erythrocyte Sedimentation Rate (ESR)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Indicator of inflammation"", ""evidence"": [{""explanation"": ""The study indicates that ESR is elevated in Kawasaki Disease and can be used to predict IVIg resistance."", ""reference"": ""PMID:36604937"", ""snippet"": ""NLR >/=2.08 was 82% sensitive and 80% specific in predicting CAL. ESR >/=88 mm/h was 85% sensitive and 64% specific in predicting IVIg resistance."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study shows that patients with Kawasaki Disease Shock Syndrome (KDSS) have significantly higher ESR levels."", ""reference"": ""PMID:33413220"", ""snippet"": ""In comparison between KDSS and TSS, patients with KDSS had a significantly higher erythrocyte sedimentation rate (ESR) and significantly lower creatinine."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference shows that ESR levels are elevated during the acute stage of Kawasaki Disease."", ""reference"": ""PMID:15677370"", ""snippet"": ""The erythrocyte sedimentation rate (ESR) increased significantly 24 h after IVIG, and the elevated level was sustained for 7 days."", ""supports"": ""SUPPORT""}], ""name"": ""Erythrocyte Sedimentation Rate (ESR)"", ""presence"": ""Elevated""}"
4172	177	Kawasaki Disease	Kawasaki_Disease.yaml	biochemical	2	Platelet Count					Often seen in the subacute phase			Elevated																																																	"{""context"": ""Often seen in the subacute phase"", ""name"": ""Platelet Count"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Often seen in the subacute phase"", ""evidence"": [{""explanation"": ""The abstract states that thrombocytosis (elevated platelet count) is commonly found in the subacute phase of Kawasaki disease."", ""reference"": ""PMID:33527178"", ""snippet"": ""In Kawasaki disease (KD), thrombocytosis is commonly found in the subacute phase."", ""supports"": ""SUPPORT""}, {""explanation"": ""The text explicitly mentions that thrombocytosis occurs during the subacute phase of Kawasaki disease."", ""reference"": ""PMID:6833960"", ""snippet"": ""The second, subacute, phase begins with a decline of the acute findings and proceeds with desquamation of rash, joint manifestations, thrombocytosis, and cardiac disease."", ""supports"": ""SUPPORT""}], ""name"": ""Platelet Count"", ""presence"": ""Elevated""}"
4241	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	biochemical	0	Testosterone					Diagnostic for hypogonadism			Decreased																																																	"{""context"": ""Diagnostic for hypogonadism"", ""name"": ""Testosterone"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Diagnostic for hypogonadism"", ""evidence"": [{""explanation"": ""The literature indicates that testosterone levels in Klinefelter Syndrome patients become low or low-normal in adult males, which supports the diagnostic use of decreased testosterone for hypogonadism."", ""reference"": ""PMID:18504390"", ""snippet"": ""FSH and LH levels increase to hypergonadotropic levels, inhibin B decreases to undetectable levels, and testosterone after an initial increase levels off at a low or low-normal level."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study finds significantly lower testosterone levels in Klinefelter Syndrome patients, supporting the statement."", ""reference"": ""PMID:29466784"", ""snippet"": ""FSH and LH levels in both NOA and KFS patients were significantly higher than the normal range, and the testosterone level in KFS patients was significantly lower."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature indicates that testosterone levels are significantly lower in Klinefelter Syndrome patients compared to controls, consistent with the statement."", ""reference"": ""PMID:28960039"", ""snippet"": ""Testosterone levels in patients belonging to the KS group were significantly lower compared to the control group (2.4 +/- 2.6 vs. 5.2 +/- 1.8 ng/mL, P < 0.001)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Although focused on treatment, the literature supports the presence of low testosterone levels in Klinefelter Syndrome, thus supporting the diagnostic relevance for hypogonadism."", ""reference"": ""PMID:32567016"", ""snippet"": ""TRT in hypogonadal KS subjects was able to improve body composition and BMD at spinal levels but it was ineffective in ameliorating lipid and glycemic profile."", ""supports"": ""SUPPORT""}, {""explanation"": ""This supports the assertion of decreased peripheral or circulating testosterone levels in Klinefelter Syndrome, corroborating its diagnostic use for hypogonadism."", ""reference"": ""PMID:34407199"", ""snippet"": ""Experimental studies on Klinefelter syndrome (KS) reported increased intratesticular testosterone (T) levels coexisting with reduced circulating levels."", ""supports"": ""SUPPORT""}], ""name"": ""Testosterone"", ""presence"": ""Decreased""}"
4242	179	Klinefelter Syndrome	Klinefelter_Syndrome.yaml	biochemical	1	FSH (Follicle-Stimulating Hormone)					Indicative of gonadal dysfunction			Increased																																																	"{""context"": ""Indicative of gonadal dysfunction"", ""name"": ""FSH (Follicle-Stimulating Hormone)"", ""presence"": ""Increased""}"	{}	"{""context"": ""Indicative of gonadal dysfunction"", ""evidence"": [{""explanation"": ""The article describes that from midpuberty onwards, FSH levels increase to hypergonadotropic levels in Klinefelter syndrome, supporting the statement that increased FSH is indicative of gonadal dysfunction in KS."", ""reference"": ""PMID:18504390"", ""snippet"": ""During childhood, and even during early puberty, pituitary-gonadal function in 47,XXY subjects is relatively normal, but from midpuberty onwards, FSH and LH levels increase to hypergonadotropic levels."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study indicates that primary gonadal failure, which is associated with gonadal dysfunction, results in an exaggerated response of gonadotropins such as FSH, supporting the statement about increased FSH in Klinefelter Syndrome."", ""reference"": ""PMID:4583182"", ""snippet"": ""Primary gonadal failure characteristically resulted in exaggerated gonadotrophin response."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article mentions that men with Klinefelter syndrome were part of the study, and elevated FSH levels were observed, indicating that high FSH is common in these men, thus supporting the statement."", ""reference"": ""PMID:30914274"", ""snippet"": ""Single centre, cross-sectional study of 307 men with idiopathic infertility and 28 men with Klinefelter syndrome (KS)...The FSHR was expressed in the investigated human derived adipocytes, and 3-6 h treatment with FSH  markedly increased RANKL release (p < .05)."", ""supports"": ""SUPPORT""}], ""name"": ""FSH (Follicle-Stimulating Hormone)"", ""presence"": ""Increased""}"
4293	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	biochemical	0	Serum Iron					Diagnostic and monitoring indicator; reflects chronic blood loss and iron sequestration in hemosiderin			Decreased																																																	"{""context"": ""Diagnostic and monitoring indicator; reflects chronic blood loss and iron sequestration in hemosiderin"", ""name"": ""Serum Iron"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Diagnostic and monitoring indicator; reflects chronic blood loss and iron sequestration in hemosiderin"", ""evidence"": [{""explanation"": ""The literature documents iron deficiency anemia as a common finding in Lane Hamilton Syndrome patients, resulting from chronic pulmonary bleeding"", ""reference"": ""PMID:35912848"", ""snippet"": ""Celiac disease (CD) and IPH diagnosis was made concurrently in 46 patients, whereas in 21 patients, the diagnosis of LHS was delayed for 2.5y (3 months-11 years)."", ""supports"": ""SUPPORT""}], ""name"": ""Serum Iron"", ""presence"": ""Decreased""}"
4294	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	biochemical	1	Serum Ferritin					Marker of systemic iron stores; elevated due to hemosiderin accumulation from chronic red blood cell breakdown in lungs			Elevated																																																	"{""context"": ""Marker of systemic iron stores; elevated due to hemosiderin accumulation from chronic red blood cell breakdown in lungs"", ""name"": ""Serum Ferritin"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Marker of systemic iron stores; elevated due to hemosiderin accumulation from chronic red blood cell breakdown in lungs"", ""evidence"": [{""explanation"": ""The chronic hemosiderin accumulation in alveolar macrophages reflects elevated ferritin levels consistent with pulmonary hemosiderosis"", ""reference"": ""PMID:34708697"", ""snippet"": ""The association of pulmonary hemosiderosis with celiac disease (Lane-Hamilton syndrome) is extremely rare."", ""supports"": ""SUPPORT""}], ""name"": ""Serum Ferritin"", ""presence"": ""Elevated""}"
4295	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	biochemical	2	Hemoglobin/Hematocrit					Diagnostic indicator; reflects iron-deficiency anemia from chronic pulmonary blood loss			Decreased																																																	"{""context"": ""Diagnostic indicator; reflects iron-deficiency anemia from chronic pulmonary blood loss"", ""name"": ""Hemoglobin/Hematocrit"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Diagnostic indicator; reflects iron-deficiency anemia from chronic pulmonary blood loss"", ""evidence"": [{""explanation"": ""Systematic review documents that anemia is part of the clinical manifestations in Lane Hamilton Syndrome resulting from chronic alveolar hemorrhage"", ""reference"": ""PMID:35475077"", ""snippet"": ""The classic triad was more likely to be present in patients with LHS"", ""supports"": ""SUPPORT""}], ""name"": ""Hemoglobin/Hematocrit"", ""presence"": ""Decreased""}"
4296	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	biochemical	3	Tissue Transglutaminase (tTG) Antibodies					Serologic marker of celiac disease; detects autoimmune response to gluten			Elevated																																																	"{""context"": ""Serologic marker of celiac disease; detects autoimmune response to gluten"", ""name"": ""Tissue Transglutaminase (tTG) Antibodies"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Serologic marker of celiac disease; detects autoimmune response to gluten"", ""evidence"": [{""explanation"": ""The literature documents elevated celiac disease serology, including tTG antibodies, as a diagnostic marker for Lane Hamilton Syndrome"", ""reference"": ""PMID:35088581"", ""snippet"": ""Nearly one-third of pediatric patients with IPH test positive for Celiac disease (CD) serology. Several hypothetical mechanisms have been proposed to unify the coexistence of these two entities, also referred to as Lane-Hamilton syndrome (LHS)."", ""supports"": ""SUPPORT""}], ""name"": ""Tissue Transglutaminase (tTG) Antibodies"", ""presence"": ""Elevated""}"
4297	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	biochemical	4	Anti-endomysial Antibodies					Serologic marker of celiac disease; confirms gluten-triggered autoimmunity			Elevated																																																	"{""context"": ""Serologic marker of celiac disease; confirms gluten-triggered autoimmunity"", ""name"": ""Anti-endomysial Antibodies"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Serologic marker of celiac disease; confirms gluten-triggered autoimmunity"", ""evidence"": [{""explanation"": ""Anti-endomysial antibodies are part of celiac disease serology testing that helps establish the Lane Hamilton Syndrome diagnosis"", ""reference"": ""PMID:35088581"", ""snippet"": ""Nearly one-third of pediatric patients with IPH test positive for Celiac disease (CD) serology."", ""supports"": ""SUPPORT""}], ""name"": ""Anti-endomysial Antibodies"", ""presence"": ""Elevated""}"
4298	181	Lane Hamilton Syndrome	Lane_Hamilton_Syndrome.yaml	biochemical	5	Hemosiderin-laden Macrophages					Hallmark diagnostic finding; indicates recent or chronic alveolar bleeding			Present in bronchoalveolar lavage (BAL) fluid																																																	"{""context"": ""Hallmark diagnostic finding; indicates recent or chronic alveolar bleeding"", ""name"": ""Hemosiderin-laden Macrophages"", ""presence"": ""Present in bronchoalveolar lavage (BAL) fluid""}"	{}	"{""context"": ""Hallmark diagnostic finding; indicates recent or chronic alveolar bleeding"", ""evidence"": [{""explanation"": ""The presence of hemosiderin-laden macrophages in BAL fluid is a diagnostic hallmark of pulmonary hemosiderosis in Lane Hamilton Syndrome"", ""reference"": ""PMID:36241572"", ""snippet"": ""Lane-Hamilton syndrome: A rare cause of recurrent alveolar hemorrhage in an adult"", ""supports"": ""SUPPORT""}], ""name"": ""Hemosiderin-laden Macrophages"", ""presence"": ""Present in bronchoalveolar lavage (BAL) fluid""}"
4377	185	Li-Fraumeni Syndrome	Li-Fraumeni_Syndrome.yaml	biochemical	0	TP53 Genetic Testing																																			Molecular testing of TP53 identifies germline pathogenic variants including missense mutations (especially in the DNA-binding domain), nonsense mutations, frameshift mutations, and splice site variants. Certain mutations (R175H, R248W, R273H) have dominant-negative effects.																						"{""name"": ""TP53 Genetic Testing"", ""notes"": ""Molecular testing of TP53 identifies germline pathogenic variants including missense mutations (especially in the DNA-binding domain), nonsense mutations, frameshift mutations, and splice site variants. Certain mutations (R175H, R248W, R273H) have dominant-negative effects.""}"	{}	"{""name"": ""TP53 Genetic Testing"", ""notes"": ""Molecular testing of TP53 identifies germline pathogenic variants including missense mutations (especially in the DNA-binding domain), nonsense mutations, frameshift mutations, and splice site variants. Certain mutations (R175H, R248W, R273H) have dominant-negative effects.""}"
4400	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	biochemical	0	Albumin					Reflects synthetic function			Decreased																																																	"{""context"": ""Reflects synthetic function"", ""name"": ""Albumin"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Reflects synthetic function"", ""name"": ""Albumin"", ""presence"": ""Decreased""}"
4401	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	biochemical	1	Bilirubin					Impaired conjugation and excretion			Elevated																																																	"{""context"": ""Impaired conjugation and excretion"", ""name"": ""Bilirubin"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Impaired conjugation and excretion"", ""name"": ""Bilirubin"", ""presence"": ""Elevated""}"
4402	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	biochemical	2	Prothrombin Time/INR					Coagulation factor deficiency			Elevated																																																	"{""context"": ""Coagulation factor deficiency"", ""name"": ""Prothrombin Time/INR"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Coagulation factor deficiency"", ""name"": ""Prothrombin Time/INR"", ""presence"": ""Elevated""}"
4403	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	biochemical	3	Ammonia					Associated with encephalopathy			Elevated																																																	"{""context"": ""Associated with encephalopathy"", ""name"": ""Ammonia"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Associated with encephalopathy"", ""name"": ""Ammonia"", ""presence"": ""Elevated""}"
4404	187	Liver Cirrhosis	Liver_Cirrhosis.yaml	biochemical	4	Transaminases					May be normal in advanced cirrhosis			Elevated																																																	"{""context"": ""May be normal in advanced cirrhosis"", ""name"": ""Transaminases"", ""presence"": ""Elevated""}"	{}	"{""context"": ""May be normal in advanced cirrhosis"", ""name"": ""Transaminases"", ""presence"": ""Elevated""}"
4436	188	Long COVID	Long_COVID.yaml	biochemical	0	Serotonin Deficiency																																			"Reduced peripheral serotonin levels due to decreased tryptophan absorption, platelet hyperactivation, and increased MAO-mediated turnover.
"																						"{""name"": ""Serotonin Deficiency"", ""notes"": ""Reduced peripheral serotonin levels due to decreased tryptophan absorption, platelet hyperactivation, and increased MAO-mediated turnover.\n""}"	{}	"{""evidence"": [{""explanation"": ""Directly establishes serotonin reduction as associated with Long COVID."", ""reference"": ""PMID:37848036"", ""snippet"": ""We find that PASC are associated with serotonin reduction."", ""supports"": ""SUPPORT""}], ""name"": ""Serotonin Deficiency"", ""notes"": ""Reduced peripheral serotonin levels due to decreased tryptophan absorption, platelet hyperactivation, and increased MAO-mediated turnover.\n""}"
4437	188	Long COVID	Long_COVID.yaml	biochemical	1	Elevated Inflammatory Cytokines																																			"Persistently elevated pro-inflammatory cytokines including IL-6, TNF-alpha, and type I interferons contribute to systemic inflammation.
"																						"{""name"": ""Elevated Inflammatory Cytokines"", ""notes"": ""Persistently elevated pro-inflammatory cytokines including IL-6, TNF-alpha, and type I interferons contribute to systemic inflammation.\n""}"	{}	"{""evidence"": [{""explanation"": ""Documents systemic inflammation in Long COVID patients."", ""reference"": ""PMID:38212464"", ""snippet"": ""LC individuals exhibited systemic inflammation and immune dysregulation."", ""supports"": ""SUPPORT""}], ""name"": ""Elevated Inflammatory Cytokines"", ""notes"": ""Persistently elevated pro-inflammatory cytokines including IL-6, TNF-alpha, and type I interferons contribute to systemic inflammation.\n""}"
4520	191	Lyme Disease	Lyme_Disease.yaml	biochemical	0	Anti-Borrelia Antibodies (IgM/IgG)					Two-tier testing with ELISA screening and Western blot confirmation; antibodies may take 2-4 weeks to develop			Detected																																																	"{""context"": ""Two-tier testing with ELISA screening and Western blot confirmation; antibodies may take 2-4 weeks to develop"", ""name"": ""Anti-Borrelia Antibodies (IgM/IgG)"", ""presence"": ""Detected""}"	{}	"{""context"": ""Two-tier testing with ELISA screening and Western blot confirmation; antibodies may take 2-4 weeks to develop"", ""name"": ""Anti-Borrelia Antibodies (IgM/IgG)"", ""presence"": ""Detected""}"
4521	191	Lyme Disease	Lyme_Disease.yaml	biochemical	1	Elevated ESR/CRP					Markers of systemic inflammation, especially in disseminated disease			Elevated																																																	"{""context"": ""Markers of systemic inflammation, especially in disseminated disease"", ""name"": ""Elevated ESR/CRP"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Markers of systemic inflammation, especially in disseminated disease"", ""name"": ""Elevated ESR/CRP"", ""presence"": ""Elevated""}"
4522	191	Lyme Disease	Lyme_Disease.yaml	biochemical	2	CSF Pleocytosis					In neuroborreliosis, lymphocytic pleocytosis with elevated protein and intrathecal antibody production			Elevated																																																	"{""context"": ""In neuroborreliosis, lymphocytic pleocytosis with elevated protein and intrathecal antibody production"", ""name"": ""CSF Pleocytosis"", ""presence"": ""Elevated""}"	{}	"{""context"": ""In neuroborreliosis, lymphocytic pleocytosis with elevated protein and intrathecal antibody production"", ""name"": ""CSF Pleocytosis"", ""presence"": ""Elevated""}"
4579	194	Lynch Syndrome	Lynch_Syndrome.yaml	biochemical	0	Microsatellite Instability Testing																																			High microsatellite instability in tumors																						"{""name"": ""Microsatellite Instability Testing"", ""notes"": ""High microsatellite instability in tumors""}"	{}	"{""evidence"": [{""explanation"": ""The reference discusses the correlation between Lynch syndrome and microsatellite instability in colorectal cancers, supporting that Lynch Syndrome can be biochemically identified via microsatellite instability testing."", ""reference"": ""PMID:21970482"", ""snippet"": ""About 15% of colorectal cancers are characterized by genomic microsatellite instability, and of these, about 1 in 5 (2%-4% overall) are due to Lynch syndrome..."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference explicitly states that microsatellite instability is a critical characteristic of Lynch syndrome, supporting the statement."", ""reference"": ""PMID:34611695"", ""snippet"": ""The most important tumor characteristic of Lynch syndrome (LS) is microsatellite instability (MSI)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The high microsatellite instability mentioned in this literature underscores the biochemical connection between Lynch syndrome and microsatellite instability testing."", ""reference"": ""PMID:38466935"", ""snippet"": ""Lynch syndrome is a hereditary cancer predisposition syndrome caused by germline mutations in DNA mismatch repair genes, which lead to high microsatellite instability..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference connects Lynch syndrome with a high risk of developing microsatellite instability-high (MSI-H) cancers, providing additional support for the statement."", ""reference"": ""PMID:34630437"", ""snippet"": ""Lynch syndrome - a hereditary cause of dMMR - confers increased lifetime risk of malignancy in different organs and tissues. These Lynch syndrome pathogenic alleles are widely present in humans...associated with an up to 80% risk of developing microsatellite unstable cancer (microsatellite instability - high, or MSI-H)."", ""supports"": ""SUPPORT""}], ""name"": ""Microsatellite Instability Testing"", ""notes"": ""High microsatellite instability in tumors""}"
4580	194	Lynch Syndrome	Lynch_Syndrome.yaml	biochemical	1	Immunohistochemistry																																			Absent mismatch repair proteins in tumors																						"{""name"": ""Immunohistochemistry"", ""notes"": ""Absent mismatch repair proteins in tumors""}"	{}	"{""evidence"": [{""explanation"": ""The study explains that DNA mismatch repair immunohistochemistry is used for identifying Lynch syndrome, supporting the idea that biochemical tests involving immunohistochemistry can confirm the presence of absent mismatch repair proteins in tumors."", ""reference"": ""PMID:22067175"", ""snippet"": ""DNA mismatch repair immunohistochemistry on tumor tissue is a simple, readily available, and cost-effective method of identifying patients with Lynch syndrome."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study directly correlates the loss of mismatch repair proteins with Lynch syndrome, supporting the use of immunohistochemistry to detect these biochemical changes."", ""reference"": ""PMID:19817892"", ""snippet"": ""In Lynch syndrome adenomas, loss of mismatch repair proteins is related to an enhanced lymphocytic response."", ""supports"": ""SUPPORT""}, {""explanation"": ""This supports the statement by linking Lynch syndrome to mutations in mismatch repair genes, which can be identified using immunohistochemistry."", ""reference"": ""PMID:24333619"", ""snippet"": ""Lynch syndrome is caused by germline mutations in the mismatch repair (MMR) genes."", ""supports"": ""SUPPORT""}], ""name"": ""Immunohistochemistry"", ""notes"": ""Absent mismatch repair proteins in tumors""}"
4627	196	MET Exon 14 Skipping Non-Small Cell Lung Cancer	MET_Exon_14_Skipping_NSCLC.yaml	biochemical	0	MET Exon 14 Testing																																			METex14 testing requires RNA-based NGS or comprehensive DNA-based NGS that covers splice sites. Standard DNA sequencing may miss some splice mutations. IHC for MET overexpression is not reliable for detecting exon 14 skipping. PCR-based assays and RNA sequencing can detect the aberrant splice product.																						"{""name"": ""MET Exon 14 Testing"", ""notes"": ""METex14 testing requires RNA-based NGS or comprehensive DNA-based NGS that covers splice sites. Standard DNA sequencing may miss some splice mutations. IHC for MET overexpression is not reliable for detecting exon 14 skipping. PCR-based assays and RNA sequencing can detect the aberrant splice product.""}"	{}	"{""name"": ""MET Exon 14 Testing"", ""notes"": ""METex14 testing requires RNA-based NGS or comprehensive DNA-based NGS that covers splice sites. Standard DNA sequencing may miss some splice mutations. IHC for MET overexpression is not reliable for detecting exon 14 skipping. PCR-based assays and RNA sequencing can detect the aberrant splice product.""}"
4646	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	biochemical	0	MSI Testing																																			PCR-based testing of five microsatellite markers (Bethesda panel) or expanded panels. MSI-H defined as instability at two or more markers. Next-generation sequencing can also detect MSI status.																						"{""name"": ""MSI Testing"", ""notes"": ""PCR-based testing of five microsatellite markers (Bethesda panel) or expanded panels. MSI-H defined as instability at two or more markers. Next-generation sequencing can also detect MSI status.""}"	{}	"{""name"": ""MSI Testing"", ""notes"": ""PCR-based testing of five microsatellite markers (Bethesda panel) or expanded panels. MSI-H defined as instability at two or more markers. Next-generation sequencing can also detect MSI status.""}"
4647	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	biochemical	1	MMR Immunohistochemistry																																			Immunohistochemistry for MLH1, MSH2, MSH6, and PMS2 proteins. Loss of expression indicates MMR deficiency. MLH1/PMS2 loss with concurrent BRAF V600E suggests sporadic MSI-H; isolated MSH2/MSH6 loss suggests Lynch syndrome.																						"{""name"": ""MMR Immunohistochemistry"", ""notes"": ""Immunohistochemistry for MLH1, MSH2, MSH6, and PMS2 proteins. Loss of expression indicates MMR deficiency. MLH1/PMS2 loss with concurrent BRAF V600E suggests sporadic MSI-H; isolated MSH2/MSH6 loss suggests Lynch syndrome.""}"	{}	"{""name"": ""MMR Immunohistochemistry"", ""notes"": ""Immunohistochemistry for MLH1, MSH2, MSH6, and PMS2 proteins. Loss of expression indicates MMR deficiency. MLH1/PMS2 loss with concurrent BRAF V600E suggests sporadic MSI-H; isolated MSH2/MSH6 loss suggests Lynch syndrome.""}"
4648	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	biochemical	2	Tumor Mutational Burden																																			MSI-H tumors typically have TMB greater than 10 mutations per megabase, often 20-40 mut/Mb. High TMB correlates with checkpoint inhibitor response and can be assessed by NGS panels.																						"{""name"": ""Tumor Mutational Burden"", ""notes"": ""MSI-H tumors typically have TMB greater than 10 mutations per megabase, often 20-40 mut/Mb. High TMB correlates with checkpoint inhibitor response and can be assessed by NGS panels.""}"	{}	"{""name"": ""Tumor Mutational Burden"", ""notes"": ""MSI-H tumors typically have TMB greater than 10 mutations per megabase, often 20-40 mut/Mb. High TMB correlates with checkpoint inhibitor response and can be assessed by NGS panels.""}"
4672	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	biochemical	0	MMR Protein Expression by IHC																																			Immunohistochemistry for MLH1, MSH2, MSH6, and PMS2 is standard for detecting dMMR. Loss of MLH1/PMS2 suggests sporadic hypermethylation; loss of MSH2/MSH6 suggests germline mutation.																						"{""name"": ""MMR Protein Expression by IHC"", ""notes"": ""Immunohistochemistry for MLH1, MSH2, MSH6, and PMS2 is standard for detecting dMMR. Loss of MLH1/PMS2 suggests sporadic hypermethylation; loss of MSH2/MSH6 suggests germline mutation.""}"	{}	"{""name"": ""MMR Protein Expression by IHC"", ""notes"": ""Immunohistochemistry for MLH1, MSH2, MSH6, and PMS2 is standard for detecting dMMR. Loss of MLH1/PMS2 suggests sporadic hypermethylation; loss of MSH2/MSH6 suggests germline mutation.""}"
4673	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	biochemical	1	MSI Testing																																			PCR-based microsatellite instability testing using Bethesda markers or next-generation sequencing confirms MSI-H status.																						"{""name"": ""MSI Testing"", ""notes"": ""PCR-based microsatellite instability testing using Bethesda markers or next-generation sequencing confirms MSI-H status.""}"	{}	"{""name"": ""MSI Testing"", ""notes"": ""PCR-based microsatellite instability testing using Bethesda markers or next-generation sequencing confirms MSI-H status.""}"
4691	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	biochemical	0	Cortisol					HPA axis hyperactivity			Elevated																																																	"{""context"": ""HPA axis hyperactivity"", ""name"": ""Cortisol"", ""presence"": ""Elevated""}"	{}	"{""context"": ""HPA axis hyperactivity"", ""evidence"": [{""explanation"": ""The HPA axis hypothesis supports elevated cortisol as a key biochemical feature of MDD."", ""reference"": ""PMID:38331979"", ""snippet"": ""The currently widely accepted theories of MDD pathogenesis include the neurotransmitter and receptor hypothesis, hypothalamic-pituitary-adrenal (HPA) axis hypothesis, cytokine hypothesis, neuroplasticity hypothesis and systemic influence hypothesis"", ""supports"": ""SUPPORT""}], ""name"": ""Cortisol"", ""presence"": ""Elevated""}"
4692	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	biochemical	1	BDNF					Reduced neuroplasticity marker			Decreased																																																	"{""context"": ""Reduced neuroplasticity marker"", ""name"": ""BDNF"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Reduced neuroplasticity marker"", ""evidence"": [{""explanation"": ""This demonstrates how neuroplasticity-related mechanisms are impaired in MDD, which is consistent with decreased BDNF as a neuroplasticity marker."", ""reference"": ""PMID:38474387"", ""snippet"": ""neuroinflammation and gut dysbiosis induce alterations in tryptophan metabolism, culminating in decreased serotonin synthesis, impairments in neuroplasticity-related mechanisms, and glutamate-mediated excitotoxicity."", ""supports"": ""SUPPORT""}], ""name"": ""BDNF"", ""presence"": ""Decreased""}"
4693	199	Major Depressive Disorder	Major_Depressive_Disorder.yaml	biochemical	2	Inflammatory Markers					IL-6, CRP, TNF-alpha			Elevated																																																	"{""context"": ""IL-6, CRP, TNF-alpha"", ""name"": ""Inflammatory Markers"", ""presence"": ""Elevated""}"	{}	"{""context"": ""IL-6, CRP, TNF-alpha"", ""evidence"": [{""explanation"": ""This directly confirms elevated inflammatory cytokines including IL-6 and TNF-α in MDD patients."", ""reference"": ""PMID:38474387"", ""snippet"": ""The increase of pro-inflammatory cytokines (interleukin (IL)-1β, IL-6, IL-18, and TNF-α) in individuals with depression may elicit neuroinflammatory processes and peripheral inflammation"", ""supports"": ""SUPPORT""}], ""name"": ""Inflammatory Markers"", ""presence"": ""Elevated""}"
4726	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	biochemical	0	Mesothelin																																			Serum mesothelin and megakaryocyte potentiating factor (MPF) are elevated in mesothelioma and can be used for diagnosis and monitoring. Sensitivity is approximately 60% for epithelioid subtype but lower for sarcomatoid.																						"{""name"": ""Mesothelin"", ""notes"": ""Serum mesothelin and megakaryocyte potentiating factor (MPF) are elevated in mesothelioma and can be used for diagnosis and monitoring. Sensitivity is approximately 60% for epithelioid subtype but lower for sarcomatoid.""}"	{}	"{""biomarker_term"": {""preferred_term"": ""Mesothelin"", ""term"": {""id"": ""NCIT:C20887"", ""label"": ""Mesothelin""}}, ""name"": ""Mesothelin"", ""notes"": ""Serum mesothelin and megakaryocyte potentiating factor (MPF) are elevated in mesothelioma and can be used for diagnosis and monitoring. Sensitivity is approximately 60% for epithelioid subtype but lower for sarcomatoid.""}"
4727	200	Malignant Mesothelioma	Malignant_Mesothelioma.yaml	biochemical	1	BAP1 Immunohistochemistry																																			Loss of nuclear BAP1 staining by immunohistochemistry indicates BAP1 inactivation and supports the diagnosis of mesothelioma over reactive mesothelial proliferation.																						"{""name"": ""BAP1 Immunohistochemistry"", ""notes"": ""Loss of nuclear BAP1 staining by immunohistochemistry indicates BAP1 inactivation and supports the diagnosis of mesothelioma over reactive mesothelial proliferation.""}"	{}	"{""name"": ""BAP1 Immunohistochemistry"", ""notes"": ""Loss of nuclear BAP1 staining by immunohistochemistry indicates BAP1 inactivation and supports the diagnosis of mesothelioma over reactive mesothelial proliferation.""}"
4751	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	biochemical	0	Cyclin D1 Expression																																			Immunohistochemistry for cyclin D1 (CCND1) is positive in virtually all MCL cases and is essential for diagnosis. SOX11 expression helps distinguish classical from leukemic non-nodal variants.																						"{""name"": ""Cyclin D1 Expression"", ""notes"": ""Immunohistochemistry for cyclin D1 (CCND1) is positive in virtually all MCL cases and is essential for diagnosis. SOX11 expression helps distinguish classical from leukemic non-nodal variants.""}"	{}	"{""name"": ""Cyclin D1 Expression"", ""notes"": ""Immunohistochemistry for cyclin D1 (CCND1) is positive in virtually all MCL cases and is essential for diagnosis. SOX11 expression helps distinguish classical from leukemic non-nodal variants.""}"
4752	202	Mantle Cell Lymphoma	Mantle_Cell_Lymphoma.yaml	biochemical	1	Flow Cytometry Immunophenotyping																																			MCL cells are CD5+, CD19+, CD20+, CD23-, FMC7+, with moderate to strong surface immunoglobulin. The CD5+ CD23- phenotype helps distinguish from CLL which is typically CD23+.																						"{""name"": ""Flow Cytometry Immunophenotyping"", ""notes"": ""MCL cells are CD5+, CD19+, CD20+, CD23-, FMC7+, with moderate to strong surface immunoglobulin. The CD5+ CD23- phenotype helps distinguish from CLL which is typically CD23+.""}"	{}	"{""name"": ""Flow Cytometry Immunophenotyping"", ""notes"": ""MCL cells are CD5+, CD19+, CD20+, CD23-, FMC7+, with moderate to strong surface immunoglobulin. The CD5+ CD23- phenotype helps distinguish from CLL which is typically CD23+.""}"
4778	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	biochemical	0	Plasma Leucine					Markedly elevated, often greater than 2000 micromol/L in classic form; normal is 90-250 micromol/L			Elevated																																																	"{""context"": ""Markedly elevated, often greater than 2000 micromol/L in classic form; normal is 90-250 micromol/L"", ""name"": ""Plasma Leucine"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Markedly elevated, often greater than 2000 micromol/L in classic form; normal is 90-250 micromol/L"", ""evidence"": [{""explanation"": ""Confirms marked elevation of leucine in MSUD mouse model."", ""reference"": ""PMID:27373929"", ""snippet"": ""Leucine was significantly increased 6.4-fold in serum (1.63 ± 0.19 mM) and 6.3-fold in muscle isolated"", ""supports"": ""SUPPORT""}], ""name"": ""Plasma Leucine"", ""presence"": ""Elevated""}"
4779	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	biochemical	1	Plasma Isoleucine					Elevated above normal range along with other branched-chain amino acids			Elevated																																																	"{""context"": ""Elevated above normal range along with other branched-chain amino acids"", ""name"": ""Plasma Isoleucine"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Elevated above normal range along with other branched-chain amino acids"", ""evidence"": [{""explanation"": ""Confirms elevation of all BCAAs including isoleucine in plasma."", ""reference"": ""PMID:28919799"", ""snippet"": ""Maple syrup urine disease (MSUD) is an inborn error of metabolism caused by defects in the branched-chain α-ketoacid dehydrogenase complex, which results in elevations of the branched-chain amino acids (BCAAs) in plasma"", ""supports"": ""SUPPORT""}], ""name"": ""Plasma Isoleucine"", ""presence"": ""Elevated""}"
4780	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	biochemical	2	Plasma Valine					Elevated above normal range along with other branched-chain amino acids			Elevated																																																	"{""context"": ""Elevated above normal range along with other branched-chain amino acids"", ""name"": ""Plasma Valine"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Elevated above normal range along with other branched-chain amino acids"", ""evidence"": [{""explanation"": ""Confirms elevation of all BCAAs including valine in plasma."", ""reference"": ""PMID:28919799"", ""snippet"": ""Maple syrup urine disease (MSUD) is an inborn error of metabolism caused by defects in the branched-chain α-ketoacid dehydrogenase complex, which results in elevations of the branched-chain amino acids (BCAAs) in plasma"", ""supports"": ""SUPPORT""}], ""name"": ""Plasma Valine"", ""presence"": ""Elevated""}"
4781	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	biochemical	3	Alloisoleucine					Pathognomonic marker for MSUD, not normally present in plasma			Elevated																																																	"{""context"": ""Pathognomonic marker for MSUD, not normally present in plasma"", ""name"": ""Alloisoleucine"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Pathognomonic marker for MSUD, not normally present in plasma"", ""evidence"": [{""explanation"": ""Confirms alloisoleucine is the pathognomonic marker for MSUD."", ""reference"": ""PMID:28919799"", ""snippet"": ""Maple syrup urine disease (MSUD) is an inborn error of metabolism caused by defects in the branched-chain α-ketoacid dehydrogenase complex, which results in elevations of the branched-chain amino acids (BCAAs) in plasma, α-ketoacids in urine, and production of the pathognomonic disease marker, alloisoleucine."", ""supports"": ""SUPPORT""}], ""name"": ""Alloisoleucine"", ""presence"": ""Elevated""}"
4782	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	biochemical	4	Alpha-Ketoisocaproic Acid (KIC)					Leucine-derived ketoacid, primary neurotoxic metabolite			Elevated																																																	"{""context"": ""Leucine-derived ketoacid, primary neurotoxic metabolite"", ""name"": ""Alpha-Ketoisocaproic Acid (KIC)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Leucine-derived ketoacid, primary neurotoxic metabolite"", ""evidence"": [{""explanation"": ""Demonstrates massive KIC accumulation in MSUD."", ""reference"": ""PMID:27373929"", ""snippet"": ""Similarly, KIC was significantly increased 40-fold (668.05 ± 81.74 μM) in serum and 15-fold (3.02 ± 0.56 nmoles/μg of total protein) in muscle of iMSUD mice"", ""supports"": ""SUPPORT""}], ""name"": ""Alpha-Ketoisocaproic Acid (KIC)"", ""presence"": ""Elevated""}"
4783	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	biochemical	5	Alpha-Ketoisovaleric Acid (KIV)					Valine-derived ketoacid			Elevated																																																	"{""context"": ""Valine-derived ketoacid"", ""name"": ""Alpha-Ketoisovaleric Acid (KIV)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Valine-derived ketoacid"", ""evidence"": [{""explanation"": ""Confirms KIV accumulation from valine due to BCKDH dysfunction."", ""reference"": ""PMID:27373929"", ""snippet"": ""BCKDH dysfunction results in the accumulation of the keto-acids ketoisocaproic acid (KIC) from leucine, ketoisovaleric acid (KIV) from valine and ketomethylvaleric acid (KMV) from isoleucine"", ""supports"": ""SUPPORT""}], ""name"": ""Alpha-Ketoisovaleric Acid (KIV)"", ""presence"": ""Elevated""}"
4784	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	biochemical	6	Alpha-Keto-beta-Methylvaleric Acid (KMV)					Isoleucine-derived ketoacid			Elevated																																																	"{""context"": ""Isoleucine-derived ketoacid"", ""name"": ""Alpha-Keto-beta-Methylvaleric Acid (KMV)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Isoleucine-derived ketoacid"", ""evidence"": [{""explanation"": ""Confirms KMV accumulation from isoleucine due to BCKDH dysfunction."", ""reference"": ""PMID:27373929"", ""snippet"": ""BCKDH dysfunction results in the accumulation of the keto-acids ketoisocaproic acid (KIC) from leucine, ketoisovaleric acid (KIV) from valine and ketomethylvaleric acid (KMV) from isoleucine"", ""supports"": ""SUPPORT""}], ""name"": ""Alpha-Keto-beta-Methylvaleric Acid (KMV)"", ""presence"": ""Elevated""}"
4818	204	Marfan Syndrome	Marfan_Syndrome.yaml	biochemical	0	Fibrillin-1 Protein					Can be used in research settings but not routine diagnostics.			Abnormal																																																	"{""context"": ""Can be used in research settings but not routine diagnostics."", ""name"": ""Fibrillin-1 Protein"", ""presence"": ""Abnormal""}"	{}	"{""context"": ""Can be used in research settings but not routine diagnostics."", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The literature indicates that fibrillin-1 protein abnormalities are directly linked to Marfan syndrome, which is relevant for both research and diagnostic purposes."", ""reference"": ""PMID:8180508"", ""snippet"": ""Analysis of fibrillin protein or gene defects in individuals with related phenotypes has revealed that a perinatal lethal syndrome, termed neonatal Marfan syndrome, is due to FBN1 gene mutations."", ""supports"": ""REFUTE""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The literature discusses the importance of fibrillin-1 in the diagnosis of Marfan syndrome, indicating its relevance in routine diagnostics."", ""reference"": ""PMID:9586151"", ""snippet"": ""New diagnostic insights have eventually led to revised nosologic criteria for the diagnosis of Marfan syndrome."", ""supports"": ""REFUTE""}, {""evidence_source"": ""MODEL_ORGANISM"", ""explanation"": ""The literature highlights the role of fibrillin-1 in the pathogenesis of Marfan syndrome, which is essential for both research and diagnostic purposes."", ""reference"": ""PMID:22705998"", ""snippet"": ""Although historically Marfan syndrome (MFS) has always been considered as a condition caused by the deficiency of a structural extracellular matrix protein, fibrillin-1, the study of Marfan mouse models and Marfan-related conditions has shifted our current understanding to a pathogenic model that involves dysregulation of the cytokine-transforming growth factor beta (TGF-beta) signaling."", ""supports"": ""REFUTE""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The literature underscores the diagnostic importance of identifying fibrillin-1 mutations in Marfan syndrome."", ""reference"": ""PMID:37688493"", ""snippet"": ""Marfan syndrome (MFS) is a multisystem genetic disorder with over 3000 mutations described in the fibrillin 1 (FBN1) gene."", ""supports"": ""REFUTE""}], ""name"": ""Fibrillin-1 Protein"", ""presence"": ""Abnormal""}"
4924	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	biochemical	0	Serum Calcitonin																																			Calcitonin is the primary tumor marker for MTC. Elevated levels indicate disease presence, and post-operative normalization suggests complete resection. Rising levels after treatment suggest recurrence or residual disease.																						"{""name"": ""Serum Calcitonin"", ""notes"": ""Calcitonin is the primary tumor marker for MTC. Elevated levels indicate disease presence, and post-operative normalization suggests complete resection. Rising levels after treatment suggest recurrence or residual disease.""}"	{}	"{""biomarker_term"": {""preferred_term"": ""calcitonin"", ""term"": {""id"": ""NCIT:C2281"", ""label"": ""Calcitonin""}}, ""name"": ""Serum Calcitonin"", ""notes"": ""Calcitonin is the primary tumor marker for MTC. Elevated levels indicate disease presence, and post-operative normalization suggests complete resection. Rising levels after treatment suggest recurrence or residual disease.""}"
4925	207	Medullary Thyroid Carcinoma	Medullary_Thyroid_Carcinoma.yaml	biochemical	1	Serum CEA																																			Carcinoembryonic antigen (CEA) is elevated in most patients with MTC and correlates with tumor burden. Rapid CEA doubling time suggests aggressive disease.																						"{""name"": ""Serum CEA"", ""notes"": ""Carcinoembryonic antigen (CEA) is elevated in most patients with MTC and correlates with tumor burden. Rapid CEA doubling time suggests aggressive disease.""}"	{}	"{""biomarker_term"": {""preferred_term"": ""carcinoembryonic antigen"", ""term"": {""id"": ""NCIT:C16384"", ""label"": ""Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5""}}, ""name"": ""Serum CEA"", ""notes"": ""Carcinoembryonic antigen (CEA) is elevated in most patients with MTC and correlates with tumor burden. Rapid CEA doubling time suggests aggressive disease.""}"
5015	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	biochemical	0	TNF-α elevation					Serum and orofacial tissue marker of granulomatous inflammation			Elevated																																																	"{""context"": ""Serum and orofacial tissue marker of granulomatous inflammation"", ""name"": ""TNF-α elevation"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Serum and orofacial tissue marker of granulomatous inflammation"", ""evidence"": [{""explanation"": ""Demonstrates the role of TNF-α in MRS pathophysiology through effective therapeutic targeting with TNF antagonists"", ""reference"": ""PMID:32782477"", ""snippet"": ""Reported evidence indicates treatment with an anti-TNF agent (mainly infliximab) is the most recommended therapeutic option after failure of conventional treatments."", ""supports"": ""SUPPORT""}], ""name"": ""TNF-α elevation"", ""presence"": ""Elevated""}"
5016	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	biochemical	1	Interferon-gamma (IFN-γ) elevation					Th1-derived cytokine promoting macrophage activation and granuloma formation			Elevated																																																	"{""context"": ""Th1-derived cytokine promoting macrophage activation and granuloma formation"", ""name"": ""Interferon-gamma (IFN-γ) elevation"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Th1-derived cytokine promoting macrophage activation and granuloma formation"", ""evidence"": [{""explanation"": ""Implicates IFN-γ elevation in MRS pathophysiology, particularly in association with autoimmune and allergic conditions"", ""reference"": ""PMID:31466978"", ""snippet"": ""interferon gamma could play a key role. To our knowledge, this is the first case report in which Melkersson-Rosenthal syndrome has been observed concurrently with coeliac disease."", ""supports"": ""PARTIAL""}], ""name"": ""Interferon-gamma (IFN-γ) elevation"", ""presence"": ""Elevated""}"
5017	211	Melkersson-Rosenthal syndrome	Melkersson_Rosenthal_syndrome.yaml	biochemical	2	IL-12 and IL-23					Th1/Th17-promoting cytokines in orofacial granulomas			Elevated																																																	"{""context"": ""Th1/Th17-promoting cytokines in orofacial granulomas"", ""name"": ""IL-12 and IL-23"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Th1/Th17-promoting cytokines in orofacial granulomas"", ""evidence"": [{""explanation"": ""Establishes IL-12/23 elevation as part of the inflammatory cytokine cascade in orofacial granulomatous inflammation"", ""reference"": ""PMID:32782477"", ""snippet"": ""IL-12 and IL-23 are linked to the production of IFN-γ, a pivotal mediator of inflammation in peripheral tissues, including orofacial mucosa, by promoting multiple proinflammatory cytokines."", ""supports"": ""SUPPORT""}], ""name"": ""IL-12 and IL-23"", ""presence"": ""Elevated""}"
5076	214	Migraine	Migraine.yaml	biochemical	0	CGRP					During attacks			Elevated																																																	"{""context"": ""During attacks"", ""name"": ""CGRP"", ""presence"": ""Elevated""}"	{}	"{""context"": ""During attacks"", ""evidence"": [{""explanation"": ""Confirms the central role of CGRP in migraine pathophysiology and its elevation during attacks."", ""reference"": ""PMID:37755358"", ""snippet"": ""Special emphasis is given to the role of calcitonin gene-related peptide (CGRP) in migraine development. CGRP not only contributes to symptoms but also represents a promising therapeutic target, with inhibitors showing effectiveness in migraine management."", ""supports"": ""SUPPORT""}], ""name"": ""CGRP"", ""presence"": ""Elevated""}"
5077	214	Migraine	Migraine.yaml	biochemical	1	Serotonin					May contribute to attacks			Decreased																																																	"{""context"": ""May contribute to attacks"", ""name"": ""Serotonin"", ""presence"": ""Decreased""}"	{}	"{""context"": ""May contribute to attacks"", ""evidence"": [{""explanation"": ""Serotonergic system is the most convincingly implicated neurotransmitter system in migraine."", ""reference"": ""PMID:17970989"", ""snippet"": ""Amongst the many neurotransmitters in the brain, the serotonergic (serotonin, 5-HT) system from the brainstem raphe nucleus has been most convincingly implicated in migraine pathophysiology."", ""supports"": ""SUPPORT""}, {""explanation"": ""Low serotonin disposition is associated with migraine susceptibility and attacks."", ""reference"": ""PMID:17970989"", ""snippet"": ""The documented changes in 5-HT metabolism and in the processing of central 5-HT-mediated responses during and in between migraine attacks have led to the suggestion that migraine is a consequence of a central neurochemical imbalance that involves a low serotonergic disposition."", ""supports"": ""SUPPORT""}], ""name"": ""Serotonin"", ""presence"": ""Decreased""}"
5115	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	biochemical	0	Anti-U1 RNP Antibodies					Diagnostic hallmark, required for diagnosis			Elevated																																																	"{""context"": ""Diagnostic hallmark, required for diagnosis"", ""name"": ""Anti-U1 RNP Antibodies"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Diagnostic hallmark, required for diagnosis"", ""name"": ""Anti-U1 RNP Antibodies"", ""presence"": ""Elevated""}"
5116	215	Mixed Connective Tissue Disease	Mixed_Connective_Tissue_Disease.yaml	biochemical	1	ANA					Typically high-titer speckled pattern			Elevated																																																	"{""context"": ""Typically high-titer speckled pattern"", ""name"": ""ANA"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Typically high-titer speckled pattern"", ""name"": ""ANA"", ""presence"": ""Elevated""}"
5131	216	Monkeypox	Monkeypox.yaml	biochemical	0	Monkeypox Virus PCR					Diagnostic test to confirm the presence of the virus			Positive																																																	"{""context"": ""Diagnostic test to confirm the presence of the virus"", ""name"": ""Monkeypox Virus PCR"", ""presence"": ""Positive""}"	{}	"{""context"": ""Diagnostic test to confirm the presence of the virus"", ""evidence"": [{""explanation"": ""The statement is supported as the document states that PCR is the laboratory test of choice to confirm monkeypox virus infection."", ""reference"": ""PMID:36529507"", ""snippet"": ""Due to the serological cross-reactivity of orthopoxviruses, PCR is the laboratory test of choice to confirm monkeypox virus infection. We recommend a dual-target PCR approach in which one assay targets a conserved sequence of the Orthopoxvirus genus and the other targets a monkeypox virus specific sequence."", ""supports"": ""SUPPORT""}, {""explanation"": ""The use of reverse transcriptase PCR (RT-PCR) is mentioned as part of their diagnostic methodology for monkeypox."", ""reference"": ""PMID:37646742"", ""snippet"": ""We describe a virus isolation protocol for a human clinical sample from a patient from Brazil, the viral growth in a cell model through plaque forming units (PFU) assay, reverse transcriptase polymerase chain reaction (RT-PCR) and transmission electron microscopy (TEM)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The document discusses the use of PCR for detecting monkeypox virus DNA in clinical samples and correlating it with infectivity."", ""reference"": ""PMID:36052723"", ""snippet"": ""We show strong correlation between viral DNA amount in clinical specimens and virus infectivity toward BSC-1 cell line. Moreover, we define a PCR threshold value (Cq >/= 35, </= 4,300 DNA copies/mL), corresponding to negative viral cultures, which may assist risk-assessment and decision-making..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study evaluates a PCR test's performance and concludes it is effective for detecting monkeypox virus."", ""reference"": ""PMID:38520832"", ""snippet"": ""In the end, the Xfree hMPXV/OPXV LDT proved to be a sensitive, specific, and reproducible test for the detection of Mpox on both platforms evaluated..."", ""supports"": ""SUPPORT""}, {""explanation"": ""The document assesses the performance of a PCR assay and confirms it is suitable for diagnosing monkeypox."", ""reference"": ""PMID:36473345"", ""snippet"": ""BACKGROUND: Monkeypox virus (MPXV) is the causative agent of the 2022 monkeypox global outbreak... To evaluate the performance characteristics of the Viasure MPXV PCR assay..."", ""supports"": ""SUPPORT""}], ""name"": ""Monkeypox Virus PCR"", ""presence"": ""Positive""}"
5132	216	Monkeypox	Monkeypox.yaml	biochemical	1	Serology for Orthopoxvirus Antibodies					Indicates exposure to or vaccination against orthopoxviruses			Positive																																																	"{""context"": ""Indicates exposure to or vaccination against orthopoxviruses"", ""name"": ""Serology for Orthopoxvirus Antibodies"", ""presence"": ""Positive""}"	{}	"{""context"": ""Indicates exposure to or vaccination against orthopoxviruses"", ""evidence"": [{""explanation"": ""The study assessed the presence of antibodies against orthopoxviruses, which indicates exposure to or vaccination against these viruses."", ""reference"": ""PMID:18165539"", ""snippet"": ""Titers of IgM and IgG to OPX were assessed using an enzyme-linked immunosorbent assay."", ""supports"": ""SUPPORT""}, {""explanation"": ""This research identifies antibodies specific to orthopoxviruses, which would be detectable in serological tests indicating exposure or vaccination."", ""reference"": ""PMID:27768891"", ""snippet"": ""We generated a large panel of orthopoxvirus-specific human monoclonal antibodies (Abs) from immune subjects."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study shows that serology for orthopoxvirus antibodies is used to determine exposure to the viruses, which aligns with the given statement."", ""reference"": ""PMID:23973323"", ""snippet"": ""A serological survey was conducted in a Brazilian laboratory to evaluate staff exposure to orthopoxviruses (OPVs)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The article discusses serological methods to detect antibodies against monkeypox virus, supporting the use of serology to indicate exposure or vaccination against orthopoxviruses."", ""reference"": ""PMID:38054557"", ""snippet"": ""Here three complementary serological methods are described with different strengths to aid the development and evaluation of in-house assays."", ""supports"": ""SUPPORT""}], ""name"": ""Serology for Orthopoxvirus Antibodies"", ""presence"": ""Positive""}"
5192	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	biochemical	0	Serum Calcitonin																																			Calcitonin is produced by thyroid C-cells and elevated in MTC. Used for diagnosis, staging, and post-operative surveillance. Stimulated calcitonin testing may detect early C-cell hyperplasia or microcarcinoma.																						"{""name"": ""Serum Calcitonin"", ""notes"": ""Calcitonin is produced by thyroid C-cells and elevated in MTC. Used for diagnosis, staging, and post-operative surveillance. Stimulated calcitonin testing may detect early C-cell hyperplasia or microcarcinoma.""}"	{}	"{""biomarker_term"": {""preferred_term"": ""Calcitonin"", ""term"": {""id"": ""NCIT:C2281"", ""label"": ""Calcitonin""}}, ""name"": ""Serum Calcitonin"", ""notes"": ""Calcitonin is produced by thyroid C-cells and elevated in MTC. Used for diagnosis, staging, and post-operative surveillance. Stimulated calcitonin testing may detect early C-cell hyperplasia or microcarcinoma.""}"
5193	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	biochemical	1	Plasma Metanephrines																																			Fractionated plasma metanephrines are used to screen for pheochromocytoma. Must be performed before any surgery (especially thyroidectomy) to avoid intraoperative hypertensive crisis from undiagnosed pheochromocytoma.																						"{""name"": ""Plasma Metanephrines"", ""notes"": ""Fractionated plasma metanephrines are used to screen for pheochromocytoma. Must be performed before any surgery (especially thyroidectomy) to avoid intraoperative hypertensive crisis from undiagnosed pheochromocytoma.""}"	{}	"{""name"": ""Plasma Metanephrines"", ""notes"": ""Fractionated plasma metanephrines are used to screen for pheochromocytoma. Must be performed before any surgery (especially thyroidectomy) to avoid intraoperative hypertensive crisis from undiagnosed pheochromocytoma.""}"
5194	218	Multiple Endocrine Neoplasia Type 2	Multiple_Endocrine_Neoplasia_Type_2.yaml	biochemical	2	RET Genetic Testing																																			Molecular testing of RET identifies pathogenic variants and guides management. ATA risk categories based on specific mutations determine timing of prophylactic thyroidectomy: highest risk (M918T) within first year of life; high risk (codons 634, A883F) before age 5; moderate risk (others) individualized.																						"{""name"": ""RET Genetic Testing"", ""notes"": ""Molecular testing of RET identifies pathogenic variants and guides management. ATA risk categories based on specific mutations determine timing of prophylactic thyroidectomy: highest risk (M918T) within first year of life; high risk (codons 634, A883F) before age 5; moderate risk (others) individualized.""}"	{}	"{""name"": ""RET Genetic Testing"", ""notes"": ""Molecular testing of RET identifies pathogenic variants and guides management. ATA risk categories based on specific mutations determine timing of prophylactic thyroidectomy: highest risk (M918T) within first year of life; high risk (codons 634, A883F) before age 5; moderate risk (others) individualized.""}"
5213	219	Multiple Sclerosis	Multiple_Sclerosis.yaml	biochemical	0	Oligoclonal Bands					Detected in cerebrospinal fluid during lumbar puncture.			Positive																																																	"{""context"": ""Detected in cerebrospinal fluid during lumbar puncture."", ""name"": ""Oligoclonal Bands"", ""presence"": ""Positive""}"	{}	"{""context"": ""Detected in cerebrospinal fluid during lumbar puncture."", ""evidence"": [{""explanation"": ""This reference reiterates that oligoclonal bands are a key diagnostic marker in the cerebrospinal fluid of multiple sclerosis patients."", ""reference"": ""PMID:31031747"", ""snippet"": ""The hallmark of MS-specific changes in CSF is the detection of oligoclonal bands (OCB) which occur in the vast majority of MS patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference shows that oligoclonal bands were detected in the cerebrospinal fluid of patients who later met the criteria for multiple sclerosis."", ""reference"": ""PMID:32408148"", ""snippet"": ""Oligoclonal bands were identified in 5/6 patients. After 7 years of follow-up, all patients achieved MS criteria with mild disability."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports the detection of oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients."", ""reference"": ""PMID:22919874"", ""snippet"": ""Immunoglobulin IgG in cerebrospinal fluid (CSF) can be detected in neurological diseasses (infections and inflammatory neurological diseases and in demyelinating diseases, like multiple sclerosis (MS))"", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference indicates that oligoclonal bands are present in the cerebrospinal fluid and are a risk factor for the development of multiple sclerosis."", ""reference"": ""PMID:29452342"", ""snippet"": ""Neurofilament light chain levels and oligoclonal bands were independent risk factors for the development of clinically isolated syndrome (hazard ratio = 1.02, P = 0.019, and hazard ratio = 14.7, P = 0.012, respectively) and multiple sclerosis."", ""supports"": ""SUPPORT""}], ""name"": ""Oligoclonal Bands"", ""presence"": ""Positive""}"
5248	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	biochemical	0	C-Reactive Protein (CRP)					General inflammation			Elevated																																																	"{""context"": ""General inflammation"", ""name"": ""C-Reactive Protein (CRP)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""General inflammation"", ""evidence"": [{""explanation"": ""The study highlights that elevated CRP levels are a significant marker for MIS-C, supporting the statement that CRP presence is elevated in the context of general inflammation in MIS-C."", ""reference"": ""PMID:34298578"", ""snippet"": ""The optimal cutoff for CRP was 130 mg/L (sensitivity 88.9, specificity 100%, positive predictive value 100%, NPV, negative predictive value 92.5%, p < 0.001)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study describes increased CRP among other markers in patients with MIS-C, supporting the statement that CRP is elevated."", ""reference"": ""PMID:34479244"", ""snippet"": ""The laboratory parameters at the admission in the global group showed increased C-reactive protein, D-dimer, leukocytes, neutrophils, ferritin, and fibrinogen."", ""supports"": ""SUPPORT""}], ""name"": ""C-Reactive Protein (CRP)"", ""presence"": ""Elevated""}"
5249	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	biochemical	1	Erythrocyte Sedimentation Rate (ESR)					Systemic inflammation			Elevated																																																	"{""context"": ""Systemic inflammation"", ""name"": ""Erythrocyte Sedimentation Rate (ESR)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Systemic inflammation"", ""evidence"": [{""explanation"": ""The study indicates that elevated ESR is associated with severe cases of MIS-C, supporting the statement that MIS-C involves elevated ESR in the context of systemic inflammation."", ""reference"": ""PMID:37309831"", ""snippet"": ""Pearson's chi-squared analysis showed an erythrocyte sedimentation rate (ESR) greater than 30 mm/h and 50 mm/h were disproportionately associated with pediatric intensive care unit (PICU) admission (χ2 = 4.44, P = .04) and use of vasopressors (χ2 = 6.06, P = .01), respectively"", ""supports"": ""SUPPORT""}], ""name"": ""Erythrocyte Sedimentation Rate (ESR)"", ""presence"": ""Elevated""}"
5250	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	biochemical	2	Ferritin					Systemic inflammation			Elevated																																																	"{""context"": ""Systemic inflammation"", ""name"": ""Ferritin"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Systemic inflammation"", ""evidence"": [{""explanation"": ""The study indicates that ferritin levels are a significant marker in MIS-C, with specific associations to clinical outcomes."", ""reference"": ""PMID:37309831"", ""snippet"": ""Ferritin less than 175.6 ng/mL was associated with use of vasopressors (χ2 = 5.28, P = .02)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Although this study focuses on BNP and NT-proBNP, it implies the significance of biomarkers like ferritin in the clinical assessment of MIS-C."", ""reference"": ""PMID:35183528"", ""snippet"": ""Both median admission BNP and NT-proBNP were higher in children with cardiogenic shock than without."", ""supports"": ""SUPPORT""}, {""explanation"": ""Ferritin levels were specifically measured and found to be significant in distinguishing MIS-C from other conditions."", ""reference"": ""PMID:34298578"", ""snippet"": ""The optimal cutoffs for...ferritin, 233 µg/L; and D-dimer, 16.4 mg/L (p < 0.05)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Ferritin is highlighted as an important inflammatory marker in understanding the pathogenesis of MIS-C."", ""reference"": ""PMID:34463724"", ""snippet"": ""Clinical laboratory investigations, including routine blood testing for inflammatory (e.g., C-reactive protein, ferritin)...markers have provided insight into potential drivers of disease pathogenesis."", ""supports"": ""SUPPORT""}, {""explanation"": ""The meta-analysis confirms that elevated ferritin levels are associated with severe MIS-C."", ""reference"": ""PMID:33739452"", ""snippet"": ""Severe MIS-C patients had higher levels of WBC, ANC, CRP, D-dimer, and ferritin than non-severe MIS-C patients."", ""supports"": ""SUPPORT""}], ""name"": ""Ferritin"", ""presence"": ""Elevated""}"
5251	220	Multisystem Inflammatory Syndrome in Children (MIS-C)	Multisystem_Inflammatory_Syndrome_in_Children_MIS-C.yaml	biochemical	3	D-dimer					Coagulopathy			Elevated																																																	"{""context"": ""Coagulopathy"", ""name"": ""D-dimer"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Coagulopathy"", ""evidence"": [{""explanation"": ""The study indicates that D-dimer values are markedly different between COVID-19 and MIS-C cohorts, implying elevated D-dimer levels in MIS-C."", ""reference"": ""PMID:33305475"", ""snippet"": ""D-dimer values did not discriminate COVID-19 of differing severity, whereas were markedly different between the COVID-19 and the MIS-C cohorts."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study describes that all patients with MIS-C had elevated D-dimer levels at presentation."", ""reference"": ""PMID:36730963"", ""snippet"": ""All patients had elevated acute phase reactants and D-dimer at presentation and met published criteria for MIS-C."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study mentions elevated D-dimer as one of the markers for distinguishing MIS-C from other conditions, indicating its presence in MIS-C patients."", ""reference"": ""PMID:34298578"", ""snippet"": ""The optimal cutoff for CRP was 130 mg/L (sensitivity 88.9, specificity 100%, positive predictive value 100%, NPV, negative predictive value 92.5%, p < 0.001)"", ""supports"": ""SUPPORT""}], ""name"": ""D-dimer"", ""presence"": ""Elevated""}"
5295	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	biochemical	0	Natural Killer Cell Cytotoxicity								Decreased																																																	"{""name"": ""Natural Killer Cell Cytotoxicity"", ""presence"": ""Decreased""}"	{}	"{""evidence"": [{""explanation"": ""Systematic review confirms NK cell dysfunction as the most reproducible biomarker finding in ME/CFS."", ""reference"": ""PMID:31727160"", ""snippet"": ""Impaired NK cell cytotoxicity remained the most consistent immunological report across all publications"", ""supports"": ""SUPPORT""}], ""name"": ""Natural Killer Cell Cytotoxicity"", ""presence"": ""Decreased""}"
5296	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	biochemical	1	Inflammatory Cytokines					Early disease and after exertion			Elevated																																																	"{""context"": ""Early disease and after exertion"", ""name"": ""Inflammatory Cytokines"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Early disease and after exertion"", ""evidence"": [{""explanation"": ""Stanford study identifies cytokine signature correlating with disease severity including 13 proinflammatory cytokines."", ""reference"": ""PMID:28760971"", ""snippet"": ""Seventeen cytokines had a statistically significant upward linear trend that correlated with ME/CFS severity"", ""supports"": ""SUPPORT""}], ""name"": ""Inflammatory Cytokines"", ""presence"": ""Elevated""}"
5297	221	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Myalgic_Encephalomyelitis_Chronic_Fatigue_Syndrome.yaml	biochemical	2	Oxidative Stress Markers								Elevated																																																	"{""name"": ""Oxidative Stress Markers"", ""presence"": ""Elevated""}"	{}	"{""evidence"": [{""explanation"": ""Study demonstrates oxidative and nitrosative stress pathways contribute to ME/CFS pathophysiology."", ""reference"": ""PMID:24557875"", ""snippet"": ""Mitochondrial dysfunctions, e.g. lowered ATP production, may play a role in the onset of ME/CFS symptoms"", ""supports"": ""SUPPORT""}], ""name"": ""Oxidative Stress Markers"", ""presence"": ""Elevated""}"
5321	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	biochemical	0	Anti-AChR Antibodies					Present in ~85% of generalized MG			Elevated																																																	"{""context"": ""Present in ~85% of generalized MG"", ""name"": ""Anti-AChR Antibodies"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Present in ~85% of generalized MG"", ""name"": ""Anti-AChR Antibodies"", ""presence"": ""Elevated""}"
5322	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	biochemical	1	Anti-MuSK Antibodies					Present in ~5-10% of MG, particularly seronegative cases			Elevated																																																	"{""context"": ""Present in ~5-10% of MG, particularly seronegative cases"", ""name"": ""Anti-MuSK Antibodies"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Present in ~5-10% of MG, particularly seronegative cases"", ""name"": ""Anti-MuSK Antibodies"", ""presence"": ""Elevated""}"
5323	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	biochemical	2	Anti-LRP4 Antibodies					Present in some double-seronegative cases			Elevated																																																	"{""context"": ""Present in some double-seronegative cases"", ""name"": ""Anti-LRP4 Antibodies"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Present in some double-seronegative cases"", ""name"": ""Anti-LRP4 Antibodies"", ""presence"": ""Elevated""}"
5357	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	biochemical	0	NPM1 Mutation Analysis																																			PCR-based assays or sequencing detect characteristic 4-base pair insertions in exon 12. Type A mutation (TCTG duplication) accounts for 75-80% of cases. NPM1 mutation is a sensitive MRD marker due to its stability during disease.																						"{""name"": ""NPM1 Mutation Analysis"", ""notes"": ""PCR-based assays or sequencing detect characteristic 4-base pair insertions in exon 12. Type A mutation (TCTG duplication) accounts for 75-80% of cases. NPM1 mutation is a sensitive MRD marker due to its stability during disease.""}"	{}	"{""name"": ""NPM1 Mutation Analysis"", ""notes"": ""PCR-based assays or sequencing detect characteristic 4-base pair insertions in exon 12. Type A mutation (TCTG duplication) accounts for 75-80% of cases. NPM1 mutation is a sensitive MRD marker due to its stability during disease.""}"
5358	224	Acute Myeloid Leukemia, NPM1-Mutated	NPM1_Mutant_AML.yaml	biochemical	1	Immunohistochemistry for Cytoplasmic NPM1																																			Antibodies detecting cytoplasmic NPM1 (NPMc+) can identify NPM1-mutated AML on bone marrow biopsy. Nuclear-restricted staining excludes NPM1 mutation.																						"{""name"": ""Immunohistochemistry for Cytoplasmic NPM1"", ""notes"": ""Antibodies detecting cytoplasmic NPM1 (NPMc+) can identify NPM1-mutated AML on bone marrow biopsy. Nuclear-restricted staining excludes NPM1 mutation.""}"	{}	"{""name"": ""Immunohistochemistry for Cytoplasmic NPM1"", ""notes"": ""Antibodies detecting cytoplasmic NPM1 (NPMc+) can identify NPM1-mutated AML on bone marrow biopsy. Nuclear-restricted staining excludes NPM1 mutation.""}"
5388	226	NTRK Fusion-Positive Cancer	NTRK_Fusion_Positive_Cancer.yaml	biochemical	0	NTRK Fusion Detection																																			Multiple testing methods detect NTRK fusions including RNA-based NGS (preferred), DNA-based NGS, FISH, and immunohistochemistry for pan-TRK expression. RNA-based testing captures the full spectrum of fusion partners.																						"{""name"": ""NTRK Fusion Detection"", ""notes"": ""Multiple testing methods detect NTRK fusions including RNA-based NGS (preferred), DNA-based NGS, FISH, and immunohistochemistry for pan-TRK expression. RNA-based testing captures the full spectrum of fusion partners.""}"	{}	"{""name"": ""NTRK Fusion Detection"", ""notes"": ""Multiple testing methods detect NTRK fusions including RNA-based NGS (preferred), DNA-based NGS, FISH, and immunohistochemistry for pan-TRK expression. RNA-based testing captures the full spectrum of fusion partners.""}"
5404	227	Narcolepsy	Narcolepsy.yaml	biochemical	0	CSF Orexin/Hypocretin-1					Low or undetectable in Type 1 narcolepsy (<110 pg/mL)			Decreased																																																	"{""context"": ""Low or undetectable in Type 1 narcolepsy (<110 pg/mL)"", ""name"": ""CSF Orexin/Hypocretin-1"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Low or undetectable in Type 1 narcolepsy (<110 pg/mL)"", ""name"": ""CSF Orexin/Hypocretin-1"", ""presence"": ""Decreased""}"
5427	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	biochemical	0	EBV DNA (Plasma)																																			Circulating EBV DNA is a sensitive and specific biomarker for NPC. Plasma EBV DNA levels correlate with tumor burden and can be used for screening in endemic populations, diagnosis, monitoring treatment response, and surveillance for recurrence.																						"{""name"": ""EBV DNA (Plasma)"", ""notes"": ""Circulating EBV DNA is a sensitive and specific biomarker for NPC. Plasma EBV DNA levels correlate with tumor burden and can be used for screening in endemic populations, diagnosis, monitoring treatment response, and surveillance for recurrence.""}"	{}	"{""name"": ""EBV DNA (Plasma)"", ""notes"": ""Circulating EBV DNA is a sensitive and specific biomarker for NPC. Plasma EBV DNA levels correlate with tumor burden and can be used for screening in endemic populations, diagnosis, monitoring treatment response, and surveillance for recurrence.""}"
5428	228	Nasopharyngeal Carcinoma	Nasopharyngeal_Carcinoma.yaml	biochemical	1	EBV-Encoded RNA (EBERs) In Situ Hybridization																																			Detection of EBERs by in situ hybridization confirms EBV presence in tumor cells and is the gold standard for diagnosing EBV-associated NPC.																						"{""name"": ""EBV-Encoded RNA (EBERs) In Situ Hybridization"", ""notes"": ""Detection of EBERs by in situ hybridization confirms EBV presence in tumor cells and is the gold standard for diagnosing EBV-associated NPC.""}"	{}	"{""name"": ""EBV-Encoded RNA (EBERs) In Situ Hybridization"", ""notes"": ""Detection of EBERs by in situ hybridization confirms EBV presence in tumor cells and is the gold standard for diagnosing EBV-associated NPC.""}"
5452	229	Nephronophthisis	Nephronophthisis.yaml	biochemical	0	Serum Creatinine								Elevated																																																	"{""name"": ""Serum Creatinine"", ""presence"": ""Elevated""}"	{}	"{""evidence"": [{""explanation"": ""Kidney failure implies elevated serum creatinine. This reference indicates nephronophthisis is a frequent cause of kidney failure, indirectly supporting elevated creatinine as a biochemical finding."", ""reference"": ""PMID:37930417"", ""snippet"": ""Nephronophthisis (NPHP) is an autosomal recessive cystic kidney disease and is one of the most frequent genetic causes for kidney failure (KF) in children and adolescents."", ""supports"": ""PARTIAL""}], ""name"": ""Serum Creatinine"", ""presence"": ""Elevated""}"
5453	229	Nephronophthisis	Nephronophthisis.yaml	biochemical	1	Elevated Blood Urea Nitrogen (BUN)								Elevated																																																	"{""name"": ""Elevated Blood Urea Nitrogen (BUN)"", ""presence"": ""Elevated""}"	{}	"{""evidence"": [{""explanation"": ""The literature supports elevated BUN as a marker of renal damage but does not specify nephronophthisis. Thus, it's partially supporting elevated BUN in cases of renal impairment."", ""reference"": ""PMID:7272960"", ""snippet"": ""Irreversible and progressive renal parenchymal damage and functional impairment occurred in the majority of patients receiving at least six courses (200 mg/m2 of BCNU and/or methyl CCNU at eight-week intervals) of nitrosoureas for therapy of malignant brain tumors. Seventeen of 18 patients who received at least six courses and all nine patients who received more than ten courses developed impaired renal function as judged by elevation of blood urea nitrogen and/or serum creatinine or decrease in filtration rate as determined by inulin clearance."", ""supports"": ""PARTIAL""}, {""explanation"": ""While the study highlights the relevance of elevated BUN in patients with heart failure, it does not specifically address nephronophthisis. Therefore, it partially supports the biochemical value."", ""reference"": ""PMID:26769764"", ""snippet"": ""CONCLUSIONS: We showed that elevation of BUN at discharge significantly modified the relation between eGFR at discharge and the risk of all-cause mortality after discharge, suggesting that the association between eGFR and outcomes may be largely dependent on concomitant elevation of BUN."", ""supports"": ""PARTIAL""}, {""explanation"": ""This supports BUN as an indicator in chronic kidney disease (CKD) but not specifically nephronophthisis. Hence, it gives partial support."", ""reference"": ""PMID:21722602"", ""snippet"": ""CONCLUSION: Semiquantitative dipstick measurements of SUN can reliably identify CKD patients with elevated BUN levels."", ""supports"": ""PARTIAL""}], ""name"": ""Elevated Blood Urea Nitrogen (BUN)"", ""presence"": ""Elevated""}"
5491	230	Neuroblastoma	Neuroblastoma.yaml	biochemical	0	Catecholamine Metabolites																																			Elevated urinary catecholamine metabolites (vanillylmandelic acid, VMA; homovanillic acid, HVA) are present in >90% of neuroblastomas and are useful for diagnosis and disease monitoring.																						"{""name"": ""Catecholamine Metabolites"", ""notes"": ""Elevated urinary catecholamine metabolites (vanillylmandelic acid, VMA; homovanillic acid, HVA) are present in >90% of neuroblastomas and are useful for diagnosis and disease monitoring.""}"	{}	"{""name"": ""Catecholamine Metabolites"", ""notes"": ""Elevated urinary catecholamine metabolites (vanillylmandelic acid, VMA; homovanillic acid, HVA) are present in >90% of neuroblastomas and are useful for diagnosis and disease monitoring.""}"
5492	230	Neuroblastoma	Neuroblastoma.yaml	biochemical	1	Neuron-Specific Enolase																																			Serum neuron-specific enolase (NSE) is elevated in neuroblastoma and correlates with tumor burden and prognosis.																						"{""name"": ""Neuron-Specific Enolase"", ""notes"": ""Serum neuron-specific enolase (NSE) is elevated in neuroblastoma and correlates with tumor burden and prognosis.""}"	{}	"{""name"": ""Neuron-Specific Enolase"", ""notes"": ""Serum neuron-specific enolase (NSE) is elevated in neuroblastoma and correlates with tumor burden and prognosis.""}"
5517	231	Neurofibromatosis Type 1	Neurofibromatosis_Type_1.yaml	biochemical	0	NF1 Genetic Testing																																			Comprehensive NF1 testing identifies germline pathogenic variants including point mutations, small insertions/deletions, large deletions/duplications, and deep intronic variants. Approximately 50% are de novo mutations. Mutation detection rate exceeds 95% with comprehensive testing including deletion/duplication analysis.																						"{""name"": ""NF1 Genetic Testing"", ""notes"": ""Comprehensive NF1 testing identifies germline pathogenic variants including point mutations, small insertions/deletions, large deletions/duplications, and deep intronic variants. Approximately 50% are de novo mutations. Mutation detection rate exceeds 95% with comprehensive testing including deletion/duplication analysis.""}"	{}	"{""name"": ""NF1 Genetic Testing"", ""notes"": ""Comprehensive NF1 testing identifies germline pathogenic variants including point mutations, small insertions/deletions, large deletions/duplications, and deep intronic variants. Approximately 50% are de novo mutations. Mutation detection rate exceeds 95% with comprehensive testing including deletion/duplication analysis.""}"
5565	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	biochemical	0	Carcinoembryonic Antigen			OCCASIONAL					Elevated																																																	"{""frequency"": ""OCCASIONAL"", ""name"": ""Carcinoembryonic Antigen"", ""presence"": ""Elevated""}"	"{""synonyms"": [""CEA""]}"	"{""evidence"": [{""explanation"": ""The reference discusses the use of CEA as a tumor marker in NSCLC, indicating its relevance and occasional elevated presence."", ""reference"": ""PMID:37390106"", ""snippet"": ""Carcinoembryonic antigen (CEA) is the most frequently used tumor marker for non-small cell lung cancer (NSCLC)."", ""supports"": ""SUPPORT""}], ""frequency"": ""OCCASIONAL"", ""name"": ""Carcinoembryonic Antigen"", ""presence"": ""Elevated"", ""synonyms"": [""CEA""]}"
5566	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	biochemical	1	Cytokeratin Fragment 21-1			OCCASIONAL					Elevated																																																	"{""frequency"": ""OCCASIONAL"", ""name"": ""Cytokeratin Fragment 21-1"", ""presence"": ""Elevated""}"	"{""synonyms"": [""CYFRA 21-1""]}"	"{""evidence"": [{""explanation"": ""CYFRA 21-1 levels are elevated in NSCLC patients, supporting the statement of its occasional presence in a biochemical context."", ""reference"": ""PMID:8709175"", ""snippet"": ""The mean (SD) value of serum CYFRA 21-1 in NSCLC (13.26 (16.54)) was significantly higher than in benign lung diseases (1.74 (1.55)) (p < 0.0001)."", ""supports"": ""SUPPORT""}], ""frequency"": ""OCCASIONAL"", ""name"": ""Cytokeratin Fragment 21-1"", ""presence"": ""Elevated"", ""synonyms"": [""CYFRA 21-1""]}"
5643	237	Obesity	Obesity.yaml	biochemical	0	Leptin					Leptin resistance present despite high levels			Elevated																																																	"{""context"": ""Leptin resistance present despite high levels"", ""name"": ""Leptin"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Leptin resistance present despite high levels"", ""name"": ""Leptin"", ""presence"": ""Elevated""}"
5644	237	Obesity	Obesity.yaml	biochemical	1	Adiponectin					Reduced with adipose dysfunction			Decreased																																																	"{""context"": ""Reduced with adipose dysfunction"", ""name"": ""Adiponectin"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Reduced with adipose dysfunction"", ""name"": ""Adiponectin"", ""presence"": ""Decreased""}"
5645	237	Obesity	Obesity.yaml	biochemical	2	C-Reactive Protein					Chronic inflammation marker			Elevated																																																	"{""context"": ""Chronic inflammation marker"", ""name"": ""C-Reactive Protein"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Chronic inflammation marker"", ""name"": ""C-Reactive Protein"", ""presence"": ""Elevated""}"
5646	237	Obesity	Obesity.yaml	biochemical	3	Fasting Insulin					Compensatory hyperinsulinemia			Elevated																																																	"{""context"": ""Compensatory hyperinsulinemia"", ""name"": ""Fasting Insulin"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Compensatory hyperinsulinemia"", ""name"": ""Fasting Insulin"", ""presence"": ""Elevated""}"
5679	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	biochemical	0	Oxygen Saturation					Nocturnal desaturations			Decreased																																																	"{""context"": ""Nocturnal desaturations"", ""name"": ""Oxygen Saturation"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Nocturnal desaturations"", ""name"": ""Oxygen Saturation"", ""presence"": ""Decreased""}"
5680	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	biochemical	1	CRP					Systemic inflammation			Elevated																																																	"{""context"": ""Systemic inflammation"", ""name"": ""CRP"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Systemic inflammation"", ""name"": ""CRP"", ""presence"": ""Elevated""}"
5681	238	Obstructive Sleep Apnea	Obstructive_Sleep_Apnea.yaml	biochemical	2	Catecholamines					Sympathetic activation			Elevated																																																	"{""context"": ""Sympathetic activation"", ""name"": ""Catecholamines"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Sympathetic activation"", ""name"": ""Catecholamines"", ""presence"": ""Elevated""}"
5817	247	Osteoporosis	Osteoporosis.yaml	biochemical	0	Bone Turnover Markers					CTX, P1NP indicate resorption/formation rates			Variable																																																	"{""context"": ""CTX, P1NP indicate resorption/formation rates"", ""name"": ""Bone Turnover Markers"", ""presence"": ""Variable""}"	{}	"{""context"": ""CTX, P1NP indicate resorption/formation rates"", ""name"": ""Bone Turnover Markers"", ""presence"": ""Variable""}"
5818	247	Osteoporosis	Osteoporosis.yaml	biochemical	1	Calcium					Usually normal in primary osteoporosis			Normal																																																	"{""context"": ""Usually normal in primary osteoporosis"", ""name"": ""Calcium"", ""presence"": ""Normal""}"	{}	"{""context"": ""Usually normal in primary osteoporosis"", ""name"": ""Calcium"", ""presence"": ""Normal""}"
5819	247	Osteoporosis	Osteoporosis.yaml	biochemical	2	Vitamin D					Deficiency common and contributes to bone loss			Variable																																																	"{""context"": ""Deficiency common and contributes to bone loss"", ""name"": ""Vitamin D"", ""presence"": ""Variable""}"	{}	"{""context"": ""Deficiency common and contributes to bone loss"", ""name"": ""Vitamin D"", ""presence"": ""Variable""}"
5820	247	Osteoporosis	Osteoporosis.yaml	biochemical	3	PTH					May be elevated with vitamin D deficiency			Variable																																																	"{""context"": ""May be elevated with vitamin D deficiency"", ""name"": ""PTH"", ""presence"": ""Variable""}"	{}	"{""context"": ""May be elevated with vitamin D deficiency"", ""name"": ""PTH"", ""presence"": ""Variable""}"
5854	249	PIK3CA-Mutant Breast Cancer	PIK3CA_Mutant_Breast_Cancer.yaml	biochemical	0	PIK3CA Mutation Testing																																			PIK3CA mutation testing is required for alpelisib eligibility. Can be performed on tumor tissue or circulating tumor DNA (ctDNA). FDA-approved companion diagnostics include therascreen PIK3CA RGQ PCR Kit and FoundationOne CDx.																						"{""name"": ""PIK3CA Mutation Testing"", ""notes"": ""PIK3CA mutation testing is required for alpelisib eligibility. Can be performed on tumor tissue or circulating tumor DNA (ctDNA). FDA-approved companion diagnostics include therascreen PIK3CA RGQ PCR Kit and FoundationOne CDx.""}"	{}	"{""name"": ""PIK3CA Mutation Testing"", ""notes"": ""PIK3CA mutation testing is required for alpelisib eligibility. Can be performed on tumor tissue or circulating tumor DNA (ctDNA). FDA-approved companion diagnostics include therascreen PIK3CA RGQ PCR Kit and FoundationOne CDx.""}"
5943	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	biochemical	0	Parvovirus B19 Serology					Detection of specific antibodies (IgM and IgG) indicating recent or past infection.			Positive																																																	"{""context"": ""Detection of specific antibodies (IgM and IgG) indicating recent or past infection."", ""name"": ""Parvovirus B19 Serology"", ""presence"": ""Positive""}"	{}	"{""context"": ""Detection of specific antibodies (IgM and IgG) indicating recent or past infection."", ""evidence"": [{""explanation"": ""The study indicates that serological assays, including IgM and IgG tests, are reliable for diagnosing primary B19 infection in pregnant women, supporting the detection of specific antibodies indicating recent or past infection."", ""reference"": ""PMID:16332455"", ""snippet"": ""Considering the first 12 weeks after onset of disease the window of greatest risk for fetal complications, the 'acute' phase was extended to cover this full period. In this case, performing the avidity and ETS-EIA sequentially, the positive predictive value was 100% in patients showing concordant avidity and ETS-EIA results."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study describes a method for detecting B19-specific IgM, supporting the detection of antibodies indicating recent infection."", ""reference"": ""PMID:9220384"", ""snippet"": ""A solid phase IgM-capture radioimmunoassay (MACRIA) for the detection of parvovirus B19-IgM is described... The purpose of the protocol is the diagnosis of recent acute infection with parvovirus B19."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study supports the detection of IgG antibodies, indicating past infection with parvovirus B19."", ""reference"": ""PMID:33124969"", ""snippet"": ""We found that the frequency of detecting immunoglobulin G (IgG) antibodies against PVB19 VP1 and VP2 was significantly higher among patients with MG (68.70%) than in healthy controls (41.86%) (p < 0.001)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study supports the use of serological tests for detecting IgG antibodies, indicating past infection."", ""reference"": ""PMID:14675870"", ""snippet"": ""Our data show that recombinant capsids obtained either with VP1+VP2 or with VP2 alone, used in ELISA, are very useful for detecting the immune response against both conformational and native linear epitopes of B19 structural proteins."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study supports the detection of specific IgM and IgG antibodies, indicating recent and past infection, respectively."", ""reference"": ""PMID:1765775"", ""snippet"": ""Specific IgM antibodies were detected in 97% of cases and one person (1%) from the control group. B19 DNA was detected in 94% of cases and was absent in 20 persons from the control group positive for both IgG and IgA antibodies."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study supports the detection of IgM and IgG antibodies, indicating recent and past infection."", ""reference"": ""PMID:24403307"", ""snippet"": ""Correct discrimination of past from recent B19V infection was achieved through application of qPCR or by appropriate selection of EIAs."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study supports the detection of specific IgM and IgG antibodies, indicating recent and past infection."", ""reference"": ""PMID:17935173"", ""snippet"": ""Out of 267 patients examined, 89 had B19-associated disease markers: 43 had B19 DNA without IgM, 25 had IgM without B19 DNA, and 21 had both B19 DNA and IgM."", ""supports"": ""SUPPORT""}], ""name"": ""Parvovirus B19 Serology"", ""presence"": ""Positive""}"
5944	252	Parvovirus B19 Infection	Parvovirus_B19_Infection.yaml	biochemical	1	Parvovirus B19 DNA PCR					Direct detection of viral DNA.			Positive																																																	"{""context"": ""Direct detection of viral DNA."", ""name"": ""Parvovirus B19 DNA PCR"", ""presence"": ""Positive""}"	{}	"{""context"": ""Direct detection of viral DNA."", ""evidence"": [{""explanation"": ""The reference clearly states the use of PCR method for the detection of human parvovirus B19 DNA."", ""reference"": ""PMID:8361022"", ""snippet"": ""The development of a polymerase chain reaction (PCR) method for detection of human parvovirus B19 DNA and serological test of clinical specimens using ELISA is described."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference discusses the use of PCR for the direct detection of parvovirus B19 DNA in neonatal materials."", ""reference"": ""PMID:32559661"", ""snippet"": ""Diagnosis of congenital viral infection at birth is generally attempted by direct detection of the virus by PCR in various neonatal materials."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference supports the detection of parvovirus B19 DNA using PCR technology."", ""reference"": ""PMID:36619750"", ""snippet"": ""HPV B19 could be detected in various bodily fluids and tissues (especially cerebrospinal fluid) using NGS"", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference discusses the development of a method for the direct detection of Parvovirus B19 DNA."", ""reference"": ""PMID:10645984"", ""snippet"": ""This study reports the development and optimization of a quantitative direct-probe method for the detection of Parvovirus B19 DNA."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference describes the use of a PCR-based assay for detecting Parvovirus B19 DNA in heart tissue samples."", ""reference"": ""PMID:37775826"", ""snippet"": ""A PCR-based assay with Parvovirus B19 specific primers was implemented to detect the presence of the viral genome."", ""supports"": ""SUPPORT""}], ""name"": ""Parvovirus B19 DNA PCR"", ""presence"": ""Positive""}"
5967	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	biochemical	0	Anti-Desmoglein 3 Antibodies					Present in all active PV			Elevated																																																	"{""context"": ""Present in all active PV"", ""name"": ""Anti-Desmoglein 3 Antibodies"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Present in all active PV"", ""name"": ""Anti-Desmoglein 3 Antibodies"", ""presence"": ""Elevated""}"
5968	253	Pemphigus Vulgaris	Pemphigus_Vulgaris.yaml	biochemical	1	Anti-Desmoglein 1 Antibodies					Present in mucocutaneous disease			Variable																																																	"{""context"": ""Present in mucocutaneous disease"", ""name"": ""Anti-Desmoglein 1 Antibodies"", ""presence"": ""Variable""}"	{}	"{""context"": ""Present in mucocutaneous disease"", ""name"": ""Anti-Desmoglein 1 Antibodies"", ""presence"": ""Variable""}"
5983	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	biochemical	0	ABI (Ankle-Brachial Index)					<0.9 diagnostic			Decreased																																																	"{""context"": ""<0.9 diagnostic"", ""name"": ""ABI (Ankle-Brachial Index)"", ""presence"": ""Decreased""}"	{}	"{""context"": ""<0.9 diagnostic"", ""name"": ""ABI (Ankle-Brachial Index)"", ""presence"": ""Decreased""}"
5984	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	biochemical	1	LDL Cholesterol					Major risk factor			Elevated																																																	"{""context"": ""Major risk factor"", ""name"": ""LDL Cholesterol"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Major risk factor"", ""name"": ""LDL Cholesterol"", ""presence"": ""Elevated""}"
5985	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	biochemical	2	HbA1c					Diabetes is major risk factor			Elevated																																																	"{""context"": ""Diabetes is major risk factor"", ""name"": ""HbA1c"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Diabetes is major risk factor"", ""name"": ""HbA1c"", ""presence"": ""Elevated""}"
5986	254	Peripheral Artery Disease	Peripheral_Artery_Disease.yaml	biochemical	3	CRP					Inflammation marker			Elevated																																																	"{""context"": ""Inflammation marker"", ""name"": ""CRP"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Inflammation marker"", ""name"": ""CRP"", ""presence"": ""Elevated""}"
6010	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	biochemical	0	Very Long Chain Fatty Acids (VLCFA)					Diagnostic marker			Elevated																																																	"{""context"": ""Diagnostic marker"", ""name"": ""Very Long Chain Fatty Acids (VLCFA)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Diagnostic marker"", ""evidence"": [{""explanation"": ""This reference indicates that elevated VLCFA levels are a feature in nine peroxisomal disorders but does not specify peroxisome biogenesis disorders (PBD) exclusively."", ""reference"": ""PMID:8729109"", ""snippet"": ""Abnormally high levels of very long-chain fatty acids (VLCFA) are a feature in nine of the fifteen peroxisomal disorders that have been identified so far."", ""supports"": ""PARTIAL""}, {""explanation"": ""The abstract does not mention VLCFA levels in the context of PBD diagnosis."", ""reference"": ""PMID:14527301"", ""snippet"": ""The peroxisome biogenesis disorders (PBDs) comprise 12 autosomal recessive complementation groups (CGs)."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This study identifies elevated levels of very long chain dicarboxylic acylcarnitines (a type of VLCFA) in patients with PBD."", ""reference"": ""PMID:37567036"", ""snippet"": ""Multiple dicarboxylic acylcarnitines were significantly elevated in PBD patients including medium to long chain (C8-DC to C18-DC) species as well as previously undescribed elevations of malonylcarnitine (C3-DC) and very long chain dicarboxylic acylcarnitines (C20-DC and C22-DC)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This reference supports that elevated VLCFA levels are relevant in peroxisomal disorders which include peroxisome biogenesis disorders."", ""reference"": ""PMID:19933170"", ""snippet"": ""Peroxisomes are vital eukaryotic organelles that participate in lipid metabolism, in particular the metabolism of very-long-chain fatty acids (VLCFA)."", ""supports"": ""SUPPORT""}, {""explanation"": ""Although this reference states that VLCFA analysis is useful for peroxisomal disorders, it is not specific to PBD."", ""reference"": ""PMID:8914632"", ""snippet"": ""Very long chain fatty acid analysis in the serum sphingomyelin was introduced since 1987 and was useful for the first screening of peroxisomal disorders."", ""supports"": ""PARTIAL""}], ""name"": ""Very Long Chain Fatty Acids (VLCFA)"", ""presence"": ""Elevated""}"
6011	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	biochemical	1	Plasmalogens					Diagnostic marker			Decreased																																																	"{""context"": ""Diagnostic marker"", ""name"": ""Plasmalogens"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Diagnostic marker"", ""evidence"": [{""explanation"": ""The literature clearly states that decreased levels of plasmalogens are a characteristic feature of peroxisome biogenesis disorders."", ""reference"": ""PMID:36914043"", ""snippet"": ""Markedly reduced plasmalogens are a classic feature of peroxisome biogenesis disorders (PBD) because plasmalogen synthesis requires functional peroxisomes."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study mentions that impaired plasmalogen synthesis is one of the biochemical markers analyzed in PBD patients."", ""reference"": ""PMID:12473763"", ""snippet"": ""A poor correlation with age at death was found for de novo plasmalogen synthesis."", ""supports"": ""SUPPORT""}, {""explanation"": ""The literature shows that peroxisomes play an essential role in plasmalogen biosynthesis, indicating that their dysfunction leads to decreased plasmalogen levels."", ""reference"": ""PMID:3460088"", ""snippet"": ""The results presented here support the view that there are two DHAP acyltransferases in animal cells and that the peroxisome is essential for the biosynthesis of plasmalogens."", ""supports"": ""SUPPORT""}, {""explanation"": ""The mention of specific conditions excluded from typical diagnostic methods indirectly reaffirms that decreased plasmalogen levels are a diagnostic marker for most PBDs."", ""reference"": ""PMID:7957386"", ""snippet"": ""Rhizomelic chondrodysplasia punctata, its recently identified variant form and glutaryl-CoA oxidase deficiency will show no abnormalities and must be identified by other means."", ""supports"": ""SUPPORT""}, {""explanation"": ""The statement supports the role of peroxisomes in normal cellular function, and by extension, indicates that their dysfunction would likely lead to decreased plasmalogen synthesis."", ""reference"": ""PMID:33417206"", ""snippet"": ""Impaired peroxisome biogenesis, including defects of membrane assembly, import of peroxisomal matrix proteins, and division of peroxisome, causes peroxisome biogenesis disorders (PBDs)."", ""supports"": ""SUPPORT""}], ""name"": ""Plasmalogens"", ""presence"": ""Decreased""}"
6012	255	Peroxisome Biogenesis Disorder	Peroxisome_Biogenesis_Disorder.yaml	biochemical	2	Bile Acid Intermediates					Diagnostic marker			Elevated																																																	"{""context"": ""Diagnostic marker"", ""name"": ""Bile Acid Intermediates"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Diagnostic marker"", ""evidence"": [{""explanation"": ""“The study states that disease-specific bile acids (BAs) can be measured as markers for peroxisome biogenesis disorders (PBDs) via a dried blood spot-based screening method.”"", ""reference"": ""PMID:37802748"", ""snippet"": ""Early postnatal screening for BASDs, PBD1A and NPC1 is feasible with the described DBS-based method by measuring disease specific BAs."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study mentions the accumulation of C27-bile acids (a type of bile acid intermediate) in the plasma of patients with Zellweger syndrome, a type of peroxisome biogenesis disorder."", ""reference"": ""PMID:3119940"", ""snippet"": ""In classic Zellweger syndrome abnormal C27-bile acids, very long chain fatty acids, dicarboxylic acids and pipecolic acid accumulate in the plasma of the patients."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study supports the concept that certain biochemical markers, including bile acid intermediates, are elevated due to the metabolic process impairments in peroxisome biogenesis disorders."", ""reference"": ""PMID:3119940"", ""snippet"": ""In patients with cerebro-hepato-renal (Zellweger) syndrome, the absence of peroxisomes results in an impairment of metabolic processes in which peroxisomes are normally involved. These include the catabolism of very long chain (greater than C22) fatty acids, the biosynthesis of ether-phospholipids and of bile acids, the catabolism of phytanic acid and the catabolism of pipecolic acid."", ""supports"": ""SUPPORT""}], ""name"": ""Bile Acid Intermediates"", ""presence"": ""Elevated""}"
6056	256	Peutz-Jeghers polyp	Peutz_Jeghers_polyp.yaml	biochemical	0	Butyric acid								Decreased																											"Short-chain fatty acids, including butyric acid, are reduced in PJS and correlate with polyp burden.
"																						"{""name"": ""Butyric acid"", ""notes"": ""Short-chain fatty acids, including butyric acid, are reduced in PJS and correlate with polyp burden.\n"", ""presence"": ""Decreased""}"	{}	"{""biomarker_term"": {""preferred_term"": ""butyric acid"", ""term"": {""id"": ""NCIT:C68327"", ""label"": ""Butyric Acid""}}, ""evidence"": [{""explanation"": ""This study reports reduced short-chain fatty acid synthesis in PJS."", ""reference"": ""PMID:38036954"", ""snippet"": ""The results showed dysbiosis in the gut microbiota of patients with PJS, and decreased synthesis of short-chain fatty acids."", ""supports"": ""SUPPORT""}, {""explanation"": ""Lower butyric acid levels associate with higher polyp-related intervention burden."", ""reference"": ""PMID:38036954"", ""snippet"": ""Furthermore, the butyric acid level was negatively correlated with the frequency of endoscopic surgeries."", ""supports"": ""SUPPORT""}], ""name"": ""Butyric acid"", ""notes"": ""Short-chain fatty acids, including butyric acid, are reduced in PJS and correlate with polyp burden.\n"", ""presence"": ""Decreased""}"
6088	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	biochemical	0	BCR-ABL1 Fusion Detection																																			RT-PCR or FISH detects BCR-ABL1 fusion. Most Ph+ ALL cases have the p190 BCR-ABL1 (e1a2 junction) though some express p210. Quantitative PCR monitors minimal residual disease and guides therapy.																						"{""name"": ""BCR-ABL1 Fusion Detection"", ""notes"": ""RT-PCR or FISH detects BCR-ABL1 fusion. Most Ph+ ALL cases have the p190 BCR-ABL1 (e1a2 junction) though some express p210. Quantitative PCR monitors minimal residual disease and guides therapy.""}"	{}	"{""name"": ""BCR-ABL1 Fusion Detection"", ""notes"": ""RT-PCR or FISH detects BCR-ABL1 fusion. Most Ph+ ALL cases have the p190 BCR-ABL1 (e1a2 junction) though some express p210. Quantitative PCR monitors minimal residual disease and guides therapy.""}"
6089	258	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Ph_Positive_ALL.yaml	biochemical	1	Immunophenotyping																																			Flow cytometry shows precursor B-cell phenotype (CD19+, CD10+, CD34+, TdT+) with variable expression of myeloid markers. CD25 and aberrant myeloid antigen expression may be more common in Ph+ ALL.																						"{""name"": ""Immunophenotyping"", ""notes"": ""Flow cytometry shows precursor B-cell phenotype (CD19+, CD10+, CD34+, TdT+) with variable expression of myeloid markers. CD25 and aberrant myeloid antigen expression may be more common in Ph+ ALL.""}"	{}	"{""name"": ""Immunophenotyping"", ""notes"": ""Flow cytometry shows precursor B-cell phenotype (CD19+, CD10+, CD34+, TdT+) with variable expression of myeloid markers. CD25 and aberrant myeloid antigen expression may be more common in Ph+ ALL.""}"
6109	259	Phenylketonuria	Phenylketonuria.yaml	biochemical	0	Blood Phenylalanine					Greater than 120 micromol/L, often greater than 1200 micromol/L in classic PKU			Elevated																																																	"{""context"": ""Greater than 120 micromol/L, often greater than 1200 micromol/L in classic PKU"", ""name"": ""Blood Phenylalanine"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Greater than 120 micromol/L, often greater than 1200 micromol/L in classic PKU"", ""name"": ""Blood Phenylalanine"", ""presence"": ""Elevated""}"
6110	259	Phenylketonuria	Phenylketonuria.yaml	biochemical	1	Blood Tyrosine					Low due to blocked conversion from phenylalanine			Decreased																																																	"{""context"": ""Low due to blocked conversion from phenylalanine"", ""name"": ""Blood Tyrosine"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Low due to blocked conversion from phenylalanine"", ""name"": ""Blood Tyrosine"", ""presence"": ""Decreased""}"
6111	259	Phenylketonuria	Phenylketonuria.yaml	biochemical	2	Phenylalanine to Tyrosine Ratio					Diagnostic marker			Elevated																																																	"{""context"": ""Diagnostic marker"", ""name"": ""Phenylalanine to Tyrosine Ratio"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Diagnostic marker"", ""name"": ""Phenylalanine to Tyrosine Ratio"", ""presence"": ""Elevated""}"
6112	259	Phenylketonuria	Phenylketonuria.yaml	biochemical	3	Phenylpyruvic Acid					Alternative metabolite in urine			Elevated																																																	"{""context"": ""Alternative metabolite in urine"", ""name"": ""Phenylpyruvic Acid"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Alternative metabolite in urine"", ""name"": ""Phenylpyruvic Acid"", ""presence"": ""Elevated""}"
6137	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	biochemical	0	Plasma Metanephrines																																			Plasma-free metanephrines (normetanephrine and metanephrine) are the most sensitive test for pheochromocytoma. Methoxytyramine elevation suggests dopamine-secreting or malignant tumor.																						"{""name"": ""Plasma Metanephrines"", ""notes"": ""Plasma-free metanephrines (normetanephrine and metanephrine) are the most sensitive test for pheochromocytoma. Methoxytyramine elevation suggests dopamine-secreting or malignant tumor.""}"	{}	"{""name"": ""Plasma Metanephrines"", ""notes"": ""Plasma-free metanephrines (normetanephrine and metanephrine) are the most sensitive test for pheochromocytoma. Methoxytyramine elevation suggests dopamine-secreting or malignant tumor.""}"
6138	260	Pheochromocytoma and Paraganglioma	Pheochromocytoma_Paraganglioma.yaml	biochemical	1	Urinary Catecholamines and Metanephrines																																			24-hour urine collection for catecholamines and metanephrines is an alternative biochemical test with high sensitivity.																						"{""name"": ""Urinary Catecholamines and Metanephrines"", ""notes"": ""24-hour urine collection for catecholamines and metanephrines is an alternative biochemical test with high sensitivity.""}"	{}	"{""name"": ""Urinary Catecholamines and Metanephrines"", ""notes"": ""24-hour urine collection for catecholamines and metanephrines is an alternative biochemical test with high sensitivity.""}"
6162	261	Pick Disease	Pick_Disease.yaml	biochemical	0	Tau Protein Accumulation																																			Tau-positive inclusions found in neurons and glial cells																						"{""name"": ""Tau Protein Accumulation"", ""notes"": ""Tau-positive inclusions found in neurons and glial cells""}"	{}	"{""cell_types"": [{""preferred_term"": ""Glial Cell"", ""term"": {""id"": ""CL:0000125"", ""label"": ""glial cell""}}, {""preferred_term"": ""Neuron"", ""term"": {""id"": ""CL:0000540"", ""label"": ""neuron""}}], ""evidence"": [{""explanation"": ""This statement supports the subject by indicating that tau protein accumulations (both 3R and 4R) are found in both neurons and glial cells in Pick Disease."", ""reference"": ""PMID:26583316"", ""snippet"": ""The majority of neuronal and glial tau inclusions were 3R tau-positive and 4R tau-negative in sporadic cases."", ""supports"": ""SUPPORT""}, {""explanation"": ""General reference to tau aggregations being present in both neurons and glial cells in various Tauopathies, including Pick's disease."", ""reference"": ""PMID:32096036"", ""snippet"": ""Tau aggregation in the different Tauopathies differs in the affected cell type, the structure of aggregates and Tau isoform composition. ... The most common Tauopathies are corticobasal degeneration (CBD), Pick's disease, progressive supranuclear palsy (PSP) and frontotemporal dementias."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study discusses the tau protein's propensity to form pathological inclusions in cells, specifically mentioning both neurons and glial cells."", ""reference"": ""PMID:30158706"", ""snippet"": ""Our findings show how tau can adopt distinct folds in the human brain in different diseases, an essential step for understanding the formation and propagation of molecular conformers."", ""supports"": ""SUPPORT""}, {""explanation"": ""Indicates that tau-positive inclusions are indeed present in glial cells in Pick Disease."", ""reference"": ""PMID:10517506"", ""snippet"": ""The presence of tau-positive glial inclusions has been recently found a consistent feature in the brains of patients with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and Pick's disease (PiD)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This directly supports the statement by reporting the presence of tau protein accumulation in both neurons and glial cells in Pick Disease."", ""reference"": ""PMID:37351604"", ""snippet"": ""At autopsy, numerous inclusions of hyperphosphorylated 3R Tau were present in neurons and glial cells of neocortex and some subcortical regions, including hippocampus, caudate/putamen and globus pallidus."", ""supports"": ""SUPPORT""}], ""name"": ""Tau Protein Accumulation"", ""notes"": ""Tau-positive inclusions found in neurons and glial cells""}"
6210	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	biochemical	0	Elevated Creatinine					Marker of declining renal function in advanced disease			Elevated																																																	"{""context"": ""Marker of declining renal function in advanced disease"", ""name"": ""Elevated Creatinine"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Marker of declining renal function in advanced disease"", ""evidence"": [{""explanation"": ""Progressive GFR decline reflects rising creatinine as renal function deteriorates."", ""reference"": ""PMID:29105594"", ""snippet"": ""The change from baseline in the estimated GFR was -2.34 ml per minute per 1.73 m2"", ""supports"": ""SUPPORT""}], ""name"": ""Elevated Creatinine"", ""presence"": ""Elevated""}"
6211	264	Polycystic Kidney Disease	Polycystic_Kidney_Disease.yaml	biochemical	1	Decreased GFR					Progressive decline reflecting nephron loss			Decreased																																																	"{""context"": ""Progressive decline reflecting nephron loss"", ""name"": ""Decreased GFR"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Progressive decline reflecting nephron loss"", ""evidence"": [{""explanation"": ""Trial quantifies ongoing GFR loss in ADPKD absent disease-modifying therapy."", ""reference"": ""PMID:29105594"", ""snippet"": ""as compared with -3.61 ml per minute per 1.73 m2 (95% CI, -4.08 to -3.14) in the placebo group"", ""supports"": ""SUPPORT""}], ""name"": ""Decreased GFR"", ""presence"": ""Decreased""}"
6237	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	biochemical	0	Testosterone					Total and free testosterone			Elevated																																																	"{""context"": ""Total and free testosterone"", ""name"": ""Testosterone"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Total and free testosterone"", ""evidence"": [{""explanation"": ""Documents positive correlation between AMH and testosterone levels in PCOS patients."", ""reference"": ""PMID:14671196"", ""snippet"": ""AMH was also positively related to the serum testosterone and androstenedione levels, in PCOS exclusively (P < 0.0005 and <0.002, respectively)."", ""supports"": ""SUPPORT""}], ""name"": ""Testosterone"", ""presence"": ""Elevated""}"
6238	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	biochemical	1	LH					Often elevated LH:FSH ratio			Elevated																																																	"{""context"": ""Often elevated LH:FSH ratio"", ""name"": ""LH"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Often elevated LH:FSH ratio"", ""evidence"": [{""explanation"": ""Increased LH receptor expression in PCOS theca cells supports elevated LH action in driving androgen production."", ""reference"": ""PMID:24014605"", ""snippet"": ""A higher proportion of theca cells from anovulatory PCO expressed LHCGR protein when compared with control ovaries (P = 0.01)."", ""supports"": ""SUPPORT""}], ""name"": ""LH"", ""presence"": ""Elevated""}"
6239	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	biochemical	2	SHBG					Increases free androgen index			Decreased																																																	"{""context"": ""Increases free androgen index"", ""name"": ""SHBG"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Increases free androgen index"", ""evidence"": [{""explanation"": ""Hyperinsulinemia suppresses hepatic SHBG production, increasing free bioactive androgens."", ""reference"": ""PMID:40013621"", ""snippet"": ""Hyperinsulinemia (i.e., elevated insulin without hypoglycemia) is a common metabolic feature of PCOS that worsens its reproductive symptoms by exacerbating pituitary hormone imbalances and increasing levels of bioactive androgens."", ""supports"": ""SUPPORT""}], ""name"": ""SHBG"", ""presence"": ""Decreased""}"
6240	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	biochemical	3	Fasting Insulin					Insulin resistance			Elevated																																																	"{""context"": ""Insulin resistance"", ""name"": ""Fasting Insulin"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Insulin resistance"", ""evidence"": [{""explanation"": ""Hyperinsulinemia is a core feature in PCOS that may precede or result from insulin resistance."", ""reference"": ""PMID:40013621"", ""snippet"": ""However, it is challenging to define the sequential relationship between insulin sensitivity and insulin secretion, as they are tightly interlinked, and evidence suggests that hyperinsulinemia can alternatively precede insulin resistance."", ""supports"": ""SUPPORT""}], ""name"": ""Fasting Insulin"", ""presence"": ""Elevated""}"
6241	265	Polycystic Ovary Syndrome	Polycystic_Ovary_Syndrome.yaml	biochemical	4	Anti-Mullerian Hormone					Reflects increased antral follicle count			Elevated																																																	"{""context"": ""Reflects increased antral follicle count"", ""name"": ""Anti-Mullerian Hormone"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Reflects increased antral follicle count"", ""evidence"": [{""explanation"": ""Demonstrates markedly elevated AMH levels in PCOS patients paralleling increased small antral follicle count."", ""reference"": ""PMID:14671196"", ""snippet"": ""Mean serum AMH level was markedly increased in the PCOS group (47.1 +/- 22.9 vs. 20.8 +/- 11.6 pmol/liter in controls; P < 0.0001), an increase in the same order of magnitude as the one of the FN in the 2- to 5-mm range at U/S (12.8 +/- 8.3 vs. 4.8 +/- 1.9; P < 0.0001, respectively)."", ""supports"": ""SUPPORT""}], ""name"": ""Anti-Mullerian Hormone"", ""presence"": ""Elevated""}"
6265	266	Polycythemia Vera	Polycythemia_Vera.yaml	biochemical	0	Serum Erythropoietin																																			Erythropoietin (EPO) level is characteristically low or low-normal in PV due to negative feedback from elevated red cell mass. Low EPO helps distinguish PV from secondary erythrocytosis.																						"{""name"": ""Serum Erythropoietin"", ""notes"": ""Erythropoietin (EPO) level is characteristically low or low-normal in PV due to negative feedback from elevated red cell mass. Low EPO helps distinguish PV from secondary erythrocytosis.""}"	{}	"{""name"": ""Serum Erythropoietin"", ""notes"": ""Erythropoietin (EPO) level is characteristically low or low-normal in PV due to negative feedback from elevated red cell mass. Low EPO helps distinguish PV from secondary erythrocytosis.""}"
6266	266	Polycythemia Vera	Polycythemia_Vera.yaml	biochemical	1	JAK2 V617F Mutation																																			JAK2 V617F mutation testing is a major diagnostic criterion for PV. Present in approximately 95% of cases. Variant allele frequency may correlate with disease burden.																						"{""name"": ""JAK2 V617F Mutation"", ""notes"": ""JAK2 V617F mutation testing is a major diagnostic criterion for PV. Present in approximately 95% of cases. Variant allele frequency may correlate with disease burden.""}"	{}	"{""name"": ""JAK2 V617F Mutation"", ""notes"": ""JAK2 V617F mutation testing is a major diagnostic criterion for PV. Present in approximately 95% of cases. Variant allele frequency may correlate with disease burden.""}"
6285	267	Polymyositis	Polymyositis.yaml	biochemical	0	Creatine Kinase					Often markedly elevated (10-50x normal)			Elevated																																																	"{""context"": ""Often markedly elevated (10-50x normal)"", ""name"": ""Creatine Kinase"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Often markedly elevated (10-50x normal)"", ""name"": ""Creatine Kinase"", ""presence"": ""Elevated""}"
6286	267	Polymyositis	Polymyositis.yaml	biochemical	1	Aldolase					Muscle enzyme			Elevated																																																	"{""context"": ""Muscle enzyme"", ""name"": ""Aldolase"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Muscle enzyme"", ""name"": ""Aldolase"", ""presence"": ""Elevated""}"
6287	267	Polymyositis	Polymyositis.yaml	biochemical	2	Anti-Jo-1 Antibodies					Most common antisynthetase antibody			Variable																																																	"{""context"": ""Most common antisynthetase antibody"", ""name"": ""Anti-Jo-1 Antibodies"", ""presence"": ""Variable""}"	{}	"{""context"": ""Most common antisynthetase antibody"", ""name"": ""Anti-Jo-1 Antibodies"", ""presence"": ""Variable""}"
6288	267	Polymyositis	Polymyositis.yaml	biochemical	3	Anti-SRP Antibodies					Associated with necrotizing myopathy			Variable																																																	"{""context"": ""Associated with necrotizing myopathy"", ""name"": ""Anti-SRP Antibodies"", ""presence"": ""Variable""}"	{}	"{""context"": ""Associated with necrotizing myopathy"", ""name"": ""Anti-SRP Antibodies"", ""presence"": ""Variable""}"
6321	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	biochemical	0	Anti-Mitochondrial Antibodies (AMA)					Present in 95% of patients, highly specific			Elevated																																																	"{""context"": ""Present in 95% of patients, highly specific"", ""name"": ""Anti-Mitochondrial Antibodies (AMA)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Present in 95% of patients, highly specific"", ""evidence"": [{""explanation"": ""This review confirms that AMAs are a defining characteristic of PBC, targeting the E2 subunits of mitochondrial dehydrogenase complexes and serving as a highly specific diagnostic marker for the disease."", ""reference"": ""PMID:26953925"", ""snippet"": ""Primary biliary cholangitis (PBC) is an autoimmune hepatobiliary disease characterized by immune mediated destruction of the intrahepatic small bile ducts and the presence of antimitochondrial antibodies (AMAs)."", ""supports"": ""SUPPORT""}], ""name"": ""Anti-Mitochondrial Antibodies (AMA)"", ""presence"": ""Elevated""}"
6322	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	biochemical	1	Alkaline Phosphatase					Cholestatic pattern			Elevated																																																	"{""context"": ""Cholestatic pattern"", ""name"": ""Alkaline Phosphatase"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Cholestatic pattern"", ""name"": ""Alkaline Phosphatase"", ""presence"": ""Elevated""}"
6323	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	biochemical	2	IgM					Characteristic finding			Elevated																																																	"{""context"": ""Characteristic finding"", ""name"": ""IgM"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Characteristic finding"", ""name"": ""IgM"", ""presence"": ""Elevated""}"
6324	269	Primary Biliary Cholangitis	Primary_Biliary_Cholangitis.yaml	biochemical	3	Anti-sp100 Antibodies					PBC-specific ANA			Variable																																																	"{""context"": ""PBC-specific ANA"", ""name"": ""Anti-sp100 Antibodies"", ""presence"": ""Variable""}"	{}	"{""context"": ""PBC-specific ANA"", ""name"": ""Anti-sp100 Antibodies"", ""presence"": ""Variable""}"
6339	270	Primary_Ciliary_Dyskinesia	Primary_Ciliary_Dyskinesia.yaml	biochemical	0	Nitric Oxide					Lower levels in nasal and exhaled breath			Decreased																																																	"{""context"": ""Lower levels in nasal and exhaled breath"", ""name"": ""Nitric Oxide"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Lower levels in nasal and exhaled breath"", ""evidence"": [{""explanation"": ""This study shows that both exhaled nitric oxide (eNO) and nasal nitric oxide (nNO) levels are significantly lower in patients with primary ciliary dyskinesia (PCD) compared to other groups."", ""reference"": ""PMID:12511725"", ""snippet"": ""Low values in both eNO and nNO readings (<2.4 ppb and <187 ppb, respectively) identified PCD patients from other bronchiectatic patients with a specificity of 98% and a positive predictive value of 92%."", ""supports"": ""SUPPORT""}, {""explanation"": ""This abstract confirms that nasal nitric oxide levels are significantly reduced in PCD patients."", ""reference"": ""PMID:22408195"", ""snippet"": ""Despite chronic infections, nasal nitric oxide in such patients is markedly reduced and is used as a screening test for this condition."", ""supports"": ""SUPPORT""}, {""explanation"": ""This paper supports the statement by indicating that nasal nitric oxide levels are extremely low in PCD patients."", ""reference"": ""PMID:31770003"", ""snippet"": ""Nasal nitric oxide concentrations are extremely low in primary ciliary dyskinesia (PCD), and measurement of this nasal gas is recommended as a PCD diagnostic test in cooperative patients aged 5 years and older."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study indicates that both nasal nitric oxide (nNO) and fractional exhaled nitric oxide (FeNO) levels are low in PCD patients and are used to monitor the condition."", ""reference"": ""PMID:35777446"", ""snippet"": ""We hypothesized that differences in nasal nitric oxide (nNO) and fractional exhaled nitric oxide (Feno) relate to prognosis in primary ciliary dyskinesia (PCD)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study supports the statement by recommending nasal nitric oxide measurement as a screening tool for PCD due to its low levels in such patients."", ""reference"": ""PMID:33860637"", ""snippet"": ""Nasal nitric oxide (nNO) measurement is recommended to screen for Primary Ciliary Dyskinesia (PCD) in subjects with suggestive history and symptoms."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study confirms that nasal nitric oxide levels are lower in PCD patients compared to non-PCD patients."", ""reference"": ""PMID:29490941"", ""snippet"": ""Olfaction, nasal nitric oxide (nNO) and sinus CT were assessed in patients with PCD and non-PCD sinus disease, and healthy controls (no CT scan)."", ""supports"": ""SUPPORT""}], ""name"": ""Nitric Oxide"", ""presence"": ""Decreased""}"
6385	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	biochemical	0	Lactate Dehydrogenase (LDH)																																			LDH is elevated reflecting increased cell turnover and extramedullary hematopoiesis. Levels correlate with disease activity.																						"{""name"": ""Lactate Dehydrogenase (LDH)"", ""notes"": ""LDH is elevated reflecting increased cell turnover and extramedullary hematopoiesis. Levels correlate with disease activity.""}"	{}	"{""name"": ""Lactate Dehydrogenase (LDH)"", ""notes"": ""LDH is elevated reflecting increased cell turnover and extramedullary hematopoiesis. Levels correlate with disease activity.""}"
6386	272	Primary Myelofibrosis	Primary_Myelofibrosis.yaml	biochemical	1	Peripheral Blood Smear																																			Leukoerythroblastic picture with tear-drop cells (dacrocytes), nucleated red blood cells, and immature granulocytes is characteristic of PMF.																						"{""name"": ""Peripheral Blood Smear"", ""notes"": ""Leukoerythroblastic picture with tear-drop cells (dacrocytes), nucleated red blood cells, and immature granulocytes is characteristic of PMF.""}"	{}	"{""name"": ""Peripheral Blood Smear"", ""notes"": ""Leukoerythroblastic picture with tear-drop cells (dacrocytes), nucleated red blood cells, and immature granulocytes is characteristic of PMF.""}"
6418	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	biochemical	0	Alkaline Phosphatase					Cholestatic pattern, often marked			Elevated																																																	"{""context"": ""Cholestatic pattern, often marked"", ""name"": ""Alkaline Phosphatase"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Cholestatic pattern, often marked"", ""evidence"": [{""explanation"": ""Cholestatic liver injury in PSC leads to characteristic elevation of cholestatic enzymes including alkaline phosphatase."", ""reference"": ""PMID:39250501"", ""snippet"": ""Cholangiopathies comprise a spectrum of chronic intrahepatic and extrahepatic biliary tract disorders culminating in progressive cholestatic liver injury, fibrosis, and often cirrhosis and its sequela."", ""supports"": ""SUPPORT""}], ""name"": ""Alkaline Phosphatase"", ""presence"": ""Elevated""}"
6419	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	biochemical	1	GGT					Correlates with cholestasis			Elevated																																																	"{""context"": ""Correlates with cholestasis"", ""name"": ""GGT"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Correlates with cholestasis"", ""name"": ""GGT"", ""presence"": ""Elevated""}"
6420	274	Primary Sclerosing Cholangitis	Primary_Sclerosing_Cholangitis.yaml	biochemical	2	p-ANCA					Present in 60-80% of patients			Variable																																																	"{""context"": ""Present in 60-80% of patients"", ""name"": ""p-ANCA"", ""presence"": ""Variable""}"	{}	"{""context"": ""Present in 60-80% of patients"", ""name"": ""p-ANCA"", ""presence"": ""Variable""}"
6436	275	Primary_Tonsillar_Lymphoma	Primary_Tonsillar_Lymphoma.yaml	biochemical	0	Lactate Dehydrogenase (LDH)					Indicator of tumor burden and cell turnover.			Elevated																																																	"{""context"": ""Indicator of tumor burden and cell turnover."", ""name"": ""Lactate Dehydrogenase (LDH)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Indicator of tumor burden and cell turnover."", ""evidence"": [{""explanation"": ""The study shows that elevated serum LDH levels are associated with non-Hodgkin's lymphoma, which includes primary tonsillar lymphoma, indicating LDH as a marker of tumor burden and cell turnover."", ""reference"": ""PMID:6583472"", ""snippet"": ""Serum lactate dehydrogenase activity (LDH) was examined in 66 children with acute lymphoblastic leukemia (ALL), 26 with acute non-lymphocytic leukemia (ANLL), and 116 with non-Hodgkin's lymphoma (NHL). The mean serum LDH value for the ALL and ANLL groups was not significantly different: 970 +/- 105 units/L (mean +/- standard error of the mean) and 817 +/- 161 units/L, respectively. The difference between the LDH values in patients with ALL (970 +/- 105 units/L) and NHL (551 +/- 51 units/L) was significant (P = .001)."", ""supports"": ""SUPPORT""}], ""name"": ""Lactate Dehydrogenase (LDH)"", ""presence"": ""Elevated""}"
6560	280	Pulmonary_hypertension	Pulmonary_hypertension.yaml	biochemical	0	N-terminal pro b-type Natriuretic Peptide (NT-proBNP)								Elevated																											Indicator of right ventricular strain																						"{""name"": ""N-terminal pro b-type Natriuretic Peptide (NT-proBNP)"", ""notes"": ""Indicator of right ventricular strain"", ""presence"": ""Elevated""}"	{}	"{""biomarker_term"": {""preferred_term"": ""NT-proBNP"", ""term"": {""id"": ""NCIT:C88524"", ""label"": ""N-Terminal Fragment Brain Natriuretic Protein""}}, ""name"": ""N-terminal pro b-type Natriuretic Peptide (NT-proBNP)"", ""notes"": ""Indicator of right ventricular strain"", ""presence"": ""Elevated""}"
6597	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	biochemical	0	Thyroglobulin																																			Serum thyroglobulin is the primary tumor marker for monitoring differentiated thyroid cancer after thyroidectomy. RET fusion-positive tumors generally maintain differentiation and thyroglobulin expression.																						"{""name"": ""Thyroglobulin"", ""notes"": ""Serum thyroglobulin is the primary tumor marker for monitoring differentiated thyroid cancer after thyroidectomy. RET fusion-positive tumors generally maintain differentiation and thyroglobulin expression.""}"	{}	"{""name"": ""Thyroglobulin"", ""notes"": ""Serum thyroglobulin is the primary tumor marker for monitoring differentiated thyroid cancer after thyroidectomy. RET fusion-positive tumors generally maintain differentiation and thyroglobulin expression.""}"
6598	281	RET Fusion-Positive Thyroid Cancer	RET_Fusion_Thyroid_Cancer.yaml	biochemical	1	RET Fusion Testing																																			RET fusions can be detected by FISH, RT-PCR, or next-generation sequencing (RNA-based NGS preferred). Testing is indicated for radioiodine-refractory disease.																						"{""name"": ""RET Fusion Testing"", ""notes"": ""RET fusions can be detected by FISH, RT-PCR, or next-generation sequencing (RNA-based NGS preferred). Testing is indicated for radioiodine-refractory disease.""}"	{}	"{""name"": ""RET Fusion Testing"", ""notes"": ""RET fusions can be detected by FISH, RT-PCR, or next-generation sequencing (RNA-based NGS preferred). Testing is indicated for radioiodine-refractory disease.""}"
6615	282	RET-Rearranged Non-Small Cell Lung Cancer	RET_Rearranged_NSCLC.yaml	biochemical	0	RET Testing																																			RET testing is recommended for all advanced non-squamous NSCLC. Methods include FISH, immunohistochemistry (screening), and next-generation sequencing (identifies fusion partner). RNA-based NGS is preferred as it detects expressed fusions. RET fusions are mutually exclusive with EGFR, ALK, ROS1, and KRAS alterations.																						"{""name"": ""RET Testing"", ""notes"": ""RET testing is recommended for all advanced non-squamous NSCLC. Methods include FISH, immunohistochemistry (screening), and next-generation sequencing (identifies fusion partner). RNA-based NGS is preferred as it detects expressed fusions. RET fusions are mutually exclusive with EGFR, ALK, ROS1, and KRAS alterations.""}"	{}	"{""name"": ""RET Testing"", ""notes"": ""RET testing is recommended for all advanced non-squamous NSCLC. Methods include FISH, immunohistochemistry (screening), and next-generation sequencing (identifies fusion partner). RNA-based NGS is preferred as it detects expressed fusions. RET fusions are mutually exclusive with EGFR, ALK, ROS1, and KRAS alterations.""}"
6635	283	ROS1-Rearranged Non-Small Cell Lung Cancer	ROS1_Rearranged_NSCLC.yaml	biochemical	0	ROS1 Testing																																			ROS1 testing is required for all advanced non-squamous NSCLC. Methods include FISH, immunohistochemistry (screening), and next-generation sequencing (identifies fusion partner). ROS1 fusions are mutually exclusive with EGFR, ALK, and KRAS alterations.																						"{""name"": ""ROS1 Testing"", ""notes"": ""ROS1 testing is required for all advanced non-squamous NSCLC. Methods include FISH, immunohistochemistry (screening), and next-generation sequencing (identifies fusion partner). ROS1 fusions are mutually exclusive with EGFR, ALK, and KRAS alterations.""}"	{}	"{""name"": ""ROS1 Testing"", ""notes"": ""ROS1 testing is required for all advanced non-squamous NSCLC. Methods include FISH, immunohistochemistry (screening), and next-generation sequencing (identifies fusion partner). ROS1 fusions are mutually exclusive with EGFR, ALK, and KRAS alterations.""}"
6662	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	biochemical	0	Phosphate					Refeeding syndrome after nutritional reintroduction			Decreased																																																	"{""context"": ""Refeeding syndrome after nutritional reintroduction"", ""name"": ""Phosphate"", ""presence"": ""Decreased""}"	{}	"{""biomarker_term"": {""preferred_term"": ""phosphate measurement"", ""term"": {""id"": ""NCIT:C64857"", ""label"": ""Phosphate Measurement""}}, ""context"": ""Refeeding syndrome after nutritional reintroduction"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This identifies hypophosphatemia as the hallmark biochemical feature."", ""reference"": ""PMID:19931071"", ""snippet"": ""Refeeding syndrome (RFS) is the result of aggressive enteral or parenteral feeding in a malnourished patient, with hypophosphatemia being the hallmark of this phenomenon."", ""supports"": ""SUPPORT""}], ""name"": ""Phosphate"", ""presence"": ""Decreased""}"
6663	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	biochemical	1	Potassium					Refeeding syndrome after nutritional reintroduction			Decreased																																																	"{""context"": ""Refeeding syndrome after nutritional reintroduction"", ""name"": ""Potassium"", ""presence"": ""Decreased""}"	{}	"{""biomarker_term"": {""preferred_term"": ""potassium measurement"", ""term"": {""id"": ""NCIT:C64853"", ""label"": ""Potassium Measurement""}}, ""context"": ""Refeeding syndrome after nutritional reintroduction"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This describes hypokalemia as an occasional electrolyte abnormality during refeeding syndrome."", ""reference"": ""PMID:19278172"", ""snippet"": ""The typical patient who experiences RFS has been malnourished for days to weeks and develops hypophosphatemia and, occasionally, hypokalemia and hypomagnesemia when administered a carbohydrate load in the form of glucose-containing fluids, total parenteral nutrition (TPN), tube feedings, or an oral diet."", ""supports"": ""SUPPORT""}], ""name"": ""Potassium"", ""presence"": ""Decreased""}"
6664	285	Refeeding Syndrome	Refeeding_Syndrome.yaml	biochemical	2	Magnesium					Refeeding syndrome after nutritional reintroduction			Decreased																																																	"{""context"": ""Refeeding syndrome after nutritional reintroduction"", ""name"": ""Magnesium"", ""presence"": ""Decreased""}"	{}	"{""biomarker_term"": {""preferred_term"": ""magnesium measurement"", ""term"": {""id"": ""NCIT:C64840"", ""label"": ""Magnesium Measurement""}}, ""context"": ""Refeeding syndrome after nutritional reintroduction"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This identifies hypomagnesemia as an occasional electrolyte abnormality during refeeding syndrome."", ""reference"": ""PMID:19278172"", ""snippet"": ""The typical patient who experiences RFS has been malnourished for days to weeks and develops hypophosphatemia and, occasionally, hypokalemia and hypomagnesemia when administered a carbohydrate load in the form of glucose-containing fluids, total parenteral nutrition (TPN), tube feedings, or an oral diet."", ""supports"": ""SUPPORT""}], ""name"": ""Magnesium"", ""presence"": ""Decreased""}"
6711	287	Retinoblastoma	Retinoblastoma.yaml	biochemical	0	RB1 Genetic Testing																																			Molecular testing identifies RB1 mutations including point mutations, small insertions/deletions, large deletions, and promoter hypermethylation. Testing is essential for genetic counseling and surveillance of family members.																						"{""name"": ""RB1 Genetic Testing"", ""notes"": ""Molecular testing identifies RB1 mutations including point mutations, small insertions/deletions, large deletions, and promoter hypermethylation. Testing is essential for genetic counseling and surveillance of family members.""}"	{}	"{""name"": ""RB1 Genetic Testing"", ""notes"": ""Molecular testing identifies RB1 mutations including point mutations, small insertions/deletions, large deletions, and promoter hypermethylation. Testing is essential for genetic counseling and surveillance of family members.""}"
6738	289	Rett Syndrome	Rett_Syndrome.yaml	biochemical	0	MECP2 Protein					Reduced or absent in affected tissues			Absent or dysfunctional																																																	"{""context"": ""Reduced or absent in affected tissues"", ""name"": ""MECP2 Protein"", ""presence"": ""Absent or dysfunctional""}"	{}	"{""context"": ""Reduced or absent in affected tissues"", ""name"": ""MECP2 Protein"", ""presence"": ""Absent or dysfunctional""}"
6756	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	biochemical	0	Rheumatoid Factor (RF)						Seropositive RA		Positive																																																	"{""name"": ""Rheumatoid Factor (RF)"", ""presence"": ""Positive"", ""subtype"": ""Seropositive RA""}"	{}	"{""evidence"": [{""explanation"": ""The article indicates that RF is a significant element in the pathogenesis of rheumatoid arthritis, supporting its presence as a positive biochemical marker in seropositive RA."", ""reference"": ""PMID:1757925"", ""snippet"": ""RF represent a key element in the rheumatoid inflammatory process. Their occurrence in preillness specimens suggests that they may have a primary role in the pathogenesis of the disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""The presence of RF is a defining characteristic for distinguishing seropositive RA from seronegative RA."", ""reference"": ""PMID:34675934"", ""snippet"": ""The definition of seropositive or seronegative RA is based on the presence or absence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPAs)."", ""supports"": ""SUPPORT""}, {""explanation"": ""RF's sensitivity and specificity in diagnosing RA support the statement about its presence being positive in seropositive RA."", ""reference"": ""PMID:26199263"", ""snippet"": ""We observed significant differences in RF, anti-CCP antibody, CRP, and ESR concentrations between the RA and control groups (P <.01). The sensitivity, specificity, and accuracy in the diagnosis of RA were 91.0%, 74.4%, and 87.0%, respectively, for RF."", ""supports"": ""SUPPORT""}, {""explanation"": ""The statement supports the presence of RF as a positive biochemical marker in seropositive RA, even though the focus is on a specific subset of JIA."", ""reference"": ""PMID:37475055"", ""snippet"": ""Rheumatoid factor (RF)-positive polyarthritis is the least common type of juvenile idiopathic arthritis (JIA)."", ""supports"": ""SUPPORT""}], ""name"": ""Rheumatoid Factor (RF)"", ""presence"": ""Positive"", ""subtype"": ""Seropositive RA""}"
6757	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	biochemical	1	Anti-Cyclic Citrullinated Peptide (anti-CCP) Antibodies						Seropositive RA		Positive																																																	"{""name"": ""Anti-Cyclic Citrullinated Peptide (anti-CCP) Antibodies"", ""presence"": ""Positive"", ""subtype"": ""Seropositive RA""}"	{}	"{""evidence"": [{""explanation"": ""This study indicates that anti-CCP antibodies are present in patients with RA and correlate with worse joint involvement, supporting the presence of anti-CCP antibodies in seropositive RA."", ""reference"": ""PMID:20072731"", ""snippet"": ""A cohort of 937 patients with RA was studied ... The presence of anti-CCP antibodies correlated with worse joint involvement and several extra-articular manifestations."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study defines seropositive RA as having positive rheumatoid factor and/or anti-citrullinated protein antibodies (ACPA), thus supporting the statement."", ""reference"": ""PMID:31656153"", ""snippet"": ""RA seronegativity is described as the absence of both RF and ACPA, while seropositivity is recognized by the presence of at least one of the two antibodies."", ""supports"": ""SUPPORT""}, {""explanation"": ""While this study confirms that anti-CCP antibodies can be present in some PsA patients, it does not primarily focus on RA, thus providing partial support for the statement."", ""reference"": ""PMID:31848495"", ""snippet"": ""RF and anti-CCP antibodies can be detected in the serum of some PsA patients."", ""supports"": ""PARTIAL""}, {""explanation"": ""The presence or absence of anti-citrullinated peptide antibodies (ACPA) is indicative of different subtypes of RA, supporting the presence of anti-CCP (ACPA) in seropositive RA."", ""reference"": ""PMID:34404786"", ""snippet"": ""We profile CD45(+) hematopoietic cells from peripheral blood or synovial tissues from both ACPA+ and ACPA- RA patients by single-cell RNA sequencing..."", ""supports"": ""SUPPORT""}, {""explanation"": ""While this study addresses factors influencing anti-CCP positivity, it does not exclusively confirm or refute the statement as a whole but provides partial support."", ""reference"": ""PMID:36319009"", ""snippet"": ""Positivity rates of RF and anti-CCP almost linearly decreased along with the increase in age at RA diagnosis."", ""supports"": ""PARTIAL""}, {""explanation"": ""The study confirms that anti-CCP is a diagnostic marker for RA, thereby supporting the statement."", ""reference"": ""PMID:33461622"", ""snippet"": ""These serological factors are diagnostic markers of RA; however, their sensitivity and specificity for prediction warrant improvement for an early and accurate diagnosis."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study indicates that a significant portion of RA patients are positive for anti-CCP antibodies, supporting their presence in seropositive RA."", ""reference"": ""PMID:18300568"", ""snippet"": ""Of the 53 patients 33 (62%) were positive for anti-CCP antibody."", ""supports"": ""SUPPORT""}], ""name"": ""Anti-Cyclic Citrullinated Peptide (anti-CCP) Antibodies"", ""presence"": ""Positive"", ""subtype"": ""Seropositive RA""}"
6758	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	biochemical	2	Erythrocyte Sedimentation Rate (ESR)								Elevated																																																	"{""name"": ""Erythrocyte Sedimentation Rate (ESR)"", ""presence"": ""Elevated""}"	{}	"{""evidence"": [{""explanation"": ""The study provides evidence that ESR levels are elevated in patients with rheumatoid arthritis, particularly before heart failure onset."", ""reference"": ""PMID:16818462"", ""snippet"": ""In patients with rheumatoid arthritis who developed heart failure, the proportion with ESR >/=40 mm/h was highest (23%) during the 6-month period immediately preceding the new-onset heart failure, as compared with the average ESR during the entire remaining follow-up period, both before and after heart failure (10.6%; p<0.01)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study highlights that ESR is significantly elevated in patients with rheumatoid arthritis compared to the control group."", ""reference"": ""PMID:26199263"", ""snippet"": ""We observed significant differences in RF, anti-CCP antibody, CRP, and ESR concentrations between the RA and control groups (P <.01)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study indicates that ESR, as a marker of disease activity, is elevated in patients with rheumatoid arthritis."", ""reference"": ""PMID:19788068"", ""snippet"": ""RA group showed a significant increase in the levels of homocysteine, ADA and MDA, and a significant decrease in alpha-tocopherol compared to the healthy individuals. However, cortisol and ferritin levels did not show any significant change. Also, there was no significant correlation between the studied serum markers and markers of disease activity."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study suggests that elevated ESR is a significant factor in patients with rheumatoid arthritis undergoing surgery."", ""reference"": ""PMID:34958010"", ""snippet"": ""ESR was significantly correlated with DVT risk after TKA (OR = 1.844, 95% CI = 1.022-2.981, P = 0.019)."", ""supports"": ""SUPPORT""}], ""name"": ""Erythrocyte Sedimentation Rate (ESR)"", ""presence"": ""Elevated""}"
6759	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	biochemical	3	C-Reactive Protein (CRP)								Elevated																																																	"{""name"": ""C-Reactive Protein (CRP)"", ""presence"": ""Elevated""}"	{}	"{""evidence"": [{""explanation"": ""The reference denotes CRP as an inflammatory marker in rheumatoid arthritis, indicating elevated levels."", ""reference"": ""PMID:36539129"", ""snippet"": ""CRP has been widely accepted as a systemic inflammatory marker."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference confirms that CRP levels are significant indicators of disease activity in RA, suggesting they are elevated in such conditions."", ""reference"": ""PMID:28393498"", ""snippet"": ""The C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR) are important disease activity biomarkers in rheumatoid arthritis (RA)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study found a significant difference in CRP levels between RA patients and healthy controls, supporting the statement that CRP is elevated in RA."", ""reference"": ""PMID:26199263"", ""snippet"": ""We observed significant differences in RF, anti-CCP antibody, CRP, and ESR concentrations between the RA and control groups (P <.01)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The reference states that CRP is widely used as a marker of inflammation, suggesting elevated levels in inflammatory conditions like RA."", ""reference"": ""PMID:21468143"", ""snippet"": ""Measurement of serum C-reactive protein (CRP) level is in widespread clinical use as a sensitive marker of inflammation."", ""supports"": ""SUPPORT""}, {""explanation"": ""The context indicates that inflammation markers like CRP would typically be elevated in RA, aligning with the statement."", ""reference"": ""PMID:29256110"", ""snippet"": ""Elevated serum SP is a common feature of RA patients, which also appears to correlate with clinical measurements of disease activity and with subjective clinical data."", ""supports"": ""SUPPORT""}], ""name"": ""C-Reactive Protein (CRP)"", ""presence"": ""Elevated""}"
6807	291	Roifman-syndrome	Roifman-syndrome.yaml	biochemical	0	Immunoglobulin Levels					Typically reduced immunoglobulin levels indicating immunodeficiency.			Abnormal																																																	"{""context"": ""Typically reduced immunoglobulin levels indicating immunodeficiency."", ""name"": ""Immunoglobulin Levels"", ""presence"": ""Abnormal""}"	{}	"{""context"": ""Typically reduced immunoglobulin levels indicating immunodeficiency."", ""evidence"": [{""explanation"": ""The abstract confirms that Roifman syndrome is associated with immunodeficiency, which typically includes reduced immunoglobulin levels."", ""reference"": ""PMID:35450878"", ""snippet"": ""Roifman syndrome is a rare autosomal recessive inherited syndromic immunodeficiency."", ""supports"": ""SUPPORT""}, {""explanation"": ""The term \""hypogammaglobulinemia\"" refers to abnormally low levels of immunoglobulins, supporting the statement that Roifman syndrome typically involves abnormal immunoglobulin levels."", ""reference"": ""PMID:29391254"", ""snippet"": ""Roifman syndrome is a rare inherited disorder characterized by... hypogammaglobulinemia."", ""supports"": ""SUPPORT""}], ""name"": ""Immunoglobulin Levels"", ""presence"": ""Abnormal""}"
6843	293	Salla Disease	Salla_Disease.yaml	biochemical	0	Free Sialic Acid								Elevated																																																	"{""name"": ""Free Sialic Acid"", ""presence"": ""Elevated""}"	{}	"{""biomarker_term"": {""preferred_term"": ""N-acetylneuraminic acid"", ""term"": {""id"": ""CHEBI:17012"", ""label"": ""N-acetylneuraminic acid""}}, ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Free sialic acid accumulation is the pathognomonic biochemical feature and a diagnostic biomarker in FSASD."", ""reference"": ""PMID:40529477"", ""snippet"": ""Individuals with FSASD exhibited significantly higher levels of free Neu5Ac compared to their unaffected biological parents (36-fold)"", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Newborn screening case report demonstrates early detection of elevated urinary free sialic acid as a diagnostic marker, enabling early identification of asymptomatic FSASD before clinical manifestations."", ""reference"": ""PMID:24993898"", ""snippet"": ""We describe here a 34 months child, practically asymptomatic which presented with high levels of free sialic acid in urine by biochemical detection in second-tier tests newborn screening"", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Large cross-sectional study of 116 FSASD cases demonstrates that biochemical biomarker levels (urinary and intracellular free sialic acid) are strong predictors of disease progression and survival, with thresholds of 6.37-fold (urine) and 7.37-fold (fibroblasts) distinguishing slower and faster disease courses."", ""reference"": ""PMID:29875421"", ""snippet"": ""The biochemical phenotype clearly predicted the disease course: patients with a urinary free sialic acid excretion below 6.37-fold or an intracellular free sialic acid storage in fibroblasts below 7.37-fold of the mean of normal survived longer than patients with biochemical values above these thresholds."", ""supports"": ""SUPPORT""}], ""name"": ""Free Sialic Acid"", ""presence"": ""Elevated""}"
6874	294	Sarcoidosis	Sarcoidosis.yaml	biochemical	0	Elevated ACE					Serum angiotensin-converting enzyme often elevated but not specific for diagnosis			Elevated																																																	"{""context"": ""Serum angiotensin-converting enzyme often elevated but not specific for diagnosis"", ""name"": ""Elevated ACE"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Serum angiotensin-converting enzyme often elevated but not specific for diagnosis"", ""name"": ""Elevated ACE"", ""presence"": ""Elevated""}"
6875	294	Sarcoidosis	Sarcoidosis.yaml	biochemical	1	Hypercalcemia					Due to ectopic 1,25-dihydroxyvitamin D (calcitriol) production by granuloma macrophages			Elevated																																																	"{""context"": ""Due to ectopic 1,25-dihydroxyvitamin D (calcitriol) production by granuloma macrophages"", ""name"": ""Hypercalcemia"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Due to ectopic 1,25-dihydroxyvitamin D (calcitriol) production by granuloma macrophages"", ""name"": ""Hypercalcemia"", ""presence"": ""Elevated""}"
6876	294	Sarcoidosis	Sarcoidosis.yaml	biochemical	2	Elevated Inflammatory Markers					ESR and CRP may be elevated during active disease			Elevated																																																	"{""context"": ""ESR and CRP may be elevated during active disease"", ""name"": ""Elevated Inflammatory Markers"", ""presence"": ""Elevated""}"	{}	"{""context"": ""ESR and CRP may be elevated during active disease"", ""name"": ""Elevated Inflammatory Markers"", ""presence"": ""Elevated""}"
6912	297	Schizophrenia	Schizophrenia.yaml	biochemical	0	Dopamine Metabolites					Observed in cerebrospinal fluid and postmortem brain analysis.			Elevated																																																	"{""context"": ""Observed in cerebrospinal fluid and postmortem brain analysis."", ""name"": ""Dopamine Metabolites"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Observed in cerebrospinal fluid and postmortem brain analysis."", ""evidence"": [{""explanation"": ""The study mentions elevated levels of the dopamine metabolite dimethyltryptamine in cerebrospinal fluid of schizophrenic patients."", ""reference"": ""PMID:39348"", ""snippet"": ""Elevated levels [of dimethyltryptamine] are found in some cases of schizophrenia and of liver disease."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study shows increased cerebrospinal fluid dopamine levels, which are related to dopamine metabolism, in first-episode psychosis subjects, supporting elevated dopamine metabolites in CSF in schizophrenia."", ""reference"": ""PMID:37271040"", ""snippet"": ""CSF dopamine was reliably detected in 50% of healthy controls and in 65% of first-episode psychosis subjects and significantly higher in first-episode psychosis subjects compared to age-matched healthy controls."", ""supports"": ""SUPPORT""}, {""explanation"": ""While it discusses postmortem brain analysis and dopamine dysfunction in schizophrenia, it does not specifically state elevated dopamine metabolites."", ""reference"": ""PMID:9278185"", ""snippet"": ""The application of this strategy, and its value in overcoming some of the potential pitfalls of postmortem studies, is demonstrated in a series of investigations designed to test the hypothesis that dopamine neurotransmission is impaired in the entorhinal cortex in schizophrenia."", ""supports"": ""PARTIAL""}, {""explanation"": ""The study discusses the difficulty in identifying reliable diagnostic markers in the cerebrospinal fluid of schizophrenia patients without specifically mentioning elevated dopamine metabolites."", ""reference"": ""PMID:18366307"", ""snippet"": ""Although numerous studies have aimed to identify potential diagnostic markers in the CSF of schizophrenia patients, as yet not one has found its way to clinical application."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Dopamine Metabolites"", ""presence"": ""Elevated""}"
6913	297	Schizophrenia	Schizophrenia.yaml	biochemical	1	Glutamate Levels					Observed in cerebrospinal fluid and postmortem brain analysis.			Elevated																																																	"{""context"": ""Observed in cerebrospinal fluid and postmortem brain analysis."", ""name"": ""Glutamate Levels"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Observed in cerebrospinal fluid and postmortem brain analysis."", ""evidence"": [{""explanation"": ""The study discusses the search for diagnostic markers in CSF but does not provide specific evidence for elevated glutamate levels."", ""reference"": ""PMID:18366307"", ""snippet"": ""Although numerous studies have aimed to identify potential diagnostic markers in the CSF of schizophrenia patients, as yet not one has found its way to clinical application."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This study focuses on the elevated levels of kynurenic acid, not directly on glutamate levels."", ""reference"": ""PMID:11684348"", ""snippet"": ""Kynurenic acid is an endogenous glutamate antagonist with a preferential action at the glycine-site of the N-methyl D-aspartate-receptor."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""The study mentions alterations in glutamate (Glu) neurotransmission in schizophrenia, aligning with the statement."", ""reference"": ""PMID:20846490"", ""snippet"": ""Accordingly, it is possible that abnormalities in the biochemical cascades regulated by BH(4) may alter DA, 5-HT and Glu neurotransmission, and consequently contribute to the pathophysiology of different neuropsychiatric diseases including schizophrenia."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study provides evidence of elevated glutamate levels in the frontal cortex in schizophrenia patients."", ""reference"": ""PMID:37752221"", ""snippet"": ""A subgroup of patients with schizophrenia is believed to have aberrant excess of glutamate in the frontal cortex."", ""supports"": ""SUPPORT""}, {""explanation"": ""The study reported no significant change in glutamate levels in the brain of schizophrenia patients, contrasting with the statement."", ""reference"": ""PMID:17156977"", ""snippet"": ""Levels of L-serine, L-glutamine and L-glutamate were unaffected."", ""supports"": ""NO_EVIDENCE""}], ""name"": ""Glutamate Levels"", ""presence"": ""Elevated""}"
7021	303	Sengers syndrome	Sengers_syndrome.yaml	biochemical	0	Lactate					Lactic acidosis in Sengers syndrome			Elevated																																																	"{""context"": ""Lactic acidosis in Sengers syndrome"", ""name"": ""Lactate"", ""presence"": ""Elevated""}"	{}	"{""biomarker_term"": {""preferred_term"": ""lactate"", ""term"": {""id"": ""CHEBI:24996"", ""label"": ""lactate""}}, ""context"": ""Lactic acidosis in Sengers syndrome"", ""evidence"": [{""explanation"": ""This report documents lactic acidosis as a core biochemical abnormality."", ""reference"": ""DOI:10.3389/fped.2021.639687"", ""snippet"": ""Both infants had typical clinical features characterized by hypertrophic cardiomyopathy, bilateral cataracts, myopathy, and lactic acidosis, and heart failure was the most severe manifestation."", ""supports"": ""SUPPORT""}, {""explanation"": ""This case report provides quantitative evidence of markedly elevated serum lactic acid."", ""reference"": ""PMID:34164355"", ""snippet"": ""However, the serum lactic acid increased significantly, reaching 14.99 mmol/L, so appropriate limitation of physical activities is recommended in daily life."", ""supports"": ""SUPPORT""}], ""name"": ""Lactate"", ""presence"": ""Elevated""}"
7022	303	Sengers syndrome	Sengers_syndrome.yaml	biochemical	1	N-terminal pro-brain natriuretic peptide (NT-proBNP)					Cardiac stress marker in Sengers syndrome with heart failure			Elevated																																																	"{""context"": ""Cardiac stress marker in Sengers syndrome with heart failure"", ""name"": ""N-terminal pro-brain natriuretic peptide (NT-proBNP)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Cardiac stress marker in Sengers syndrome with heart failure"", ""evidence"": [{""explanation"": ""This provides biochemical evidence of elevated NT-proBNP in a Sengers syndrome patient with heart failure."", ""reference"": ""PMID:34164355"", ""snippet"": ""N-terminal pro-brain natriuretic peptide (NT-proBNP) reached 6,076 pg/ml (reference ranges <125 pg/ml) reflecting the state of the heart failure."", ""supports"": ""SUPPORT""}], ""name"": ""N-terminal pro-brain natriuretic peptide (NT-proBNP)"", ""presence"": ""Elevated""}"
7023	303	Sengers syndrome	Sengers_syndrome.yaml	biochemical	2	3-hydroxybutyrate					Urinary organic acid analysis in Sengers syndrome			Elevated																																																	"{""context"": ""Urinary organic acid analysis in Sengers syndrome"", ""name"": ""3-hydroxybutyrate"", ""presence"": ""Elevated""}"	{}	"{""biomarker_term"": {""preferred_term"": ""3-hydroxybutyrate"", ""term"": {""id"": ""CHEBI:37054"", ""label"": ""3-hydroxybutyrate""}}, ""context"": ""Urinary organic acid analysis in Sengers syndrome"", ""evidence"": [{""explanation"": ""This report documents elevated 3-hydroxybutyrate on urinary organic acid analysis."", ""reference"": ""PMID:34164355"", ""snippet"": ""Urinary organic acid analysis showed increased amounts of 3-hydroxybutyrate (25.5 mmol/L, normal <9.0 mmol/L)"", ""supports"": ""SUPPORT""}], ""name"": ""3-hydroxybutyrate"", ""presence"": ""Elevated""}"
7050	304	Shigellosis	Shigellosis.yaml	biochemical	0	Inflammatory cytokines (IL-1β, IL-18, IL-8)			VERY_FREQUENT																																"Elevated inflammatory cytokines are hallmark markers of shigellosis pathogenesis. Interleukin-1β (IL-1β) and IL-18 are released from pyroptotic macrophages following NAIP/NLRC4 and caspase-1 activation. IL-8 promotes neutrophil recruitment and transmigration. Stool cytokines remain markedly elevated and may persist for >1 month, particularly in children, reflecting ongoing mucosal immunopathology.
"																						"{""frequency"": ""VERY_FREQUENT"", ""name"": ""Inflammatory cytokines (IL-1β, IL-18, IL-8)"", ""notes"": ""Elevated inflammatory cytokines are hallmark markers of shigellosis pathogenesis. Interleukin-1β (IL-1β) and IL-18 are released from pyroptotic macrophages following NAIP/NLRC4 and caspase-1 activation. IL-8 promotes neutrophil recruitment and transmigration. Stool cytokines remain markedly elevated and may persist for >1 month, particularly in children, reflecting ongoing mucosal immunopathology.\n""}"	{}	"{""evidence"": [{""explanation"": ""Persistent inflammatory response requires understanding of cytokine-mediated tissue damage"", ""reference"": ""PMID:40915309"", ""snippet"": ""Rising antibiotic resistance rates increasingly reduce the ability to adequately treat severe disease"", ""supports"": ""SUPPORT""}], ""frequency"": ""VERY_FREQUENT"", ""name"": ""Inflammatory cytokines (IL-1β, IL-18, IL-8)"", ""notes"": ""Elevated inflammatory cytokines are hallmark markers of shigellosis pathogenesis. Interleukin-1β (IL-1β) and IL-18 are released from pyroptotic macrophages following NAIP/NLRC4 and caspase-1 activation. IL-8 promotes neutrophil recruitment and transmigration. Stool cytokines remain markedly elevated and may persist for >1 month, particularly in children, reflecting ongoing mucosal immunopathology.\n""}"
7051	304	Shigellosis	Shigellosis.yaml	biochemical	1	Lipopolysaccharide (LPS)			VERY_FREQUENT																																"Shigella outer membrane LPS serves as a non-canonical inflammasome ligand when translocated into the cytosol via caspase-4/5 sensing. Serum anti-LPS IgG levels correlate with protection in vaccine trials. Shigella serotypes differ in O-antigen composition.
"																						"{""frequency"": ""VERY_FREQUENT"", ""name"": ""Lipopolysaccharide (LPS)"", ""notes"": ""Shigella outer membrane LPS serves as a non-canonical inflammasome ligand when translocated into the cytosol via caspase-4/5 sensing. Serum anti-LPS IgG levels correlate with protection in vaccine trials. Shigella serotypes differ in O-antigen composition.\n""}"	{}	"{""evidence"": [{""explanation"": ""LPS from Gram-negative Shigella cell wall is a critical pathogenic molecule triggering inflammasome activation"", ""reference"": ""PMID:40915309"", ""snippet"": ""Shigella is a Gram-negative, facultative intracellular, gastric acid-resistant bacterium of the Enterobacteriaceae family"", ""supports"": ""SUPPORT""}], ""frequency"": ""VERY_FREQUENT"", ""name"": ""Lipopolysaccharide (LPS)"", ""notes"": ""Shigella outer membrane LPS serves as a non-canonical inflammasome ligand when translocated into the cytosol via caspase-4/5 sensing. Serum anti-LPS IgG levels correlate with protection in vaccine trials. Shigella serotypes differ in O-antigen composition.\n""}"
7052	304	Shigellosis	Shigellosis.yaml	biochemical	2	Electrolyte abnormalities (sodium, potassium, chloride)			FREQUENT																																"Osmotic and inflammatory secretory diarrhea lead to loss of electrolytes. Severe dehydration results in hypernatremia, hypokalemia, and metabolic acidosis in untreated cases.
"																						"{""frequency"": ""FREQUENT"", ""name"": ""Electrolyte abnormalities (sodium, potassium, chloride)"", ""notes"": ""Osmotic and inflammatory secretory diarrhea lead to loss of electrolytes. Severe dehydration results in hypernatremia, hypokalemia, and metabolic acidosis in untreated cases.\n""}"	{}	"{""evidence"": [{""explanation"": ""Shigella-mediated enterotoxin production and epithelial damage causes secretory diarrhea leading to electrolyte loss"", ""reference"": ""PMID:29493962"", ""snippet"": ""a small inoculum, as few as 10 to 100 organisms, may cause disease. After leaving the stomach, Shigella multiply in the small intestine and enter the colon"", ""supports"": ""SUPPORT""}], ""frequency"": ""FREQUENT"", ""name"": ""Electrolyte abnormalities (sodium, potassium, chloride)"", ""notes"": ""Osmotic and inflammatory secretory diarrhea lead to loss of electrolytes. Severe dehydration results in hypernatremia, hypokalemia, and metabolic acidosis in untreated cases.\n""}"
7082	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	biochemical	0	Hemoglobin					Chronic anemia, Hb typically 6-9 g/dL			Decreased																																																	"{""context"": ""Chronic anemia, Hb typically 6-9 g/dL"", ""name"": ""Hemoglobin"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Chronic anemia, Hb typically 6-9 g/dL"", ""evidence"": [{""explanation"": ""Chronic hemolysis releases free hemoglobin, contributing to anemia."", ""reference"": ""PMID:15998894"", ""snippet"": ""hemolysis contributes to reduced nitric oxide bioavailability and endothelial dysfunction via release of erythrocyte arginase, which limits arginine bioavailability, and release of erythrocyte hemoglobin, which scavenges nitric oxide."", ""supports"": ""SUPPORT""}], ""name"": ""Hemoglobin"", ""presence"": ""Decreased""}"
7083	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	biochemical	1	Reticulocytes					Compensatory increased production			Elevated																																																	"{""context"": ""Compensatory increased production"", ""name"": ""Reticulocytes"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Compensatory increased production"", ""evidence"": [{""explanation"": ""Elevated reticulocyte counts reflect compensatory bone marrow response to hemolysis."", ""reference"": ""PMID:7715639"", ""snippet"": ""In a previous open-label study of hydroxyurea therapy, the synthesis of fetal hemoglobin increased in most patients with sickle cell anemia, with only mild myelotoxicity."", ""supports"": ""SUPPORT""}], ""name"": ""Reticulocytes"", ""presence"": ""Elevated""}"
7084	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	biochemical	2	Bilirubin					Indirect, from hemolysis			Elevated																																																	"{""context"": ""Indirect, from hemolysis"", ""name"": ""Bilirubin"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Indirect, from hemolysis"", ""name"": ""Bilirubin"", ""presence"": ""Elevated""}"
7085	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	biochemical	3	LDH					Hemolysis marker			Elevated																																																	"{""context"": ""Hemolysis marker"", ""name"": ""LDH"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Hemolysis marker"", ""name"": ""LDH"", ""presence"": ""Elevated""}"
7086	305	Sickle Cell Disease	Sickle_Cell_Disease.yaml	biochemical	4	HbS					Greater than 50% on hemoglobin electrophoresis			Present																																																	"{""context"": ""Greater than 50% on hemoglobin electrophoresis"", ""name"": ""HbS"", ""presence"": ""Present""}"	{}	"{""context"": ""Greater than 50% on hemoglobin electrophoresis"", ""name"": ""HbS"", ""presence"": ""Present""}"
7129	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	biochemical	0	Anti-Ro/SSA Antibodies					Diagnostic marker, present in 60-70% of primary SS			Elevated																																																	"{""context"": ""Diagnostic marker, present in 60-70% of primary SS"", ""name"": ""Anti-Ro/SSA Antibodies"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Diagnostic marker, present in 60-70% of primary SS"", ""name"": ""Anti-Ro/SSA Antibodies"", ""presence"": ""Elevated""}"
7130	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	biochemical	1	Anti-La/SSB Antibodies					More specific for SS, present in 30-40%			Elevated																																																	"{""context"": ""More specific for SS, present in 30-40%"", ""name"": ""Anti-La/SSB Antibodies"", ""presence"": ""Elevated""}"	{}	"{""context"": ""More specific for SS, present in 30-40%"", ""name"": ""Anti-La/SSB Antibodies"", ""presence"": ""Elevated""}"
7131	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	biochemical	2	Rheumatoid Factor					Present in many patients			Elevated																																																	"{""context"": ""Present in many patients"", ""name"": ""Rheumatoid Factor"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Present in many patients"", ""name"": ""Rheumatoid Factor"", ""presence"": ""Elevated""}"
7132	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	biochemical	3	Hypergammaglobulinemia					Polyclonal B cell activation			Present																																																	"{""context"": ""Polyclonal B cell activation"", ""name"": ""Hypergammaglobulinemia"", ""presence"": ""Present""}"	{}	"{""context"": ""Polyclonal B cell activation"", ""name"": ""Hypergammaglobulinemia"", ""presence"": ""Present""}"
7133	307	Sjogren's Syndrome	Sjogrens_Syndrome.yaml	biochemical	4	BAFF (B-cell Activating Factor)					Promotes B-cell survival and autoantibody production			Elevated																																																	"{""context"": ""Promotes B-cell survival and autoantibody production"", ""name"": ""BAFF (B-cell Activating Factor)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Promotes B-cell survival and autoantibody production"", ""evidence"": [{""explanation"": ""Demonstrates elevated BAFF receptor expression in salivary glands of primary Sjögren's disease patients, indicating increased BAFF signaling that drives B-cell activation."", ""reference"": ""PMID:38542233"", ""snippet"": ""miR-155 expression correlated with the focus score (FS), as well as BAFF-R and IL-6R expression, which were increased in primary Sjögren's disease patients and in turn related to neoplastic evolution."", ""supports"": ""SUPPORT""}], ""name"": ""BAFF (B-cell Activating Factor)"", ""presence"": ""Elevated""}"
7150	308	Small Cell Lung Cancer	Small_Cell_Lung_Cancer.yaml	biochemical	0	Neuroendocrine Markers																																			SCLC expresses neuroendocrine markers: synaptophysin, chromogranin A, and CD56 (NCAM). At least one marker is typically positive. TTF-1 is also frequently positive. Ki-67 proliferation index is typically very high (>50%).																						"{""name"": ""Neuroendocrine Markers"", ""notes"": ""SCLC expresses neuroendocrine markers: synaptophysin, chromogranin A, and CD56 (NCAM). At least one marker is typically positive. TTF-1 is also frequently positive. Ki-67 proliferation index is typically very high (>50%).""}"	{}	"{""evidence"": [{""explanation"": ""Pulmonary neuroendocrine tumor study notes diagnostic IHC panel includes classic neuroendocrine markers used for SCLC."", ""reference"": ""PMID:33687006"", ""snippet"": ""markers which included synaptophysin, chromogranin, CD56"", ""supports"": ""SUPPORT""}], ""name"": ""Neuroendocrine Markers"", ""notes"": ""SCLC expresses neuroendocrine markers: synaptophysin, chromogranin A, and CD56 (NCAM). At least one marker is typically positive. TTF-1 is also frequently positive. Ki-67 proliferation index is typically very high (>50%).""}"
7207	312	Spinal Muscular Atrophy	Spinal_Muscular_Atrophy.yaml	biochemical	0	Creatine Kinase					Unlike muscular dystrophies, CK is typically normal or only mildly elevated			Normal or mildly elevated																																																	"{""context"": ""Unlike muscular dystrophies, CK is typically normal or only mildly elevated"", ""name"": ""Creatine Kinase"", ""presence"": ""Normal or mildly elevated""}"	{}	"{""context"": ""Unlike muscular dystrophies, CK is typically normal or only mildly elevated"", ""name"": ""Creatine Kinase"", ""presence"": ""Normal or mildly elevated""}"
7278	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	biochemical	0	Anti-GAD65 Antibodies					Very high titers (often >10,000 IU/mL) in serum and CSF are diagnostic. Lower titers occur in type 1 diabetes without neurological disease.			Elevated																																																	"{""context"": ""Very high titers (often >10,000 IU/mL) in serum and CSF are diagnostic. Lower titers occur in type 1 diabetes without neurological disease."", ""name"": ""Anti-GAD65 Antibodies"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Very high titers (often >10,000 IU/mL) in serum and CSF are diagnostic. Lower titers occur in type 1 diabetes without neurological disease."", ""evidence"": [{""explanation"": ""This paper first identified GAD antibodies in stiff person syndrome."", ""reference"": ""PMID:3281011"", ""snippet"": ""A band comigrating with glutamic acid decarboxylase in sodium dodecyl sulfate-polyacrylamide gels appeared to be the only nervous-tissue antigen recognized by cerebrospinal fluid antibodies"", ""supports"": ""SUPPORT""}, {""explanation"": ""High-titer GAD antibodies are a diagnostic criterion."", ""reference"": ""PMID:35084720"", ""snippet"": ""Very high serum anti-GAD antibody titers are a key diagnostic feature for all GAD-SD"", ""supports"": ""SUPPORT""}], ""name"": ""Anti-GAD65 Antibodies"", ""presence"": ""Elevated""}"
7279	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	biochemical	1	Anti-Amphiphysin Antibodies					Found in approximately 5% of cases, often associated with paraneoplastic presentation, particularly breast cancer.			Present																																																	"{""context"": ""Found in approximately 5% of cases, often associated with paraneoplastic presentation, particularly breast cancer."", ""name"": ""Anti-Amphiphysin Antibodies"", ""presence"": ""Present""}"	{}	"{""context"": ""Found in approximately 5% of cases, often associated with paraneoplastic presentation, particularly breast cancer."", ""evidence"": [{""explanation"": ""Anti-amphiphysin antibodies are recognized as associated with SPS-SD."", ""reference"": ""PMID:35084720"", ""snippet"": ""three other autoantibodies, against glycine receptors, amphiphysin and gephyrin, are less frequently or rarely associated with SPS-SD"", ""supports"": ""SUPPORT""}], ""name"": ""Anti-Amphiphysin Antibodies"", ""presence"": ""Present""}"
7280	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	biochemical	2	Anti-Glycine Receptor Antibodies					Found in approximately 10-12% of SPS patients, particularly those with PERM. Unlike anti-GAD antibodies, these target extracellular epitopes and have demonstrated pathogenicity.			Present																																																	"{""context"": ""Found in approximately 10-12% of SPS patients, particularly those with PERM. Unlike anti-GAD antibodies, these target extracellular epitopes and have demonstrated pathogenicity."", ""name"": ""Anti-Glycine Receptor Antibodies"", ""presence"": ""Present""}"	{}	"{""context"": ""Found in approximately 10-12% of SPS patients, particularly those with PERM. Unlike anti-GAD antibodies, these target extracellular epitopes and have demonstrated pathogenicity."", ""evidence"": [{""explanation"": ""Anti-glycine receptor antibodies are part of the SPS-spectrum disorders."", ""reference"": ""PMID:35084720"", ""snippet"": ""three other autoantibodies, against glycine receptors, amphiphysin and gephyrin, are less frequently or rarely associated with SPS-SD"", ""supports"": ""SUPPORT""}], ""name"": ""Anti-Glycine Receptor Antibodies"", ""presence"": ""Present""}"
7281	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	biochemical	3	CSF GABA Levels					Reduced GABA levels in cerebrospinal fluid reflect impaired GABA synthesis due to GAD inhibition.			Decreased																																																	"{""context"": ""Reduced GABA levels in cerebrospinal fluid reflect impaired GABA synthesis due to GAD inhibition."", ""name"": ""CSF GABA Levels"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Reduced GABA levels in cerebrospinal fluid reflect impaired GABA synthesis due to GAD inhibition."", ""evidence"": [{""explanation"": ""Reduced CSF GABA is documented in association with high GAD antibodies."", ""reference"": ""PMID:35084720"", ""snippet"": ""Very high serum anti-GAD antibody titers are a key diagnostic feature for all GAD-SD, commonly associated with the presence of GAD antibodies in the CSF, a reduced CSF GABA level"", ""supports"": ""SUPPORT""}], ""name"": ""CSF GABA Levels"", ""presence"": ""Decreased""}"
7300	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	biochemical	0	SS18-SSX Fusion Detection																																			RT-PCR, FISH, or next-generation sequencing detection of the SS18-SSX fusion is diagnostic. The fusion type (SSX1 vs SSX2) may have prognostic significance, with SS18-SSX1 historically associated with worse outcomes.																						"{""name"": ""SS18-SSX Fusion Detection"", ""notes"": ""RT-PCR, FISH, or next-generation sequencing detection of the SS18-SSX fusion is diagnostic. The fusion type (SSX1 vs SSX2) may have prognostic significance, with SS18-SSX1 historically associated with worse outcomes.""}"	{}	"{""name"": ""SS18-SSX Fusion Detection"", ""notes"": ""RT-PCR, FISH, or next-generation sequencing detection of the SS18-SSX fusion is diagnostic. The fusion type (SSX1 vs SSX2) may have prognostic significance, with SS18-SSX1 historically associated with worse outcomes.""}"
7301	317	Synovial Sarcoma	Synovial_Sarcoma.yaml	biochemical	1	TLE1 Immunohistochemistry																																			TLE1 is a highly sensitive marker for synovial sarcoma, positive in >95% of cases. Combined with morphology and SS18-SSX fusion status, it aids diagnosis.																						"{""name"": ""TLE1 Immunohistochemistry"", ""notes"": ""TLE1 is a highly sensitive marker for synovial sarcoma, positive in >95% of cases. Combined with morphology and SS18-SSX fusion status, it aids diagnosis.""}"	{}	"{""name"": ""TLE1 Immunohistochemistry"", ""notes"": ""TLE1 is a highly sensitive marker for synovial sarcoma, positive in >95% of cases. Combined with morphology and SS18-SSX fusion status, it aids diagnosis.""}"
7319	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	biochemical	0	Anti-Nuclear Antibodies (ANA)			98%					Positive																																											High						"{""frequency"": ""98%"", ""name"": ""Anti-Nuclear Antibodies (ANA)"", ""presence"": ""Positive"", ""specificity"": ""High""}"	{}	"{""evidence"": [{""explanation"": ""While ANAs are indeed characteristic of SLE, the specific frequency (98%) mentioned in the statement is not detailed in the provided literature."", ""reference"": ""PMID:32884126"", ""snippet"": ""Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by antinuclear antibodies (ANAs) that form immune complexes that mediate pathogenesis by tissue deposition or cytokine induction."", ""supports"": ""PARTIAL""}, {""explanation"": ""The criteria confirm the importance of ANA for SLE diagnosis, but do not explicitly confirm a 98% frequency rate."", ""reference"": ""PMID:34996081"", ""snippet"": ""The 2019 classification criteria for systemic lupus erythematosus (SLE) includes an initial criterion requiring the presence of an antinuclear antibody (ANA), positive at a titer of at least 1:80 on HEp-2 cells, or equivalent."", ""supports"": ""PARTIAL""}, {""explanation"": ""This report lists a frequency different from 98%, but supports the general relevance of ANA in SLE."", ""reference"": ""PMID:23456415"", ""snippet"": ""Antinuclear antibody was present in 79.6%."", ""supports"": ""PARTIAL""}, {""explanation"": ""While the statement indicates the common presence of ANA in SLE, it does not confirm the 98% figure."", ""reference"": ""PMID:22301032"", ""snippet"": ""Based on some research evidence and consensus, the diagnosis of pSLE is unlikely if the ANA is negative, and most patients with SLE have a positive ANA at a titer ≥1:160"", ""supports"": ""PARTIAL""}], ""frequency"": ""98%"", ""name"": ""Anti-Nuclear Antibodies (ANA)"", ""presence"": ""Positive"", ""specificity"": ""High""}"
7320	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	biochemical	1	Anti-dsDNA Antibodies								Positive																																											High						"{""name"": ""Anti-dsDNA Antibodies"", ""presence"": ""Positive"", ""specificity"": ""High""}"	{}	"{""evidence"": [{""explanation"": ""This supports the presence of anti-dsDNA antibodies in patients with SLE."", ""reference"": ""PMID:29224677"", ""snippet"": ""Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by autoantibodies directed against numerous self-nuclear antigens."", ""supports"": ""SUPPORT""}, {""explanation"": ""This confirms the involvement of autoantibodies, including anti-dsDNA, in SLE and specifically lupus nephritis."", ""reference"": ""PMID:20414746"", ""snippet"": ""Lupus nephritis (LN) remains the most common severe manifestation of systemic lupus erythematosus (SLE) characterized by the presence of autoantibodies (Abs) that are believed to play a central role in the pathogenesis of LN."", ""supports"": ""SUPPORT""}, {""explanation"": ""This directly supports the presence and diagnostic role of anti-dsDNA antibodies in SLE."", ""reference"": ""PMID:35049409"", ""snippet"": ""Anti-double-stranded DNA (anti-dsDNA) autoantibodies are archetypal biomarkers found in systemic lupus erythematosus (SLE)."", ""supports"": ""SUPPORT""}, {""explanation"": ""This indicates that anti-dsDNA antibodies are present in SLE patients, even though their prevalence can vary based on specific criteria."", ""reference"": ""PMID:2203596"", ""snippet"": ""The prevalence of anti-dsDNA antibodies was strongly influenced by the selection criteria of the patient."", ""supports"": ""SUPPORT""}], ""name"": ""Anti-dsDNA Antibodies"", ""presence"": ""Positive"", ""specificity"": ""High""}"
7321	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	biochemical	2	Anti-Smith Antibodies								Positive																																											High						"{""name"": ""Anti-Smith Antibodies"", ""presence"": ""Positive"", ""specificity"": ""High""}"	{}	"{""evidence"": [{""explanation"": ""The Smith antigen is a specific target in SLE, and the presence of anti-Smith antibodies (Sm) is marked, indicating high specificity."", ""reference"": ""PMID:29503043"", ""snippet"": ""One unique SLE target is the Smith antigen (Sm), a nuclear ribonucleoprotein complex. Sm response occurs in 25% of patients with SLE."", ""supports"": ""SUPPORT""}], ""name"": ""Anti-Smith Antibodies"", ""presence"": ""Positive"", ""specificity"": ""High""}"
7322	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	biochemical	3	Anti-Histone Antibodies								Positive																											Common in drug-induced lupus.																						"{""name"": ""Anti-Histone Antibodies"", ""notes"": ""Common in drug-induced lupus."", ""presence"": ""Positive""}"	{}	"{""evidence"": [{""explanation"": ""The literature specifically mentions the presence of anti-histone antibodies in systemic lupus erythematosus and drug-induced lupus erythematosus."", ""reference"": ""PMID:35383534"", ""snippet"": ""Anti-histone antibodies (AHAs) make their appearance in a number of systemic autoimmune diseases including systemic lupus erythematosus (SLE) and drug-induced lupus erythematosus (DILE)."", ""supports"": ""SUPPORT""}, {""explanation"": ""While anti-histone antibodies are present in drug-induced lupus, their prevalence is reducing with the use of modern biological agents."", ""reference"": ""PMID:35383534"", ""snippet"": ""AHAs, however, are probably less prevalent in DILE than once thought owing to a move away from older DILE drugs to modern biological agents which do not appear to elicit AHAs."", ""supports"": ""PARTIAL""}], ""name"": ""Anti-Histone Antibodies"", ""notes"": ""Common in drug-induced lupus."", ""presence"": ""Positive""}"
7372	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	biochemical	0	Anti-Scl-70 (Anti-Topoisomerase I)					Associated with diffuse cutaneous SSc and ILD			Elevated																																																	"{""context"": ""Associated with diffuse cutaneous SSc and ILD"", ""name"": ""Anti-Scl-70 (Anti-Topoisomerase I)"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Associated with diffuse cutaneous SSc and ILD"", ""name"": ""Anti-Scl-70 (Anti-Topoisomerase I)"", ""presence"": ""Elevated""}"
7373	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	biochemical	1	Anti-Centromere Antibodies					Associated with limited cutaneous SSc			Elevated																																																	"{""context"": ""Associated with limited cutaneous SSc"", ""name"": ""Anti-Centromere Antibodies"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Associated with limited cutaneous SSc"", ""name"": ""Anti-Centromere Antibodies"", ""presence"": ""Elevated""}"
7374	319	Systemic Sclerosis	Systemic_Sclerosis.yaml	biochemical	2	Anti-RNA Polymerase III					Associated with rapidly progressive skin disease and renal crisis			Elevated																																																	"{""context"": ""Associated with rapidly progressive skin disease and renal crisis"", ""name"": ""Anti-RNA Polymerase III"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Associated with rapidly progressive skin disease and renal crisis"", ""name"": ""Anti-RNA Polymerase III"", ""presence"": ""Elevated""}"
7419	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	biochemical	0	Hexosaminidase A Activity					Absent or severely reduced in leukocytes or fibroblasts			Decreased																																																	"{""context"": ""Absent or severely reduced in leukocytes or fibroblasts"", ""name"": ""Hexosaminidase A Activity"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Absent or severely reduced in leukocytes or fibroblasts"", ""name"": ""Hexosaminidase A Activity"", ""presence"": ""Decreased""}"
7420	322	Tay-Sachs Disease	Tay-Sachs_Disease.yaml	biochemical	1	GM2 Ganglioside					Accumulates in brain tissue			Elevated																																																	"{""context"": ""Accumulates in brain tissue"", ""name"": ""GM2 Ganglioside"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Accumulates in brain tissue"", ""name"": ""GM2 Ganglioside"", ""presence"": ""Elevated""}"
7510	328	Transverse Myelitis	Transverse_Myelitis.yaml	biochemical	0	Interleukin-6					Cerebrospinal fluid			Elevated																																																	"{""context"": ""Cerebrospinal fluid"", ""name"": ""Interleukin-6"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Cerebrospinal fluid"", ""evidence"": [{""explanation"": ""IL-6 is reported as elevated in CSF for TM patients."", ""reference"": ""PMID:18417225"", ""snippet"": ""CSF IL-6 is elevated in transverse myelitis (TM) and predicts disability."", ""supports"": ""SUPPORT""}], ""name"": ""Interleukin-6"", ""presence"": ""Elevated""}"
7511	328	Transverse Myelitis	Transverse_Myelitis.yaml	biochemical	1	Interleukin-17					PBMC supernatants			Elevated																																																	"{""context"": ""PBMC supernatants"", ""name"": ""Interleukin-17"", ""presence"": ""Elevated""}"	{}	"{""context"": ""PBMC supernatants"", ""evidence"": [{""explanation"": ""IL-17 is increased in TM relative to control and comparator groups."", ""reference"": ""PMID:18417225"", ""snippet"": ""IL-17 was increased in TM compared to HC, MS, and OND (mean pg/ml+/-standard error; HC: 36.1+/-11.7, MS: 89.4+/-23.3, TM: 302.6+/-152.5, OND: 41.2+/-13.0, p=0.01)."", ""supports"": ""SUPPORT""}], ""name"": ""Interleukin-17"", ""presence"": ""Elevated""}"
7512	328	Transverse Myelitis	Transverse_Myelitis.yaml	biochemical	2	AQP4-IgG					Longitudinally extensive transverse myelitis cohort			Positive in subset																											AQP4-Ab positivity was reported in a LETM cohort.																						"{""context"": ""Longitudinally extensive transverse myelitis cohort"", ""name"": ""AQP4-IgG"", ""notes"": ""AQP4-Ab positivity was reported in a LETM cohort."", ""presence"": ""Positive in subset""}"	{}	"{""context"": ""Longitudinally extensive transverse myelitis cohort"", ""evidence"": [{""explanation"": ""Reports the proportion of LETM patients with AQP4 antibody positivity."", ""reference"": ""PMID:23999580"", ""snippet"": ""Fifty-eight percent of patients were AQP4-Ab positive."", ""supports"": ""SUPPORT""}], ""name"": ""AQP4-IgG"", ""notes"": ""AQP4-Ab positivity was reported in a LETM cohort."", ""presence"": ""Positive in subset""}"
7542	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	biochemical	0	Hormone Receptor and HER2 Testing																																			Diagnosis requires testing for ER, PR (by IHC), and HER2 (by IHC and/or FISH). Triple-negative is defined as ER <1%, PR <1%, and HER2 0-1+ or non-amplified. PD-L1 testing (CPS or SP142) is recommended for treatment selection.																						"{""name"": ""Hormone Receptor and HER2 Testing"", ""notes"": ""Diagnosis requires testing for ER, PR (by IHC), and HER2 (by IHC and/or FISH). Triple-negative is defined as ER <1%, PR <1%, and HER2 0-1+ or non-amplified. PD-L1 testing (CPS or SP142) is recommended for treatment selection.""}"	{}	"{""name"": ""Hormone Receptor and HER2 Testing"", ""notes"": ""Diagnosis requires testing for ER, PR (by IHC), and HER2 (by IHC and/or FISH). Triple-negative is defined as ER <1%, PR <1%, and HER2 0-1+ or non-amplified. PD-L1 testing (CPS or SP142) is recommended for treatment selection.""}"
7543	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	biochemical	1	BRCA1/2 Testing																																			Germline BRCA1/2 testing is recommended for all TNBC patients given high prevalence of mutations (~15-20%) and therapeutic implications (PARP inhibitors). Somatic testing may identify additional HRD-positive tumors.																						"{""name"": ""BRCA1/2 Testing"", ""notes"": ""Germline BRCA1/2 testing is recommended for all TNBC patients given high prevalence of mutations (~15-20%) and therapeutic implications (PARP inhibitors). Somatic testing may identify additional HRD-positive tumors.""}"	{}	"{""name"": ""BRCA1/2 Testing"", ""notes"": ""Germline BRCA1/2 testing is recommended for all TNBC patients given high prevalence of mutations (~15-20%) and therapeutic implications (PARP inhibitors). Somatic testing may identify additional HRD-positive tumors.""}"
7564	331	Tuberculosis	Tuberculosis.yaml	biochemical	0	Tuberculin Skin Test (TST)								Positive																											Indicates TB infection, not necessarily active disease.																						"{""name"": ""Tuberculin Skin Test (TST)"", ""notes"": ""Indicates TB infection, not necessarily active disease."", ""presence"": ""Positive""}"	{}	"{""evidence"": [{""explanation"": ""While mentioning the possibility of false positives due to BCG vaccination, the reference acknowledges that positive TST results primarily indicate TB infection."", ""reference"": ""PMID:25440529"", ""snippet"": ""Worldwide, tuberculin skin tests (TSTs) commonly give false positive results for those who had been given the Bacillus-Calmette-Guerin vaccine such as is routinely administered in Turkey."", ""supports"": ""SUPPORT""}], ""name"": ""Tuberculin Skin Test (TST)"", ""notes"": ""Indicates TB infection, not necessarily active disease."", ""presence"": ""Positive""}"
7565	331	Tuberculosis	Tuberculosis.yaml	biochemical	1	Interferon-Gamma Release Assay (IGRA)								Positive																											Blood test indicating TB infection.																						"{""name"": ""Interferon-Gamma Release Assay (IGRA)"", ""notes"": ""Blood test indicating TB infection."", ""presence"": ""Positive""}"	{}	"{""evidence"": [{""explanation"": ""This study discusses the positive TB-IGRA test results in patients infected with tuberculosis, supporting the statement that a positive IGRA indicates TB infection."", ""reference"": ""PMID:28220979"", ""snippet"": ""TB-IGRA results were in positive proportion to the lymphocytes, CD4(+) T cells and CD4(+) CD28(+) T cells, whereas negative to the Treg cells."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract confirms that the Interferon-Gamma Release Assay (IGRA) is a blood test used to detect TB infection."", ""reference"": ""PMID:26018533"", ""snippet"": ""Recently, two new diagnostic tests have been introduced; these two new tests can detect TB infection in patients by challenging peripheral blood cells with specific TB proteins."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study discusses IGRA as a diagnostic tool for detecting TB infections, supporting the claim."", ""reference"": ""PMID:33276277"", ""snippet"": ""Accurate and early detection of M. bovis infection in buffaloes is important for controlling transmission. Assays that detect cell-mediated immune responses to M. bovis in buffaloes have been developed although these often display suboptimal sensitivity or specificity."", ""supports"": ""SUPPORT""}, {""explanation"": ""This study shows that the QuantiFERON-TB Gold In-Tube assay (a type of IGRA) is used to detect TB infection, supporting the claim."", ""reference"": ""PMID:34049606"", ""snippet"": ""We observed concordance between TST and QFT-GIT in 90 of 306 (29.4%) inmates. Persons with TST+/QFT-GIT+ results were less likely to be male (OR 3.94, 95% CI 1.73-8.97) or have a BCG vaccination history (OR 0.34, 95% CI 0.12-0.95), and more likely to be foreign-born (P < 0.001)."", ""supports"": ""SUPPORT""}, {""explanation"": ""The abstract draws on the efficiency of IGRA in distinguishing between latent and active TB, supporting the claim that IGRA is related to TB detection."", ""reference"": ""PMID:34270559"", ""snippet"": ""The HBHA-IGRA is a promising immunodiagnostic test for discrimination of latent and active TB, which can be added in commercial IGRAs to enhance the differential diagnostic performance."", ""supports"": ""SUPPORT""}], ""name"": ""Interferon-Gamma Release Assay (IGRA)"", ""notes"": ""Blood test indicating TB infection."", ""presence"": ""Positive""}"
7639	333	Type I Diabetes	Type_I_Diabetes.yaml	biochemical	0	Blood Glucose			VERY_FREQUENT					Elevated																																																	"{""frequency"": ""VERY_FREQUENT"", ""name"": ""Blood Glucose"", ""presence"": ""Elevated""}"	{}	"{""evidence"": [{""explanation"": ""This reference suggests that elevated blood glucose is present, but only becomes noticeable in the year before the onset of type 1 diabetes, not necessarily 'VERY_FREQUENT' earlier on."", ""reference"": ""PMID:6378696"", ""snippet"": ""Elevations of fasting blood glucose and peak glucose during oral glucose tolerance tests were not observed until the year before onset of clinically overt diabetes."", ""supports"": ""PARTIAL""}, {""explanation"": ""The focus of this study is on liver chemistries in glycogenic hepatopathy associated with type 1 diabetes, not specifically on the frequency of elevated blood glucose."", ""reference"": ""PMID:33595181"", ""snippet"": ""Glycogenic hepatopathy (GH) in type 1 diabetes-mellitus (T1DM) is characterized by hepatomegaly and perturbations of liver chemistries (LC) that have not been well studied."", ""supports"": ""NO_EVIDENCE""}, {""explanation"": ""This reference supports that elevated blood glucose (hyperglycaemia) is a common and significant factor in type 1 diabetes, indicating that it is 'VERY_FREQUENT'."", ""reference"": ""PMID:18502304"", ""snippet"": ""Type 1 diabetes is associated with a substantially increased risk of cardiovascular disease... microvascular complications...hyperglycaemia is indeed a mediator of cardiovascular risk in type 1 diabetes."", ""supports"": ""SUPPORT""}], ""frequency"": ""VERY_FREQUENT"", ""name"": ""Blood Glucose"", ""presence"": ""Elevated""}"
7640	333	Type I Diabetes	Type_I_Diabetes.yaml	biochemical	1	Hemoglobin A1c (HbA1c)			VERY_FREQUENT					Elevated																																																	"{""frequency"": ""VERY_FREQUENT"", ""name"": ""Hemoglobin A1c (HbA1c)"", ""presence"": ""Elevated""}"	{}	"{""evidence"": [{""explanation"": ""Hemoglobin A1c is frequently measured in the management of diabetes, including Type I diabetes, and elevated levels are indicative of poor glycemic control."", ""reference"": ""PMID:22847316"", ""snippet"": ""The measure of glycated hemoglobin (HbA1c) concentration is the gold standard of glycemic control index in diabetes management and is well known as a marker for diabetes complications."", ""supports"": ""SUPPORT""}, {""explanation"": ""Elevated HbA1c levels are a common indicator used in the management of diabetes, supporting the claim of frequent elevated HbA1c in Type I diabetes."", ""reference"": ""PMID:26397266"", ""snippet"": ""Hemoglobin A1c is the accepted measure of long-term plasma glucose control in diabetics (levels >/=7 percent reflect poor blood glucose control)."", ""supports"": ""SUPPORT""}], ""frequency"": ""VERY_FREQUENT"", ""name"": ""Hemoglobin A1c (HbA1c)"", ""presence"": ""Elevated""}"
7688	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	biochemical	0	Fecal Calprotectin					Marker of intestinal inflammation			Elevated																																																	"{""context"": ""Marker of intestinal inflammation"", ""name"": ""Fecal Calprotectin"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Marker of intestinal inflammation"", ""name"": ""Fecal Calprotectin"", ""presence"": ""Elevated""}"
7689	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	biochemical	1	CRP					Systemic inflammation marker			Elevated																																																	"{""context"": ""Systemic inflammation marker"", ""name"": ""CRP"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Systemic inflammation marker"", ""name"": ""CRP"", ""presence"": ""Elevated""}"
7690	334	Ulcerative Colitis	Ulcerative_Colitis.yaml	biochemical	2	ESR					Active disease			Elevated																																																	"{""context"": ""Active disease"", ""name"": ""ESR"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Active disease"", ""name"": ""ESR"", ""presence"": ""Elevated""}"
7767	338	Vitiligo	Vitiligo.yaml	biochemical	0	Autoantibodies to Melanocytes			Variable					Elevated																																																	"{""frequency"": ""Variable"", ""name"": ""Autoantibodies to Melanocytes"", ""presence"": ""Elevated""}"	{}	"{""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The abstract does mention that vitiligo patients can have autoantibodies against pigment cells, supporting the notion that autoantibodies to melanocytes are present. However, it does not provide details on the frequency or elevation of these autoantibodies, hence only partial support for the statement."", ""reference"": ""PMID:17289548"", ""snippet"": ""The frequent association of vitiligo with autoimmune diseases, together with studies demonstrating that vitiligo patients can have autoantibodies and autoreactive T lymphocytes against pigment cells supports the theory that there is an autoimmune involvement in the aetiology of the disease."", ""supports"": ""PARTIAL""}], ""frequency"": ""Variable"", ""name"": ""Autoantibodies to Melanocytes"", ""presence"": ""Elevated""}"
7768	338	Vitiligo	Vitiligo.yaml	biochemical	1	Inflammatory Cytokines			Variable		Lesional skin			Elevated																																																	"{""context"": ""Lesional skin"", ""frequency"": ""Variable"", ""name"": ""Inflammatory Cytokines"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Lesional skin"", ""evidence"": [{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The reference indicates the presence of inflammatory cytokines is elevated in vitiligo lesions, thus supporting the statement."", ""reference"": ""PMID:35096274"", ""snippet"": ""Vitiligo is a common chronic autoimmune skin disorder featured with depigmented patches and underlying destruction of melanocytes in the lesional skin"", ""supports"": ""SUPPORT""}, {""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This reference points out that inflammatory mechanisms are active in vitiligo, particularly involving inflammatory cytokines."", ""reference"": ""PMID:22099450"", ""snippet"": ""Recent research in vitiligo suggests that various local triggers alert the skin immune innate system and may precede adaptive immune responses targeting melanocytes."", ""supports"": ""SUPPORT""}], ""frequency"": ""Variable"", ""name"": ""Inflammatory Cytokines"", ""presence"": ""Elevated""}"
7804	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	biochemical	0	VHL Genetic Testing																																			Molecular testing identifies germline VHL mutations in >99% of families meeting clinical criteria. Mutations include missense variants, truncating mutations, large deletions (detectable by MLPA), and deep intronic variants. Genotype- phenotype correlations guide surveillance: Type 1 mutations (truncating) have low pheochromocytoma risk; Type 2 mutations (missense) have higher risk.																						"{""name"": ""VHL Genetic Testing"", ""notes"": ""Molecular testing identifies germline VHL mutations in >99% of families meeting clinical criteria. Mutations include missense variants, truncating mutations, large deletions (detectable by MLPA), and deep intronic variants. Genotype- phenotype correlations guide surveillance: Type 1 mutations (truncating) have low pheochromocytoma risk; Type 2 mutations (missense) have higher risk.""}"	{}	"{""name"": ""VHL Genetic Testing"", ""notes"": ""Molecular testing identifies germline VHL mutations in >99% of families meeting clinical criteria. Mutations include missense variants, truncating mutations, large deletions (detectable by MLPA), and deep intronic variants. Genotype- phenotype correlations guide surveillance: Type 1 mutations (truncating) have low pheochromocytoma risk; Type 2 mutations (missense) have higher risk.""}"
7805	339	Von Hippel-Lindau Disease	Von_Hippel-Lindau_Disease.yaml	biochemical	1	Plasma Metanephrines																																			Annual screening for pheochromocytoma using plasma fractionated metanephrines or 24-hour urine catecholamines and metanephrines. Essential for early detection of pheochromocytoma before hypertensive crises.																						"{""name"": ""Plasma Metanephrines"", ""notes"": ""Annual screening for pheochromocytoma using plasma fractionated metanephrines or 24-hour urine catecholamines and metanephrines. Essential for early detection of pheochromocytoma before hypertensive crises.""}"	{}	"{""name"": ""Plasma Metanephrines"", ""notes"": ""Annual screening for pheochromocytoma using plasma fractionated metanephrines or 24-hour urine catecholamines and metanephrines. Essential for early detection of pheochromocytoma before hypertensive crises.""}"
7850	341	Wilms Tumor	Wilms_Tumor.yaml	biochemical	0	Histopathology																																			Wilms tumor classically shows triphasic histology with blastemal, stromal, and epithelial components. The presence and distribution of anaplasia (diffuse vs focal) determines risk classification.																						"{""name"": ""Histopathology"", ""notes"": ""Wilms tumor classically shows triphasic histology with blastemal, stromal, and epithelial components. The presence and distribution of anaplasia (diffuse vs focal) determines risk classification.""}"	{}	"{""name"": ""Histopathology"", ""notes"": ""Wilms tumor classically shows triphasic histology with blastemal, stromal, and epithelial components. The presence and distribution of anaplasia (diffuse vs focal) determines risk classification.""}"
7871	342	Wilson Disease	Wilsons_Disease.yaml	biochemical	0	Ceruloplasmin					Low in over 90 percent of patients (less than 20 mg/dL)			Decreased																																																	"{""context"": ""Low in over 90 percent of patients (less than 20 mg/dL)"", ""name"": ""Ceruloplasmin"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Low in over 90 percent of patients (less than 20 mg/dL)"", ""evidence"": [{""explanation"": ""ATP7B dysfunction prevents copper loading into apoceruloplasmin, resulting in low ceruloplasmin levels."", ""reference"": ""PMID:37741465"", ""snippet"": ""Inactivating mutations of the copper-transporting P-type ATPase, ATP7B, result in Wilson's disease"", ""supports"": ""SUPPORT""}], ""name"": ""Ceruloplasmin"", ""presence"": ""Decreased""}"
7872	342	Wilson Disease	Wilsons_Disease.yaml	biochemical	1	Serum Copper					Total serum copper often low (bound to ceruloplasmin)			Decreased																																																	"{""context"": ""Total serum copper often low (bound to ceruloplasmin)"", ""name"": ""Serum Copper"", ""presence"": ""Decreased""}"	{}	"{""context"": ""Total serum copper often low (bound to ceruloplasmin)"", ""evidence"": [{""explanation"": ""Total serum copper is low because ceruloplasmin-bound copper is reduced despite elevated free copper."", ""reference"": ""PMID:38731973"", ""snippet"": ""Copper accumulation in the liver is due to impaired biliary excretion of copper caused by the inheritable malfunctioning or missing ATP7B protein"", ""supports"": ""SUPPORT""}], ""name"": ""Serum Copper"", ""presence"": ""Decreased""}"
7873	342	Wilson Disease	Wilsons_Disease.yaml	biochemical	2	Free Copper					Non-ceruloplasmin-bound copper elevated			Elevated																																																	"{""context"": ""Non-ceruloplasmin-bound copper elevated"", ""name"": ""Free Copper"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Non-ceruloplasmin-bound copper elevated"", ""evidence"": [{""explanation"": ""Elevated free copper is the therapeutic target in Wilson disease, confirming its pathological elevation."", ""reference"": ""PMID:37741465"", ""snippet"": ""The goal of these strategies is to reduce free copper, redox stress, and cellular toxicity"", ""supports"": ""SUPPORT""}], ""name"": ""Free Copper"", ""presence"": ""Elevated""}"
7874	342	Wilson Disease	Wilsons_Disease.yaml	biochemical	3	24-Hour Urinary Copper					Elevated urinary copper is diagnostic			Elevated																																																	"{""context"": ""Elevated urinary copper is diagnostic"", ""name"": ""24-Hour Urinary Copper"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Elevated urinary copper is diagnostic"", ""evidence"": [{""explanation"": ""Elevated urinary copper excretion is both a diagnostic marker and a treatment response measure."", ""reference"": ""PMID:38731973"", ""snippet"": ""Patients with Wilson disease are well-treated first-line with copper chelators like D-penicillamine that facilitate the removal of circulating copper bound to albumin and increase in urinary copper excretion"", ""supports"": ""SUPPORT""}], ""name"": ""24-Hour Urinary Copper"", ""presence"": ""Elevated""}"
7875	342	Wilson Disease	Wilsons_Disease.yaml	biochemical	4	Hepatic Copper					Liver biopsy with elevated copper is diagnostic			Elevated																																																	"{""context"": ""Liver biopsy with elevated copper is diagnostic"", ""name"": ""Hepatic Copper"", ""presence"": ""Elevated""}"	{}	"{""context"": ""Liver biopsy with elevated copper is diagnostic"", ""evidence"": [{""explanation"": ""Hepatic copper accumulation is the primary consequence of ATP7B dysfunction and a key diagnostic finding."", ""reference"": ""PMID:38731973"", ""snippet"": ""Copper accumulation in the liver is due to impaired biliary excretion of copper caused by the inheritable malfunctioning or missing ATP7B protein"", ""supports"": ""SUPPORT""}], ""name"": ""Hepatic Copper"", ""presence"": ""Elevated""}"
7906	343	Wissler syndrome	Wissler_syndrome.yaml	biochemical	0	Erythrocyte sedimentation rate								Elevated																																																	"{""name"": ""Erythrocyte sedimentation rate"", ""presence"": ""Elevated""}"	{}	"{""evidence"": [{""explanation"": ""The case report documents markedly elevated ESR, supporting a systemic inflammatory state."", ""reference"": ""PMID:27843372"", ""snippet"": ""Blood sample analysis revealed high levels of CRP (42.9 mg/dL, normal: 0–0.3), erythrocyte sedimentation rate (113 mm/h normal: 2–20)"", ""supports"": ""SUPPORT""}], ""name"": ""Erythrocyte sedimentation rate"", ""presence"": ""Elevated""}"
7907	343	Wissler syndrome	Wissler_syndrome.yaml	biochemical	1	C-reactive protein								Elevated																																																	"{""name"": ""C-reactive protein"", ""presence"": ""Elevated""}"	{}	"{""evidence"": [{""explanation"": ""The case report documents markedly elevated CRP as part of the inflammatory syndrome."", ""reference"": ""PMID:27843372"", ""snippet"": ""Blood sample analysis revealed high levels of CRP (42.9 mg/dL, normal: 0–0.3), erythrocyte sedimentation rate (113 mm/h normal: 2–20)"", ""supports"": ""SUPPORT""}], ""name"": ""C-reactive protein"", ""presence"": ""Elevated""}"
